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INTRODUCTION AND OUTLINE OF THE THESIS
Colorectal cancer
General
The incidence of colorectal cancer has risen over the past 50 years worldwide: it is now 
the third most common type of cancer and represents the fourth most frequent cause of 
cancer deaths. The World Health Organization estimates that altogether 945.000 new 
cases and 492.000 deaths occur yearly1. In the Netherlands, 9.600 new patients with 
colorectal cancer have been diagnosed in 2002. This number has risen with 5% over 
the last decade2. Among men the incidence ranks third, after prostate and lung cancer, 
and among women it ranks second, after breast cancer3. The male to female ratio 
shows a small excess (ratio: 1.3) in favor of men. Colorectal cancer is mainly a disease 
of the elderly. At diagnosis, more than 75% of the patients are older than 60 years4. 
Surgery is the main form of treatment and more than 85% of the colorectal cancer 
patients undergo resection. The survival rate largely depends on the stage of disease at 
diagnosis. Ultimately, most patients that die, succumb to the effects of distant metastatic 
disease. The liver is often the site of metastases of colorectal cancer.
At presentation about 50% of the patients have tumours still confined to the bowel wall 
(stage I and II) and about 25% have already metastatic disease5,6. In its initial stages, 
colorectal cancer is clinically silent. As the tumour grows, occult intestinal bleeding is 
the most common sign. Other signs are severe anemia by chronic bleeding, obstructive 
symptoms manifested as changes in bowel habits, gaseousness, and abdominal pain 
and weight loss7. Most cases of colorectal cancer are sporadic, but roughly 5 to 10% of 
the cancers are defined as hereditary cancers. The two main forms are familial 
adenomatous polyposis coli (APC) and hereditary nonpolyposis colorectal carcinoma 
(HNPCC)1. A number of risk factors have been identified that influence susceptibility to 
colorectal cancer, including a family history, the presence of adenomatous polyps, 
inflammatory bowel disease (ulcerative colitis or Crohn’s disease), and a number of 
environmental factors of which diet is the most significant8.
Both the colon and rectum are paved with epithelial cells in which the accumulation of 
several genetic changes in both tumor suppressor genes and proto-oncogenes can 
result in neoplastic growth. Aberrations in the APC-gene and in mismatch repair-genes 
have been described in the sequence of normal tissue to adenoma, and in the 
adenoma-carcinoma sequence, respectively9. Due to these and other genetic 
aberrations, epithelial cells may become insensitive to normal growth control, which can 
lead to expansive growth. Invasion of surrounding tissue may be the next phase of 
tumor development. Ultimately, when regional lymph nodes or the vasculature have 
been invaded, tumor cells may metastasize to other regions of the lymphatic and 
vascular system and to distant organs.
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Prognosis
In order to determine patient prognosis and therapeutic strategies, patients with 
colorectal cancer are staged into one of four groups. This staging is based on the 
pathological characteristics of the cancer within the patient and refers to the tumor 
extent (T), the status of regional lymph nodes (N), and the presence or absence of 
distant metastases (M). Patients with tumours that are limited to the mucosa are 
nominated T in situ and are called unofficially stage 0. Stage I and stage II tumours 
extend beyond the mucosa but are limited to the bowel wall, while in stage III regional 
lymph nodes are involved and in stage IV simultaneous distant metastases are present 
(Figure 1). The overall 5-year survival rate of colorectal cancer patients is about 60%1. 
The survival rates, specified by stage, are approximately 90%, 65-75%, 25-60%, and 
0-7% for stage I, II, III and IV patients, respectively.
The rate of survival between patients with stage II and III disease varies considerably 
and the predictive value of the tumour stages II and III is therefore limited. Selection of 
patients for specific treatment regimens is essentially based on this staging system. In 
the clinical practice in Europe, patients with stage II disease generally do not receive 
adjuvant chemotherapy whereas patients with stage III disease do. In recent studies 
into the TNM classification, it has been shown that some stage II patients have such 
poor prognosis that they should also receive adjuvant treatment10. On the other hand, 
some stage III patients show relative good prognosis and may not need such 
treatment11. In order to increase the overall survival rate, there is a need for tools that 
select patients more precisely and, preferably, at an earlier stage than occurs with the 
current system.
For patients with metastases from colorectal cancer, a similar need for predictive 
markers has been recognised. Patients with metastases in the liver are treated with 
increasing frequency by means of a hepatic resection. Cure after resection has become 
attainable and more treatment options such as experimental chemotherapy, cryo- 
ablation and radiofrequency-ablation therapy are available. The number of patients after 
hepatic resection increases and accordingly the need for more specific and increasingly 
differentiating predictive markers, which correlate with survival or predict disease 
recurrence. Furthermore, new markers may be of use in monitoring the effects of 
therapeutic treatment.
To find markers that are new and superior to those currently used, investigations in 
recent years have focused on clinical markers (e.g. age, gender, tumor location), 
pathological markers (e.g. differentiation grade, tumour depth, blood vessel density, 
blood vessel invasion, inflammatory reaction), serum markers (e.g. vascular endothelial 
growth factor12,13, carbohydrate antigen-24214, presence of tumour cells15) and other 
markers (e.g. cyclooxygenase-216, microsatellite instability17, mutations in APC, K-ras or 
p5318). For this purpose, different processes within the neoplastic sequence have been
10
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scrutinized and one of them involves the relation between tumor cells and its 
surrounding normal tissue
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muscularis 
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blood vessel
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lymph node 
blood vessel
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Figure 1 TNM classification of colorectal cancer. Stage I: Mucosa and submucosa are involved 
(T1) and tumour can even invade the muscularis (T2). Stage II: Tumour has invaded beyond the 
muscularis into the serosa (T3) or even though the bowel wall perforating the visceral peritoneum or 
invading other organs (T4). Stage III: Any extent of the tumour (T1-4) in the presence of one to three 
tumour cell positive regional lymph nodes (N1) or more (N2). Stage IV: Any extent of the tumour, with or 
without positive lymph nodes, but with distant metastases.
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E x tra c e llu la r  m a tr ix  a n d  c a n c e r
It has been shown that the adhesion o f cells to the extracellu lar m atrix (ECM) is crucial 
fo r the regulation o f cell division, cell growth and cell shape19. A lterations in the 
spectrum  of m olecules involved in the cell-ECM  interactions constitute an integral part 
o f the m echanism that regulates m alignant transform ation of cells20,21. Next to the 
synthesis and deposition of ECM com ponents, the ir proteolytic breakdown plays an 
equally im portant role in rem odeling and therefore also in m alignant transform ation. 
Proteolysis not only alters the cell-ECM  interactions but may aid neoplastic invasion 
when normal m atrix and normal tissue is degraded. It has been shown that proteases 
are involved in the final steps o f tum our progression, invasion and m etastasis22,23. Also, 
different studies indicate that proteases are also involved in tum our growth, apoptosis, 
m igration and angiogenesis and m ay therefore play an im portant role in 
tum origenesis24,25. The proteases involved can be categorized in five m ajor classes: 
cysteine (e.g. cathepsins and caspases), aspartic (e.g. cathepsins), serine (e.g. 
plasmin), m etallo- (e.g. gelatinases, collagenases) and threonine (e.g. proteasom e) 
proteases.
Am ong these proteases the m eta lloprote inases are of particular interest because they 
are collective ly capable o f degrading essentia lly all com ponents o f the ECM, thereby 
potentia lly regulating tum our environm ent, and the ir expression and activation is 
increased in a lm ost all human cancers com pared w ith normal tissue22,25-27. The latter 
has also been shown for colorecta l cancer6,8.
Matrix metalloproteinases
The M M P fa m ily
M atrix m eta lloprote inases (MM Ps) are m eta lloendopeptidases that are key players in 
tissue remodeling. C leavage by proteolysis is an ongoing process both during dynam ic 
hom eostasis in resting-state adult organs and in fu ll-b lown tissue remodeling, which 
occurs during normal tissue development, in flamm ation, wound healing, and cancer27. 
The basic function o f M MPs is to regulate ECM com position and to facilita te cell 
m igration by rem oving barriers such as collagen. However, increasingly more 
inform ation becom es available on o ther functions as well and MMPs have now also 
been im plicated in functional regulation of different non-ECM m olecules such as growth
factors and the ir receptors, cytokines, chem okines, adhesion receptors and cell surface
28proteoglycans28.
The human MMP gene fam ily consists o f more than 20 m em bers that are all structurally 
related zinc-dependent endopeptidases. Based on the ir structure and substrate
12
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specificity, M MPs are classified into subgroups o f collagenases, gelatinases, 
strom elysins, matrilysins, m em brane-type M MPs (M T-M M Ps) and other MMPs (Tab le  
1). This classification grows increasingly more inadequate, m ainly because of the still 
expanding list of substrate specificities, including those of a non-ECM nature.
All M MPs are produced w ith a secretory signal sequence, a propeptide and a catalytic 
domain. C leavage of this propeptide is required fo r activation o f the latent form. Some 
M MPs contain additional dom ains such as a haem opexin-like domain, fibronectin like 
repeats or a transm em brane domain. The latter are specific for the MT-MMPs.
R e g u la tio n  o f  M M P a c t iv ity
Regulation o f MMP activ ity is m ainly controlled by transcription, activation o f the latent 
form and inhibition by natural inhibitors. In resting-state adult tissues most MMP genes 
are expressed at low levels or not at all. Some of them are inducible by growth factors,
29cytokines, chem ical agents, physical stress, and oncogenic ce llu lar transform ation29. 
Induction but also suppression are potential effects o f stim uli that act on prom oter 
regions o f the MMP genes. Extracellu lar stim ulation via an AP-1 (activator protein-1) 
binding site is one o f the routes of transcriptional regulation that has been found (e.g. for 
MMP-1, -3, -7, -9, -10, -12 and -13)30. Activation o f M MPs occurs, apart from  a few
m em bers (MMP-11, -28, MT-MMPs), after secretion. It occurs in the perice llu lar space
26by tissue or plasma proteinases, bacterial proteinases or o ther M M Ps26. The propeptide 
sequence that is located next to the active site is disrupted by physical or chem ical 
means, which is irreversible and results in a partial activation o f the protein. Full 
activation results from the removal o f the propeptide by in term olecular processing31. At 
present, the exact mechanism  of activation is known only fo r MMP-2. M T1-M M P binds 
T issue Inhibitor of M eta lloprote inase 2 (TIM P-2) on the cell surface and recruits MMP-2, 
which binds to the im m obilized TIMP-2; a free M T1-MM P is then recruited to the 
com plex and cleaves the MMP-2 propeptide, resulting in partial M MP-2 activation, 
which is com pleted by an adjacent active M M P-232. There are four TIM Ps (TIMP-1, -2, 
-3 and -4) w ith in the TIMP gene fam ily which are known to inhibit the activ ity o f MMPs 
by binding to activated MMPs in 1:1 m olar sto ichiom etry33. O ther MMP inhibitors, such 
as a1-prote inase inhib itor and a2-m acroglobulin can also control MMP activity. TIM Ps 
are small proteins o f 21-28 kDa that bind to the highly conserved zinc-binding site of 
active MMPs. TIMP-1 and TIM P-2 inhibit the activ ity of most MMPs. TIM P-3 inhibits the 
proteolytic activ ity o f MMP-1, -2, -3, -7, -9 and -13. T IM P-4 inhibits m ainly MMP-2 and 
-7. TIM P-2 can form a com plex w ith proM M P-2 and, sim ilarly, TIMP-1 can form  a 
com plex w ith proM M P-9 to recruit MMP-3, form ing a ternary com plex that w ill inhibit 
active M M P-334. Next to active MMP inhibition, T IM Ps may also have function in 
proMMP activation, cell growth promotion, inhibition o f angiogenesis and induction of
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33apoptosis TIM P-2 is constitutively expressed in cultured cells, whereas the 
expression o f TIMP-1 and TIM P-3 needs transcriptional regulation.
Table 1 The Human Matrix Metalloproteinases
Common name MMP
designation
Mw (kDA) 
pro/active
Major substrates 
ECM
Major substrates 
Non-ECM
Collagenases
Interstitial Collagenase MMP-1 52/43 Collagens I, II, III, X, Aggrecan ProMMP-2, ProTNFa
Neutrophil collagenase MMP-8 51/42 Collagens I, II, III, Aggrecan
Collagenase 3 MMP-13 52/42 Aggrecan, Collagens I, II, III, IV, 
X, Gelatins, Fibronectin
ProMMP-9
Gelatinases
Gelatinas A MMP-2 71/62 Gelatin, Collagens IV, V, VII, 
XI, Fibronectin
Monocyt chemo- 
attractant protein 3, 
ProMMP-1, -2, -13, 
ProTNFa
Gelatinas B MMP-9 92/82* Gelatin, Collagens IV, V, XI, 
Elastin
Plasminogen, 
ProTNFa, ProIL-1ß
Stromelysins
Stromelysin 1 MMP-3 52/43 Collagens IV, V, IX, X, Gelatin, 
Laminin
E-cadherin,
ProMMP-1, -8, -9, -13
Stromelysin 2 MMP-10 52/43 Collagens IV, V, IX, X, Gelatin, 
Laminin
ProMMP-1
Macrophage elastase MMP-12 52/43 Elastin
Stromelysin 3 MMP-11 51/44 a1-proteinase inhibitor
Matrilysin
Matrilysin 1; PUMP-1 MMP-7 28/19 Collagen IV, Fibronectin, 
Laminin
ProMMP-7, E-cad- 
herin, ProTNFa, 
Plasminogen
Matrilysin-2 MMP-26 ? Gelatin
Membrane-type MMPs
MT1-MMP MMP-14 64/54 Collagens I, II, III, Gelatin, 
Vitronectin, Proteoglycans
ProMMP-2 and -13, 
CD44,
a2 Macroglobulin
MT2-MMP MMM-15 71/61 Gelatin, Fibronectin, Tenascin ProMMP-2
MT3-MMP MMP-16 66/56 Collagen III, Gelatin, Fibronectin ProMMP-2, 
a2 Macroglobulin
MT4-MMP MMP-17 62/54 Gelatin, Fibronectin, Fibrinogen Pro-TNFa
MT5-MMP MMP-24 ? Gelatin, Fibronectin ProMMP-2
MT6-MMP MMP-25 ? Collagen IV, Gelatin, Fibrin 
Fibronectin
ProMMP-2
Others
No common name MMP-19 55/47 Gelatin, laminin, aggrecan
Enamelysin
CA-MMP
MMP-20
MMP-23
52/43
?
Amelogenin, Aggrecan
Epilysin MMP-28 ND Casein
*The glycosylated form of active MMP-9.
Table information adapted from references26 28,35,36
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M M P s a n d  c a n c e r
The first conclusive evidence that MMPs prom ote tum our growth stem s from studies on 
MMP knockout m ice and studies on TIMPs. Mice that lack MMP-7 exhibit a reduction in
37intestinal tu m o rig e n e s is . Tum origenesis is also reduced after chem ical m utagenesis in 
M M P -11 knockouts38. M M P-9-defic ient m ice show a reduced form ation o f m elanom a 
m etastases39 and M M P-2-defic ient m ice a reduction in m elanom a tum or progression 
and ang iogenesis40. Low ering the presence o f TIMP-1 results in enhanced tum our
initiation and progression41. A t present, we know that MMPs contribute to all stages of
22tum our progression22 and to many types o f cancer, including colorectal, gastric, lung, 
breast, ovarian, skin, and brain cancer42. Overall, the increased MMP expression in 
tum ours is thought to be a result o f transcriptional changes rather than genetic 
a lterations25. Activation o f oncogenes or loss o f tum our suppressors may be causative 
in this respect.
The mechanism  by which M MPs prom ote tum our cell growth is thought to be at least 
two-sided. For one, M MPs degrade proteins in the ECM and the basem ent m em brane 
in such a w ay that tum our cells may physically penetrate the surrounding connective 
tissues and blood vessels in order to infiltrate and m etastasize43. Secondly, the 
degradation of m atrix com ponents and non-m atrix com ponents such as chem okines, 
growth factors, growth facto r receptors, adhesion m olecules and apoptotic m ediators 
yield factors that cause and support tum our progression and invasion. As a result of 
proteolytic degradation, the extracellu lar dom ains of proteins from the cell surface or 
growth factors stored in the m atrix becom e available, not only to cells that are in direct 
physical contact, but also to distant cells. For example, MMP-2 can influence the cell- 
surface receptor-m ediated signaling by releasing the active dom ain o f fibroblast growth 
factor receptor-144. Also, cleavage of lam inin-5 and collagen IV results in exposure of 
cryptic sites that prom ote m igration45,46. The availability o f these e ffector m olecules may 
promote, but also suppress, the neoplastic deve lopm ent which renders the role of 
M MPs in cancer fa r more com plex than in itially anticipated. The fact that synthetic 
general MMP inhibitors have not convincingly proven any therapeutic benefit in cancer 
treatm ent yet may be attributed to these divergent roles o f MMP proteolytic activ ity25.
M M P s as  p re d ic t iv e  m a rk e rs
In colorecta l cancer, patient prognosis is determ ined by the TNM -staging system. 
Dependent on the stage o f disease, clin icians determ ine if patients are selected for 
adjuvant therapy. O ver the last decades, neither the prognosis nor the therapeutic 
options fo r patients w ith colorectal cancer have changed much. It has been suggested 
that on the basis o f the current staging system som e patients are overtreated and som e 
are undertreated10,11. The increase in the num ber of patients and a growing dem and for 
more patient-specific treatm ent strategies require the developm ent o f new prognostic
15
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m arkers that may aid in improving patient selection fo r adjuvant and experim ental 
therapy. In addition, investigations into new m arkers may produce new d iagnostic tools 
that may recognize colorecta l cancer in the more early stages. Such efforts may 
eventually result in a better prognosis and in an increase o f the survival rate. In addition, 
new m arkers m ay even becom e new targets in cancer treatment.
Because the MMP fam ily has a proven role in cancer, it has been anticipated that the 
M MPs may be valuable as predictive m arkers in colorecta l cancer. A t present, there is 
sufficient evidence to link MMP proteolytic activity to colorectal cancer and therefore it 
seem s im portant to investigate the ir potentia l as d iagnostic and prognostic m arkers in 
this disease.
The gelatinases, MMP-2 and MMP-9, are o f particular interest w ith in the MMP fam ily 
because the ir prim ary substrate is type IV collagen, which is a m ajor com ponent of 
basem ent m embranes. Degradation o f basem ent m em branes is considered essential in 
invasion and m etastasis. The natural inhibitors o f the M MPs are the TIMPs. TIMP-1 and 
TIM P-2 inhibit all active MMPs, but TIMP-1 also form s a specific com plex w ith proM M P- 
9 that inhibits proM M P-9 activation. In cancer, both TIMP-1, -2 and the gelatinases have 
been studied extensively, but not specifica lly concerning the ir role in patient d iagnosis 
or prognosis. Most studies, until now, have investigated m RNA expression and protein 
localization, but what is u ltim ately most im portant is proteolytic activity. In the thesis 
presented here, we w ill m ainly focus on the bioactiv ity o f the gelatinases in both tissue 
and plasm a from colorecta l cancer patients. W e investigate the d iagnostic and 
prognostic potentia l o f these enzym es as tum our m arkers and com pare them with 
current prognostic m arkers such as TNM staging and carcinoem bryonic antigen. The 
latter is a m arker o f tum our burden in loco-regional and m etastatic colorecta l cancer and 
serves often as a m onitor o f treatm ent response47.
The c e llu la r  s o u rc e s  o f  M M P s in  tu m o u r  tis s u e
For a while, the general assum ption has been that cancer cells are responsible for 
producing the M MPs in human tumours. However, Basset e t al.48 have found that 
strom al fibroblasts w ith in breast tum ours produce M M P -11. A t present we know that 
som e MMPs, e.g. MMP-7, are produced by cancer cells and that many others are 
produced by strom al cells. Using in situ  hybrid ization techniques, it has been found that 
MMP-1, -2, -3, -9 and M T1-M M P m RNA is prim arily localized in fibroblasts in the 
proxim ity o f invading tum our cells in breast, colorectal, lung, prostate, ovarian, and head 
and neck cancer49,50. MMP-9, -12 and M T1-M M P are synthesized by in flam m atory cells 
such as mast cells, neutrophils and m acrophages25. Im m unolocalization consistently 
dem onstrates the presence o f MMP protein in cancer cells, which suggests that many 
M MPs are produced and secreted by fibroblasts and in flam m atory cells, but are bound 
to docking sites on cancer cells. This concept is supported by data dem onstrating that
16
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MMP-2 binds to the TIM P-2:M T1-M M P-com plex on the cell surface, M MP-9 binds to 
CD44 and cell surface type IV collagen, and M M P-13 binds to cell surface receptors6.
M e a s u rin g  g e la tin a s e  b io a c t iv ity
The gelatinases MMP-2 and -9 are secreted as proenzym es and require proteolytic 
activation by other m ediators or MMPs. During activation, the propeptide sequence of 
the latent enzym e is spliced off, which results in lower m olecular weight active form s31. 
The technique of quantita tive zym ography uses a detergent that charges all m olecules 
equally and separates them by e lectrophoresis on the bases o f size. Consequently, this 
technique will separate MMP-2 from M MP-9 and the inactive form s from the active 
forms. A fte r washing o f the separation gel, the gelatino lytic activ ity is restored and 
becom es visible fo r each protein that has the capacity to degrade the gelatin substrate, 
which has been added to the gel51. V isualization is achieved by a sim ple protein 
staining. The technique is quantita tive because the transparency o f the area o f gelatin 
lysis (as m easured by specialized software) is proportional to the gelatinase activity 
present52. Unique to the zym ographic m ethod is that both the active and latent 
gelatinases can be detected because the latent form is activated when the detergent is 
rem oved when washing the gel after electrophoresis. Furthermore, this technique will 
m easure total MMP-2 and -9, which includes free gelatinases and those previously 
bound to TIM P-com plexes, because the detergent separates these com plexes before 
e lectrophoresis52.
Another w ay o f m easuring proteolytic activ ity is via an activ ity assay w ith M M P-specific
53quenched fluorogenic peptide substrates53. The am ount o f fluorescence is a m easure 
fo r the relative am ount o f proteinase present. The fluorescent substrate available fo r our 
studies is not solely degraded by gelatinases and therefore the conversion o f this 
substrate reflects a broader spectrum  of MMP activ ity54.
Outline of the thesis
Here, we describe our research on the bioactiv ity and/or im m unoreactiv ity o f the 
gelatinases and TIMP-1 in both tissue and plasm a from patients, which are operated for 
colorecta l cancer. W e exam ine the presence o f gelatino lytic activity, its corre lation w ith 
clin icopathological parameters, and discuss the value o f our findings in relation to 
d iagnosis and prognosis. These studies have been perfomed in patients w ith both 
prim ary disease and secondary, metastatic, d isease and the results have been 
com pared to data obtained from healthy controls. The fo llow ing questions have been 
addressed:
17
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Is MMP-2 and M M P-9 bioactiv ity enhanced in prim ary colorecta l cancer tissue and to 
w hat extent do the levels corre late w ith clin icopathological parameters, such as tum our 
location, size, grade o f differentiation, and stage? (Chapter 2)
Is MMP-2 and M M P-9 bioactiv ity enhanced in colorecta l cancer liver m etastases and is 
there any relation w ith clin icopathological param eters and the disease-free period? 
(Chapter 3)
Are plasma levels of MMP-2 and M MP-9 affected by operative procedures? (Chapter 4) 
How do plasma levels o f MMP-2, -9 and TIMP-1 corre late w ith d isease stage, 
diagnosis, and prognosis in prim ary colorectal cancer? (Chapter 5)
Do M MP-2 and M MP-9 plasma levels have any value as m onitors o f disease status 
after prim ary colorectal cancer operation? (Chapter 6)
Are plasma MMP-2, M MP-9 and TIMP-1 predictive m arkers in the diagnosis and 
prognosis o f colorectal cancer liver m etastasis? (Chapter 7)
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CHAPTER 2
Abstract
Background and  m ethods  The bioactiv ity of m atrix m eta lloprote inases was studied in 
tissues from colorecta l cancer patients by means o f both quantita tive gelatin 
zym ography and a fluorom etric activity assay. Next to paired sam ples o f tum our tissue 
and distant normal m ucosa (n=73), transitional tissue was analysed from  a lim ited 
(n=33) num ber o f patients.
Results  Broad-spectrum  m atrix m eta lloprote inase activ ity and both the active and latent 
form s of the gelatinases m atrix m eta lloprote inase-2 and -9 were higher in tum our than 
in normal mucosa. The ratios between active and latent form s of m atrix 
m eta lloprote inase-2 and -9 were highest in tum our tissue and normal mucosa, 
respectively. M atrix m eta lloprote inase-2 levels, both active and latent forms, correlated 
inversely w ith stage o f disease, the tum ours w ithout synchronous distant m etastases 
containing significantly (P=0.005) more active m atrix m eta lloprote inase-2 than the 
others. A t much lower levels o f activity, the sam e trend was observed in d istant normal 
mucosa. The level of latent form of m atrix m eta lloprote inase-9 in tum our depended on 
tum our location. Neither the active form of m atrix m eta lloprote inase-9 nor broad- 
spectrum  m atrix m eta lloprote inase activity in tum our tissue did corre late w ith any of the 
clin icopathological param eters investigated.
Conclusion  The results dem onstrate explicit d ifferences between the activ ity of m atrix 
m eta lloprote inase-2 and -9, indicating different roles for both gelatinases in tum our 
progression. Such data are necessary in order to develop rational anti-cancer therapies 
based on inhibition o f specific m atrix m etalloprote inases.
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Introduction
Proteinase activ ity is an im portant feature in a m ultitude o f physiological and 
pathological processes. Proteinases are norm ally strictly regulated in order to prevent 
undesired degradation o f tissue com ponents. In pathological processes like arthritis, 
periodontal disease, liver fibrosis, card iovascular disease and cancer, the regulation of 
proteinase activ ity is d is turbed1. In cancer, degradation of the extracellu lar m atrix is a 
key event in tum our cell invasion and m etastasis. Various m em bers o f the m atrix 
m eta lloprote inase (MMP) fam ily have been shown to play an im portant role in these 
processes, fo r instance by facilita ting the entry o f tum our cells into the bloodstream , 
angiogenesis, tum our cell establishm ent and grow th2,3. A  good understanding o f the 
expression pattern of the various MMPs in specific types o f cancer m ay provide a basis 
fo r the developm ent o f new therapeutic strategies. For this purpose, data on the 
activities of individual MMPs in tum our tissue are needed.
In a num ber o f studies a positive corre lation has been dem onstrated between MMP 
expression and tum our invasion and m etastasis. Data pertain to different types of 
cancer located in various organs2. The assay m ethods used vary w idely and include 
analysis o f mRNA, protein content and actual proteinase activity. In colorecta l cancer 
(CRC) most o f the data are on mRNA, which is upregulated in tum our cells and/or 
tum our stroma, if com pared to normal healthy tissue. For instance, upregulation of 
m RNA has been reported fo r M M P-24, M M P-75, M M P-96, M M P-117, M M P-128 and 
M M P-149. In the im m unohistochem ical detection o f MMPs the focus has been on the 
analysis o f MMP localisation. Correlations have been described between MMP-1 
im m unoreactiv ity and surv iva l10 and also between stage o f disease and 
im m unoreactiv ity fo r M M P-111, M M P-212 and M M P-713. These studies m easure MMP 
im m unoreactiv ity w ithout discrim ination between latent proenzym e and activated 
enzyme. Ultimately, quantita tive data on proteinase activ ity are most relevant for 
determ ining the biological role o f M MPs in tum our progression.
Q uantitative gelatin zym ography allows the sim ultaneous m easurem ent o f the latent 
and active form s of the gelatinases MMP-2 and MMP-9. In recent years, a limited 
num ber o f studies used zym ography to investigate the presence o f the gelatinases in 
tissue sam ples collected from  patients operated for CRC. To som e degree, all show 
enhanced gelatinase levels in tum our tissue, at least for the latent form s of M MP-2 and 
MMP-9. However, som e stud ies14,15 have not quantified active MMP-9, while o thers16-18 
do not report specific activities but rather the absence or presence of the various 
enzym e forms. A  consistent quantification of both the latent and active form s -  and the ir 
ratio -  o f both gelatinases in m atched tum our and normal tissue is still lacking. Here, we 
supply these data on sam ples from a series o f CRC patients, which is also large enough 
to investigate corre lations w ith clin icopathological parameters. In a num ber o f cases we
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have also m easured activities in transitional tissue containing the invasive edge. In 
addition to quantita tive gelatin zym ography, we have used a recently developed broad- 
spectrum  bioassay MMP activity using an internally quenched fluorogenic peptide 
substrate.
Materials and methods
P a tie n ts  a n d  t is s u e  s a m p le s
Seventy-three patients w ith CRC w ere included in this study. The paired sam ples of 
tum our tissue (n=73), transitional tissue (n=33) and distant normal m ucosa (n=73) were 
collected im m ediate ly after surgical resection for prim ary CRC. M acroscopically vital 
tum our tissue from the protruding luminal part o f the tum our was harvested by a 
pathologist. Transitional tissue contained the invasive edge on the lum inal side including 
both tum our and normal tissue. Normal colonic m ucosa sam ples were taken at least 5 
cm away from the tumour. Random ly selected sam ples were analysed histo logically to 
confirm  the ir cellu lar content. Sam ples o f patients that received preoperative chem o- or 
radiotherapy were excluded from the study. All patients provided inform ed consent and 
the study was approved by the institutional ethical com mittee. The patients’ 
clin icopathological characteristics were determ ined and used to com pose various 
groups fo r com parison (cf. Table 2). Tum ours were designated m ucinous when 
significant parts o f the tum our contained clusters o f enlarged mucin producing cells. 
Tum our staging was according to the current TNM classification, stage I (T1-2N0M0), II 
(T3-4N0M 0), III (TxN1-3M 0) and IV (TxNxM 1) corresponding to Dukes’ stage A, B, C 
and D, respectively.
T issue sam ples w ere stored in liquid nitrogen and m echanically disaggregated using a 
M icro-D ism em brator (Braun), yie lding hom ogenous samples. The pulverised sam ples 
were extracted (40 m l/mg tissue) in buffer (0.5 M Tris, 0.2 M NaCl, 10 mM CaCl2 and 
1% Triton X-100) fo r 15 min and freeze-thaw ed twice. A fte r centrifugation (18000 rpm, 
30 min, 4 °C) the supernatant was dialysed tw ice (20 h, 4 °C) against a buffer containing 
5 mM CaCl2, 50 mM Tris-HC l and 0.2 M NaCl to remove Triton and the excess of salt. 
T issue extracts were stored at -8 0  °C until use.
P ro te in  d e te rm in a tio n
Protein content was determ ined in tissue extracts using the b icinchonin ic protein assay 
from Pierce (Rockford, IL, USA). To each extract o f 20 ^l, 130 ^  buffer (50 mM Tris, 0.2 
mM NaCl, 5 mM CaCl2, pH 7.5) and 2 ml o f b ic inchonin ic acid solution was added.
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Follow ing incubation fo r 30 min at 37 °C the absorbance was read at 562 nm. Bovine 
serum album in was used as a standard.
G e la tin  z y m o g ra p h y
Gelatin zym ography was perform ed to quantify the presence o f both activated and 
latent form s of the gelatinases MMP-2 (gelatinase A) and M M P-9 (gelatinase B) in the 
tissue extracts19,20. Each extract was diluted 1:1 w ith sam ple buffer (0.125 M Tris-HCl, 
pH 6.8, 17.4% (w/v) glycerol, 4% sodium dodecylsu lphate (SDS) and 0.01% 
brom ophenol blue) and heated at 60 °C for 20 min. A fte r centrifugation fo r a few  
seconds 5 ^  aliquots w ere loaded on a 7.5% (w/v) standard Laemmli SDS- 
polyacrylam ide gel containing 2 mg/m l gelatin (Type A: from Porcine Skin, S igm a) as a 
substrate. Gels were electrophoresed at 15 m A per gel while stacking and at 20 mA per 
gel during the separating phase until the brom ophenol blue stained front reached the 
bottom of the gel. Collagenase from C lostridium  histolyticum  (Type VII, Sigma) was 
electrophoresed on each gel as an internal standard. A fte r running, the gels were 
w ashed three tim es in 2.5%  (v/v) Triton X -100 fo r 10 min at room tem perature to 
rem ove SDS. A fte r washing tw ice in a buffer containing 50 mM Tris-HCl, 5 mM CaCl2 
and 0.1%  Triton X-100 (pH 7.8), the gels were incubated overnight at 37 °C in the same 
buffer under gentle agitation. Zym ogram s were stained fo r 45 min w ith 0.25%  (w/v) 
Coom assie Brilliant Blue R250 dissolved in 40%  m ethanol and 10% glacial acetic acid. 
Gels were destained tw ice for 10 min in the sam e solution w ithout Coom assie Blue. 
P roteolytic activities were visualised by clear zones against a dark blue background 
indicating lysis o f gelatin. Loading o f the gels was such that proteinase activity was 
linear w ith the gelatin lysis. Q uantification o f the proteinase activities, which were 
expressed as arbitrary units per mg protein on the basis o f size of the lysed area and 
intensity, was perform ed using a Sharp JX-330 scanner and Im agem aster ID software 
(Am ersham  Pharm acia Biotech, Uppsala, Sweden). In-between com parison o f values, 
obtained on different gels, was perform ed using the internal standard that was present 
on each gel. The presence o f true MMP activity was confirm ed by adding 10 mM EDTA 
or 1 mM 1,10’ phenanthroline, both MMP inhibitors, to the buffers used after 
electrophoresis. A lso human recom binant MMP-2 (1 ng/lane) and -9 (0.5 ng/lane; 
O ncogene Research Products, Cambridge, MA, USA) were added som etim es to 
com pare the ir location w ith endogenous activities (e.g. F ig u re  1). Activation of 
recom binant proform M MPs was achieved by incubation w ith 1 mM p-am ino- 
phenylm ercuric acetate (APMA).
F lu o ro m e tr ic  M M P a c t iv ity  a s s a y
Broad-spectrum  MMP activity was determ ined in 71 out o f 73 CRC patient sam ples (in 
two cases insufficient sam ple was left after zym ography to perform the activity assay)
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using the quenched fluorogenic peptide substrate TNO 211-F (Dabcyl-G aba-Pro-G ln- 
G ly-Leu-Cys(F luorescein)-A la-Lys-N H2) essentia lly as described previously21,22. The 
substrate is m ainly cleaved by the gelatinases (MM P-2 and -9) and collagenase 3 
(M M P-13) and to a lesser extent by collagenase 2 (MM P-8) and m em brane-bound 
m eta lloprote inase (MT1-M MP). As such, conversion o f this substrate m ainly reflects 
gelatino lytic activity. In short, substrate hydrolysis by tissue extracts was determ ined in 
the presence o f EDTA-free general proteinase inhib itor Com plete (Roche M olecular 
Biochem icals, Indianapolis, IN) to prevent conversion of TNO 211-F by proteinases other 
than MMPs. Further im provem ent o f the assay specific ity fo r M MPs was achieved by 
determ ining the difference in substrate conversion in presence and absence of synthetic 
MMP inhib itor BB94 (10mM). The rate o f substrate conversion (RFU/s; relative 
fluorescence units per second) at 30°C (Aex: 485 nm, Aem: 530 nm; Cytofluor4000, 
PerSeptive Biosystem s) was norm alised to the am ount o f protein present in the tissue 
extract and expressed as RFU/s per mg protein. All sam ples and reagents w ere diluted 
in buffer containing 50 mM Tris (pH 7.5), 5 mM CaCl2, 150 mM NaCl, 1 mM ZnCl2, 
0.01%  Brij-35 and 0.02%  NaN3.
m m p-2 m m p-9
_ +  _ +  T T-N N T T-N N T T-N N
MMP-9 homodimer 
(220-kDa)
^ ___  MMP-9 heterodimer
(135-kDa)
^ ------ Pro M MP-9 (92-kDa)
M ___  Active MMP-9 (82-kDa)
M ___  ProMMP-2 (72-kDa)
^ ___  Active MMP-2 (62-kDa)
Figure 1 Proteolytic MMP activity in human CRC tissue extracts detected by quantitative gelatin 
zymography. MMP-2 (-), gelatinolytic activity of recombinant proMMP-2; MMP-2 (+), APMA-activated 
recMMP-2; MMP-9 (-), recombinant proMMP-9; MMP-9 (+), APMA activated recMMP-9; T, tumour; T-N, 
transitional (tumour to normal) tissue; N, distant normal mucosa; 1-3, case numbers of three 
representative patients. Positions of active MMP-2 (62 kDa), proMMP-2 (72 kDa), active MMP-9 (82 kDa) 
and proMMP-9 (92 kDa) are indicated by arrows. Recombinant MMP-2 and -9 were applied in doses of 1 
ng and 0.5 ng per lane, respectively.
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S ta t is t ic a l a n a ly s is
Com parisons between MMP levels in m atched tum our tissue, transitional tissue and 
distant normal m ucosa were perform ed using the Friedman two-way ANOVA. As a post­
test procedure fo r pairw ise com parisons Dunn’s post-test was used. The relationship 
between MMP levels and clin icopathological param eters was analysed using the M ann­
W hitney U-test when com paring data between two groups; Kruskal-W allis test was used 
when com paring more than two groups, with, in-between com parisons using Dunn’s 
post-test. D ifferences were considered statistically significant at the P<0.05 level.
Results
P ro te in a s e  a c t iv ity  b y  g e la tin  z y m o g ra p h y
Seventy-three paired tissue sam ples o f CRC tum our tissue and m atching normal 
m ucosa were extracted and analysed by quantita tive gelatin zym ography. In addition, 
gelatinase activ ity was also determ ined in transitional (tum our to norm al) tissue which 
includes the invasive edge. F ig u re  1 shows a zym ogram  containing tissue extracts from 
three CRC patients, representative fo r all sam ples investigated. Clearly, the extracts 
contained m ultiple proteinase species o f varying m olecular w e igh t exhibiting gelatinase 
activity. A ll w ere com plete ly inhibited by EDTA (not shown) confirm ing the ir status as 
m etalloprote inases. Com parison w ith the purified MMPs showed the presence of 
proM M P-9 (92-kDa), active M MP-9 (82-kDa), proM M P-2 (72-kDa) and active MMP-2 
(62-kDa). The lytic bands of high m olecular w e igh t forms, found at approxim ate ly 220- 
kDa and 135-kDa, closely corre lated w ith both each o ther (r = 0.96) and w ith those of 
proM M P-9 (r = 0.97 and 0.96 fo r the 220-kDa and 135-kDa bands respectively).
All bands representing active and latent form s of MMP-2 and -9 w ere quantified and 
the ir ge latino lytic activity (on basis o f protein) was calculated. There was a s ignificantly 
h igher level o f active MMP-2, proMMP-2, active M MP-9 and proM M P-9 in tum our tissue 
com pared to normal m ucosa (n=73; P<0.001, P<0.001, P<0.01 and P<0.001 
respectively) (F ig u re  2). Active MMP-2, proM M P-2 and proM M P-9 were also h igher in 
transitional tissue than in normal m ucosa (n=33; P<0.001, P<0.01, P<0.001 
respectively), but active M MP-9 was not. M edian values in tum our and transitional 
tissue were essentia lly the same. T a b le  1 shows the relative increase in MMP activity in 
tum our over normal tissue: the m edian tum our to normal ratio was highest (8.6) for 
active MMP-2 and lowest (1.7) for proM MP-2. Active M MP-2 and M MP-9 were not 
detectable in 6 and 4 sam ples from normal mucosa, respectively. In all other samples, 
levels o f both pro- and active enzym es could be measured.
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The separate quantification of both the proenzym e and active enzym e also allowed the 
calculation o f the ratio active/proenzym e in the three different tissues (F ig u re  3). In 
normal mucosa, the ratio was three tim es higher (P<0.0001) fo r M M P-9 than fo r MMP-2. 
For M MP-2 this ratio increased five-fo ld (P<0.001) in tum our tissue and four-fo ld 
(P<0.001) in transitional tissue, as com pared to normal mucosa. In contrast, fo r MMP-9 
the ratio was highest in normal m ucosa and decreased (P<0.05) in the sam ples 
containing tum our tissue.
Table 1 Tum our to norm al ratio o f MMP activity in CRC
Active MMP-2 
ProM MP-2 
Active M MP-9 
ProM MP-9
n
67a
73
69a
73
tum our to norm al ratio 
median range
8.6
1.7
2.0
4.0
0.0
0.3
0.0
0.1
947.4
13.1 
351.9
35.2
MMP activity is expressed in arbitrary units per mg protein. aPatient data 
were excluded when activity in normal mucosa equaled zero.
C o rre la tio n  be tw e e n  M M P a c t iv ity  a n d  c lin ic o p a th o lo g ic a l p a ra m e te rs
The relations between clin icopathological param eters and the levels o f active and 
proform MMP-2 and -9 in tum our tissue are shown in Tab le  2. A  num ber o f corre lations 
was found fo r MMP-2 but only one fo r MMP-9. ProM M P-9 levels showed a significant 
corre lation w ith tum our location (P=0.040). Rectum tum ours showed the lowest levels of 
proM M P-9 whereas the left colon showed the highest levels. Neither age, tum our size, 
histological differentiation, tum our cell mucin, T stage nor lymph node involvem ent 
corre lated w ith gelatino lytic MMP activity. In normal m ucosa m ale patients displayed 
higher levels o f proM M P-2 com pared to fem ale patients (P=0.011), but in tum our tissue 
no such difference was seen. Com parison between prim ary tum ours w ith and w ithout 
synchronous liver m etastasis showed that tum ours w ith liver m etastasis (TxNxM 1) had
30
MMP ACTIVITY IN COLORECTAL CANCER TISSUE
20
18
16
14
12
10
8
6
4
2
0
A
û- E
160
140
f  120 O
100 
80
D
û- & 60
40
20
0
Tumour
B
T-N Normal
Mucosa
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Tumour
(n = 73; P  <0.0001)
A
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Normal Mucosa
(n = 73; P  <0.0001)
C
MMP-2 MMP-9
Figure 3 Ratio between active enzym
and proenzyme for both MMP-2 and -9. Data 
were obtained by quantitative gelatin 
zymography. A, CRC tumour tissue; 
B, transitional tissue (T-N); C, normal 
mucosa. Horizontal bars represent median 
values, boxes represent the interquartile range, 
vertical lines represent the 10 to 90 % range of 
the observations. P values represent the 
statistical differences between matched data on 
the MMP-2 and MMP-9 ratios.
Figure 2 A comparison of MMP activity in CRC tumour (n=73), transitional tissue (T-N, n=33) and 
normal mucosa (n=73). Data are shown for active MMP-2 (A), proMMP-2 (B), active MMP-9 (C) and 
proMMP-9 (D). Horizontal bars represent the median values, boxes represent the interquartile range, 
vertical lines represent the 10 to 90 % range of the observations. Enzyme activity, as measured by 
quantitative zymography, is expressed as specific activity in arbitrary units per milligram protein. 
Significant differences with normal mucosa: **P<0.001; *P<0.01.
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Table 2 Correlation between MMP-2 and -9 activities and clinicopathological parameters
Primary colorectal cancer
No. of MMP-2 MMP-9
Parameter
1cases Active Proform Ratio a/p 2 Active Proform Rati
Sex
male 43 4.4 15.5 (9.4) 4 0.3 4.4 38.4 0.1
female 30 3.6 13.9 (6.6) 0.3 6.1 46.1 0.1
P 0.797 0.622 *11.0(0. ) 0.893 0.205 0.262 0.638
Age
< 50 12 3.6 11.5 0.3 3.8 39.5 0.1
50 - 70 39 4.3 15.4 0.3 5.1 45.0 0.1
> 70 22 4.1 14.8 0.3 5.7 38.9 0.1
P 0.747 0.575 0.701 0.722 0.648 0.42
Tumour location
right 35 3.7 12.3 0.4 5.1 43.8 0.1
left 8 4.0 13.9 0.3 11.3 125.5 0.1
sigmoid 21 4.0 14.4 0.3 5.5 43.3 0.1
rectum 9 5.2 15.6 0.4 2.1 27.2 0.1
P 0.871 0.559 0.750 0.088 0.040* 0.538
Tumour size
< 3 cm 5 3.4 18.6 0.3 2.5 24.0 0.1
3 - 5 cm 29 4.0 13.7 0.4 5.0 38.4 0.1
> 5 cm 38 4.2 14.7 0.3 6.3 51.1 0.1
P 0.846 0.854 0.858 0.367 0.150 0.390
Tumour differentiation
moderate 48 4.2 14.2 0.3 5.0 46.1 0.1
poor 24 3.8 14.2 0.3 5.6 41.9 0.1
P 0.971 0.990 0.599 0.867 0.924 0.971
Mucinous tumours
No 49 3.8 13.7 0.3 5.1 43.8 0.2
Yes 23 5.7 15.2 0.4 6.9 66.0 0.1
P 0.130 0.458 0.156 0.381 0.182 0.966
T stage
Tis 1 0.8 2.4 0.3 2.5 3.7 0.7
T1 4 4.6 15.2 0.3 4.4 58.0 0.1
T2 16 4.0 13.5 0.3 4.9 41.1 0.1
T3 42 4.0 14.2 0.3 5.2 40.5 0.1
T4 10 5.9 13.9 0.3 6.6 104.7 0.1
P 0.792 0.487 0.987 0.723 0.119 0.471
N stage 3
TxN0M0 39 5.3 15.5 0.4 5.5 45.0 0.1
TxN1M0 15 3.7 13.7 0.3 5.2 26.8 0.2
P 0.390 0.946 0.213 0.721 0.145 0.765
Distant metastases
TxNxM0 54 5.0 (0.6) 15.5 0.4 (0.1) 5.4 43.6 0.1
TxNxM1 17 2.4 (0.2) 10.8 0.2 (0.0) 3.6 37.4 0.1
P 0.005* 0. 0 v *) 0.009* 0.007* (0.002*) 0.115 0.293 0.153
Stage of disease
I 15 5.3 (0.7) 16.0 0.4 (0.1) 5.8 44.0 0.1
II 23 6.3 (0.9) 15.5 0.4 (0.1) 5.5 53.0 0.1
III 16 4.1 (0.3) 15.5 0.3 (0.0) 5.9 28.8 0.2
IV 17 2.4 (0.2) 10.8 0.2 (0.0) 3.6 37.4 0.1
P 0.024* (0.019*)0.044* 0.028* (0.002*) 0.408 0.296 0.422
Mann-Whitney U-test for comparison of two groups; Kruskal-Wallis test for comparison of non-parametric
data of more than two groups. 1only evaluable cases were included. 2ratio active/proMMP. 3lymfe node
involvement as a parameter independent of T stage (Tx) excluding distant metastasis (M1). 4data 
between brackets pertain to normal distant mucosa. Activities (arbitrary units/mg protein) are shown in 
median values. Statistical significant differences are shown with an * (P<0.05).
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significantly lower activ ity o f both active M MP-2 (P=0.005) and proM M P-2 (P=0.009) 
than those w ithout liver m etastasis (TxNxM0). These differences were also observed in 
distant normal mucosa, but statistical significance was only reached fo r the activated 
form of M MP-2 (P=0.011). The absolute activity of these MMP-2 levels in normal 
m ucosa were, however, much lower (approxim ately ten tim es) than those in tum our 
tissue. The active to proenzym e ratio o f MMP-2 did also d iffer w ith this parameter. In 
both tum our and distant normal m ucosa the ratio was significantly lower in the TxN xM 1- 
group than in the TxN xM 0-group (P=0.007, P=0.002 respectively). Com paring the MMP 
activity w ith stage o f disease, a trend was observed towards lower levels of active 
MMP-2 and proM M P-2 w ith advanced stage o f d isease in tum our (P=0.024 and 
P=0.044 respectively) and in normal m ucosa (P=0.019 and NS respectively). This also 
applied to the MMP-2 active to proenzym e ratio in tum our (P=0.028) and normal 
m ucosa (P=0.002). In detail d ifferences were most explicit between stage II (T3-4NxM 0) 
and stage IV (TxNxM 1) tum ours fo r active MMP-2 (F ig u re  4) and the MMP-2 
active/proenzym e ratio (both P<0.05).
I II III IV
Stage of disease
Figure 4 Active MMP-2 in primary CRC tissue extracts of stage I (n=15), II (n=23), III (n=16) and 
IV (n=17) tumours determined by quantitative gelatin zymography. Horizontal bars represent median 
values. Stage II versus stage IV: P<0.05.
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F lu o ro m e tr ic  M M P a c t iv ity  a s s a y
Nearly all sam ples w ere also m easured w ith a broad-spectrum  MMP assay, using a 
substrate, which is m ainly recognised by the gelatinases. F ig u re  5  shows that overall 
gelatino lytic MMP activ ity was significantly h igher in both tum our (P<0.01) and 
transitional (P<0.001) tissue than in normal mucosa. In contrast to the MMP-2 activities 
as determ ined by zym ography, broad-spectrum  MMP activity in tum our tissue did not 
corre late significantly w ith any o f the clin icopathological param eters m entioned in Table  
2. The only difference found, was that the transitional tissue o f patients w ith distant 
m etastatic liver d isease (n=5) showed higher activ ity (3.9 vs 2.0, m edians in arbitrary 
units, P=0.032) com pared to patients w ithout d istant m etastases (n=24).
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Figure 5 Broad-spectrum MMP activity in CRC tumour (n=71), transitional (T-N; n=29) and normal 
tissue (n=71) determined by quenched fluorogenic substrate hydrolysis. Activity is expressed as the rate 
of substrate conversion on basis of protein. Horizontal bars represent median values, boxes represent the 
interquartile range, vertical lines represent the 10 to 90 % range of the observations. *P<0.01, **P<0.001 
versus normal mucosa.
Discussion
The present data show that tum our tissue contains h igher levels of active and proform 
MMP-2 and -9 than distant normal m ucosa in patients w ith CRC, w ith the increase in
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active MMP-2 being the m ost pronounced. The active to proform ratio of M MP-2 is 
highest in tum our tissue, w hereas this ratio fo r M M P-9 is h ighest in d istant normal 
mucosa. Furthermore, MMP-2 levels do inversely corre late w ith stage of disease.
The level o f proteinase activ ity in this study was m easured using gelatin zym ography 
and broad-spectrum  MMP substrate hydrolysis. Zym ography separates the proform s 
and active form s of M MPs but the technique w ill not d istinguish between free M MPs and 
those com plexed w ith the ir natural inhibitors, the T IM Ps23. Zym ography, therefore, 
yie lds no absolute values on the levels o f active and latent MMPs in  vivo, but rather a 
representation o f the levels o f the active and latent form s in both free and com plexed 
form in the various tissues studied. The results should always be interpreted keeping 
this in mind. The broad-spectrum  MMP activity assay, however, does not m easure 
TIM P-com plexed MMP activity. S ince levels o f TIM Ps have not been determ ined in this 
study, one could speculate that the increased levels o f MMP-2 and -9 in tum our will 
have no actual biological consequence in the in vivo  situation because of endogenous 
inhibition. However, in a recent study it is shown that the level o f TIM P-2 protein, when
m easured w ith ELISA, is s ignificantly lower in colorecta l tum ours than in normal
18
m ucosa18. W ith the high levels of active MMP-2 present in tumour, total inhibition seem s 
therefore unlikely. Moreover, using the MMP activ ity assay w ith a fluorogenic peptide 
substrate, enhanced MMP activity was observed in tum our tissue. Since this assay 
would not m easure MMP activity if all MMPs w ere inhibited by TIM Ps this indicated that 
indeed the increased MMP activation is not com pensated fo r by increased TIMP 
production. Also, the ability o f TIMP-1, which is reported to be upregulated18, to bind 
w ith all MMP-9, can be disputed. TIMP-1 availability should prevent form ation o f MMP-9 
dim ers24, while we found high levels of the hom odim er o f M M P-9 (220-kDa, F ig u re  1) 
and the heterodim er of M MP-9 and NGAL (135-kDa)16, indicating that there is unbound 
M MP-9 left in tum our tissue.
Gelatin zym ography dem onstrates that both active and proM M P-2 and -9 levels are 
elevated significantly in prim ary CRC tissue com pared to normal mucosa. These 
observations are consistent w ith previous observations on active and proform MMP-2 
and proM M P-914. The presence o f active M M P-9 has also been described before16-18,25, 
but quantita tive m easurem ent in all sam ples had not been reported up until now. Active 
MMP-2 increases more than its proform in tum our tissue. Thus there is not only more 
MMP-2 present in tum our than in normal tissue, but the ratio active to proenzym e also
increases substantia lly. A  sim ilar finding was reported by Parsons e t a l.15 and M cKerrow
26e t a l and supports the view  that the activation o f M MP-2 is a crucial step in tum our 
invasion. Expression o f MMP-2 m RNA in tum our has been described in strom al 
fibroblastic cells27,28, but MMP-2 protein appears to be localised predom inantly in the
29
cytoplasm  of tum our cells29. A  cell m em brane-bound m eta lloprote inase (MT1-MMP), 
present on tum our cells, has been shown to activate proM M P-230 and is most likely
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responsible fo r anchoring MMP-2 to these m alignant cells. O verexpression of MT1- 
MMP and enhanced M MP-2 protein activ ity may thus be induced in the process of 
tum our progression.
In contrast to MMP-2, the proform of M MP-9 increases much more than active MMP-9 
during normal to tum our conversion. This finding is new since previous studies reported 
difficu lty in m easuring the active form, because of its unstab ility15 or presum ed low 
levels14. In CRC it has been shown that M MP-9 m RNA is expressed in m acrophages 
especia lly in the invasive site. Im m unoreactivity has been shown in m acrophages and 
neutrophils but not in tum our cells31,32. It is suggested that M MP-9 levels reflect the 
presence o f in flam m atory infiltrate around the tum our rather than the characteristics of 
the tum our itself. However, Parsons e t a l.15, did not find a corre lation between MMP-9 
and the am ount of peritum oural lym phocytic infiltrates. Our observation that proM M P-9 
increases more than its active form in tum our tissue m ay result from  induced secretion 
o f large am ounts o f proform by m acrophages and neutrophils. As yet, we cannot explain 
w hy the activation o f the proM M P-9 form  to the active form, as represented by the 
active to proform ratios, appears to be lower in the tum our than in normal tissue. 
However, it would be unjustified to conclude from this that the role o f M MP-9 in tum our 
invasion and progression would be less im portant than that of MMP-2, which shows 
increased activation in tumour. M MP-9 may even be a more effective protease than 
MMP-2 w ith respect to substrates in the extracellu lar matrix, as it is in vitro fo r gelatin 
during zym ography. Still, it rem ains to be established if M MP-9 plays a s ignificant role in 
tum our progression in CRC. It is evident, however, that there are s ignificant d ifferences 
in the state of activation between the gelatinases, which m ight be indicative fo r the ir 
d ifferent roles in the progression o f cancer.
Com parison between clin icopathological param eters and gelatinase activ ity reveals 
corre lations fo r MMP-2, in particular in relation to stage of disease. Neither Liabakk et 
a l.14 nor Parsons e t a l.15 found such a correlation, but these authors have not included 
stage IV tum ours in the ir studies. Indeed, in our series activities are found in stage I, II 
and III tum ours sim ilar to those o f Parsons e t a l.15, but a significantly lower activ ity of 
both active and proM M P-2 is found in m etastatic stage IV tum ours if com pared to all 
tum ours w ithout distant (c.q. liver) metastases. It has been suggested that MMP 
activities in the separate d isease stages may vary because of d ifferences in strom al 
com ponents surrounding the tum ours14. A lthough this seem s reasonable in view  of the 
fact that different cell-cell contacts and specific cell-m atrix interactions may cause
33changes in MMP expression33, one would then also expect variations in MMP activity 
w ith depth o f invasion. However, we find no corre lations between MMP activ ity and T 
stage. The finding that active M MP-2 in normal m ucosa is also inversely corre lated w ith 
stage o f d isease and w ith d istant m etastatic d isease is remarkable. A lthough the 
activities o f active MMP-2 w ere much lower, they show a sim ilar trend. This may be due
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to the effect o f local diffusion or perfusion via lymph or blood vessels. Previous studies 
on MMP activities have not com pared normal tissue MMP activities w ith 
c lin icopathological parameters, most probably due to d ifficu lties m easuring these low 
activity levels.
The observation that in normal m ucosa the level o f proM M P-2 is h igher in m ales than in 
fem ales has not been described before. Its relevance in cancer is doubtful because 
these differences are seen in normal tissue only, w here activities are very low, and do 
not pertain to active MMP-2. Also, the corre lations between proM M P-2 levels and other 
clin icopathological param eters do not result from a disbalance in gender.
The corre lation between tum our proM M P-9 levels and colonic location has not been 
found before. Zeng e t al. did not find corre lation between M MP-9 m RNA expression and 
location6. This probably means that the increased presence of the proenzym e is caused 
by upregulation at the translational level. W hile no fu rther s ignificant corre lations 
between M MP-9 activ ity and clin icopathological param eters in e ither tum our or normal 
tissue were found, a trend towards lower levels o f M MP-9 w ith advancing stage seem s 
apparent (Tab le  2). Using im m unohistochem istry such a trend has also been observed 
by Takeha e t al.34, who suggest that M M P-9 is, next to being a tum our-prom oting factor, 
also related to the host defence m echanism . The host reaction against the tum our 
counteracts hem atogenous m etastasis and local invasive growth. If so, early or slow ly 
invading and growing tum ours may trigger more explicit effects o f this host defence 
m echanism , in this case production o f MMP-9, than fast and diffuse invading tumours. 
W e have also perform ed assays on extracts from transitional tissue. These sam ples 
contain, next to tum our and adjacent normal tissue, the invasive edge. Since only 33 
m atched sam ples were available, analysis o f relations between MMP activ ity and 
clin icopathological param eters is not feasible. Transitional tissue and tum our tissue 
contain sim ilar levels of active MMP-2, -9 and broad-spectrum  MMP activity, w ith the 
first and latter being significantly h igher than those in distant normal mucosa. One could 
speculate that proteinase activ ity is h igher in the invasive edge than in the tum our 
centre and that overall activ ity in the extract from transitional tissue is lowered by the 
presence o f the normal tissue. However, it has been reported that the adjacent ‘norm al’ 
m ucosa also exhibits increased levels o f active MMP-2 and -925,27. Thus, any defin ite 
conclusions regarding proteinase activ ity in the invasive edge m ust await further 
analysis by means of, fo r instance, m icrodissection or in situ  zym ography. 
Broad-spectrum  MMP activ ity was m easured w ith a fluorogenic substrate assay. As 
w ith zym ography, increased activity is present in both tum our and transitional tissue. A  
variety o f M MPs may be responsible fo r this observation since the substrate is 
hydrolysed by all MMPs that exhibit gelatino lytic activ ity (e. g. MMP-2, -9 and -13). By 
the use of a specific MMP inhib itor as a control in this activ ity assay and the use of a 
general protease inhibitor, only actual active M MPs are m easured and not other
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proteinases or prote in-inh ib itor com plexes. This is an im portant d ifference w ith assays 
used by o thers18,26,35. The results obtained here indicate that in the tum ours studied 
MMP (production and) activation is elevated com pared to the production of TIMPs. This 
results in an excess o f free, active MMPs, which may contribute to the invasiveness of 
the tumour.
In summary, our results show increased levels o f MMP activity in tum our and 
transitional tissues com pared to normal m ucosa in CRC patients. Explicit differences 
between MMP-2 and MMP-9, w ith respect to both levels o f active enzym e and 
corre lations w ith clin icopathological parameters, strongly suggest different roles fo r the 
gelatinases in tum our progression. The results em phasise the necessity to collect data 
on the proteinase activ ity o f individual M MPs in order to develop suitable intervention 
strategies.
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Abstract
Background  M atrix m eta lloprote inases (MM Ps) have been reported to play an im portant 
role in tum our cell invasion and metastasis. B ioactivity o f MMPs in colorecta l cancer 
(CRC) liver m etastasis were investigated and corre lated w ith clin icopathological 
parameters.
M ethods  Thirty-two patients underwent resection o f CRC liver metastases. MMP latent 
and active form  w ere m easured in tissue extracts, using both quantita tive gelatin 
zym ography and a fluorom etric activity assay.
Results  Broad-spectrum  MMP activ ity and both active and latent form s of M MP-2 and -9 
were higher in the m etastatic tum our containing tissues than in normal liver tissue. 
M edian "m etastatic tissue to normal tissue” ratios w ere 15.0 and 17.6 fo r active and 
proMMP-2, respectively, while those fo r active and proM M P-9 w ere 6.2 and 2.9. Also, 
the ratios between active and latent enzym es were h igher in m etastatic tissue than in 
normal tissue. Analysis o f corre lations w ith clin icopathological param eters revealed that 
lowered M MP-2 activ ity is associated w ith large m etastatic lesions and increased 
proM M P-9 levels w ith preoperative chem otherapy. Also, both MMP-2 and -9 activity 
were unfavourably linked to early recurrent disease.
Conclusion  These data suggest a role fo r M MPs in CRC liver metastasis, but also 
indicate possible d ifferent roles fo r individual MMPs.
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Introduction
Liver m etastasis in colorectal cancer (CRC) is a serious event w ith no chance of 
survival when untreated1. So far, resection o f the liver m etastases is the m ost effective 
treatm ent modality, w ith a 5-year survival rate o f approxim ate ly 30% 1. Subsequent 
recurrence can be expected in up to two th irds o f the patients2. In order to improve 
future perspectives in this d isease and to develop new innovative therapeutic strategies, 
a better understanding o f the biological characteristics o f CRC m etastasis is needed.
The involvem ent of m atrix m eta lloprote inases (MMPs), a fam ily o f at least twenty zinc- 
dependent m atrix-degrading endopeptidases, in tum our progression and m etastasis is 
w idely acknow ledged3. Two m em bers from the M MP-fam ily, the gelatinases M MP-2 and 
-9, have been studied extensively because of the ir specific capacity to degrade collagen 
IV, the m ajor structural com ponent o f basem ent m embranes. In prim ary CRC the 
involvem ent o f these MMPs has been dem onstrated and deregulation is shown at 
various levels including transcrip tion4,5, secretion6, activation7 and inhib ition8,9.
The m ost com m on site of CRC m etastasis, representing also the largest problem in 
CRC, is the liver. So far, most o f the know ledge collected on the involvem ent o f MMPs 
in CRC has been related to the prim ary tumour. This has lead to therapeutic anti-cancer 
interventions using synthetic and natural MMP inhibitors, aimed at the MMP activ ity in 
order to stop or reduce prim ary tum our invasion and m etastasis fo rm ation10. Knowledge 
on MMP expression, localisation and protease activ ity in human liver and liver 
m etastases is lim ited but may be o f great im portance in determ ining the (patho-) 
physiological role o f M MPs in CRC m etastasis and in predicting d isease outcome. 
MMP-2 m RNA has been found in strom a cells close to m etastatic tum our cells and 
expression appears h igher in the m etastatic tum our tissue than in the adjacent normal 
liver tissue11. The sam e has been reported fo r M MP-9 mRNA, w ith positive peritum oural 
strom a cells being identified as m acrophages12. Convincing evidence on the cellu lar 
localisation o f the MMP-2 and -9 protein in CRC liver m etastasis is not yet available. 
S ince MMP m RNA expression and MMP im m unoreactiv ity do not reflect actual protease 
activity, m easurem ents o f bioactivity are needed to u ltim ately determ ine the biological 
role o f these proteases in m etastatic tumours. A lthough som e studies have reported the 
presence o f MMP activity in CRC liver m etastases5,11,13,14 none of them have presented 
quantita tive data. The aim of the present study is to provide such data on MMP 
bioactivity in liver m etastases from CRC patients. For this purpose, th irty-two extracts 
from m etastatic and m atched transitional and normal liver tissue were analysed by 
quantita tive gelatin zym ography and a fluorom etric  broad-spectrum  MMP activ ity assay. 
Correlations between clin icopathological param eters and the levels of active and latent 
form s of both MMP-2 and M MP-9 were investigated for the first time.
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Patients and methods
P a tie n ts  a n d  t is s u e  c o lle c t io n
Thirty-tw o patients who underwent resection or resection and ablation of CRC liver 
m etastases were included. T issue sam ples were obtained from twenty-six patients w ith 
prim ary liver m etastasis and from six patients w ith recurrent liver m etastasis. A ll patients 
provided written inform ed consent and the study was approved by the institutional 
ethical committee.
Im m ediate ly after m etastasectom y sam ples of m etastatic liver tum our (n=32), 
transitional tissue (n=27) and normal liver (n=32) were collected by a pathologist and 
frozen in liquid nitrogen. The transitional tissue is com posed of the invasive edge and 
the im m ediate surrounding tum our and normal liver tissue. T issue samples, cooled in 
liquid nitrogen, w ere m echanically pulverised using a M icro-D ism em brator (Braun, 
M elsungen, Germany), yie lding a hom ogenous powder. Sam ples were then extracted in 
buffer and stored at -80 °C until use.
T issue MMP activities were related to c lin icopathological characteristics. W hen 
applicable, grouping was according to Nordlinger e t a l.15.
G e la tin  z y m o g ra p h y
Gelatin zym ography was used to quantify the presence o f both activated and latent 
form s of MMP-2 and M MP-9 in tissue extracts. This analytical method, adapted from 
Heussen and Dowdle16, has been described previously7. The intra- and interassay 
coeffic ients of variation fo r this assay are 6.5%  (n=12) and 14.0% (n=6), respectively. 
Protein content was determ ined in all extracts, using a b icinchonin ic protein assay 
(Pierce, Rockford, IL, USA). Q uantification o f the proteinase activities, which were 
expressed as arbitrary units per mg protein on the basis o f lysed area, was perform ed 
using a Sharp JX-330 scanner and Im agem aster IDTM software (Am ersham  Pharm acia 
Biotech, Uppsala, Sweden). In-between com parison o f values obtained on different gels 
was perform ed using an internal standard. The presence o f true MMP activity was 
confirm ed by adding 10 mM EDTA or 1 mM 1,10’phenanthroline, both MMP inhibitors 
(Merck, Darmstadt, Germany), to the buffers used after electrophoresis. Human 
recom binant MMP-2 (1 ng/lane) and M M P-9 (0.5 ng/lane) (Oncogene Research 
Products, Cambridge, MA, USA) were added to com pare the ir localisation w ith 
endogenous activities (e.g. Fig. 1). Activation o f recom binant M MPs was achieved by 
incubation w ith 1mM p-am ino-phenylm ercuric acetate (APM A) (Sigma, St. Louis, MO, 
USA).
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Q u e n ch e d  f lu o re s c e n t s u b s tra te  h y d ro ly s is
Broad-spectrum  MMP activ ity was determ ined by using the quenched fluorogenic 
peptide substrate TNO 211-F (Dabcyl-G aba-Pro-G ln-G ly-Leu-Cys(F luorescein)-A la-Lys- 
NH2) (TNO, Leiden, The Netherlands) as described previously17. The substrate is 
cleaved by MMP-2, MMP-9, collagenase 3 (M M P-13) and to a lesser extent by 
collagenase 2 (MM P-8) and m em brane-bound m eta lloprote inase (M T1-M M P)18. The 
rate o f substrate conversion (RFU/s; relative fluorescence units per second) at 30°C 
(Aex: 485 nm, Aem: 530 nm; Cytofluor4000, PerSeptive B iosystems, Foster City, CA, 
USA) was norm alised to the am ount of protein present in each extract and expressed 
as RFU/s per mg protein.
S ta t is t ic a l a n a ly s is
Com parisons between MMP levels in m atched tumour, transitional and normal liver 
tissue were made using the W ilcoxon signed ranks test w ith downward adjustm ent of 
the P-value fo r m ultiple com parisons. Thus, d ifferences were considered significant 
when P<0.033 (using a’= 2a/k, a being 0.050 and k being the num ber o f com parisons 
made). The re lationship between MMP levels and clin icopathological param eters was 
analysed using the M ann-W hitney U-test. Here, d ifferences were considered significant 
at the P<0.050 level.
Results
Z y m o g ra p h ic  d e te c tio n  o f  M M P s in  CRC m e ta s ta se s
Six separate bands w ith gelatino lytic activ ity could be detected in the different tissue 
samples. All bands were com plete ly inhibited by EDTA or 1,10’phenanthroline, 
confirm ing the ir status as MMPs. Also, com parison w ith recom binant MMP-2 and -9 was 
used to identify bands representing the latent or active form of these gelatinases.
The two upper bands on the zym ogram  (F ig u re  1), w ith m olecular weights of 
approxim ate ly 220 kD and 135 kD represent, respectively, the hom odim er o f proM M P-9
19and the heterodim er of proM M P-9 and neutrophil gelatinase-associated lipocalin The 
next four bands on the zym ogram  represent proM M P-9 (92 kD), active M MP-9 (82 kD), 
proM M P-2 (72 kD) and active M MP-2 (62 kD). A lm ost all samples, including those from 
normal liver tissue, contained the latter four bands. On a photograph the gelatino lytic 
activity in normal tissue is som etim es d ifficu lt to see, but scanning revealed low levels of 
activity in most cases.
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Figure 1 Gelatinolytic MMP activity in human CRC liver metastases detected by quantitative 
zymography. MMP-2 (-): recombinant proMMP-2. MMP-2 (+): APMA-activated MMP-2. MMP-9 (-): 
recombinant proMMP-9. MMP-9 (+): APMA-activated MMP-9. M: liver metastases; M-NL: transitional 
tissues containing the invasive edge, including liver metastatic tumour tissue and normal liver; NL: normal 
liver. 1-3: case numbers of three representative patients presenting matched tissues. Positions of active 
MMP-2 (62 kilodalton (kD)), proMMP-2 (72 kD), active MMP-9 (82 kD) and proMMP-9 (92 kD) are noted 
by arrows.
In m etastatic tum our tissue the levels o f gelatino lytic activ ity o f active MMP-2 and -9 and 
proM M P-2 and -9 were significantly (all P<0.001) h igher than in normal liver tissue 
(F ig u re  2). Transitional tissue also had significantly h igher MMP activity levels than 
normal liver tissue (all P<0.001, execpt fo r proM MP-9, P=0.002), but the activ ity was 
lower than that in the m etastatic tum our tissue (all statistically significant, except active 
MMP-9; proMMP-2, P<0.001; active MMP-2, P=0.003; proMMP-9, P=0.008; active 
MMP-9, P=0.069).
The relative increase in activ ity between normal and tum our tissue is represented by the 
m etastatic to normal tissue ratio, and was higher fo r M MP-2 than fo r M MP-9 (Tab le  1). 
The active to proform ratio was determ ined fo r each gelatinase in the separate tissues 
(F ig u re  3). The active to proform ratios o f MMP-2 and M M P-9 w ere highest in 
m etastatic (median values: 0.31 and 0.08, respectively) and transitional tissue (median 
values: 0.36 and 0.10) and w ere all lower (P<0.033) in normal liver tissue (median 
values: 0.08 and 0.03, respectively). The active to proform ratios o f MMP-2 were higher 
than those o f M MP-9 in all three tissues exam ined (all P<0.010).
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The corre lation between the active form  and the proform was higher fo r MMP-2 than for 
MMP-9. The corre lation coeffic ients fo r MMP-2 in m etastatic tissue, transitional tissue 
and normal liver tissue were 0.87, 0.89 and 0.68, respectively; those for M M P-9 were 
0.52, 0.59 and 0.56, respectively. A ll corre lations were statistically s ignificant (P<0.050).
CNi
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Liver
metastasis
M-NL Normal liver Liver
metastases
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Figure 2 Comparison of MMP activities between matched liver metastases (n=32), transitional 
tissue (M-NL; n=27) and normal liver tissue (n=32), as measured by quantitative gelatin zymography. (A) 
active MMP-2; (B) proMMP-2; (C) active MMP-9; (D) proMMP-9. Horizontal bars represent median 
values, boxes the interquartile range and vertical lines the 10-90 per cent range. Gelatinolytic MMP 
activity was significantly higher in metastatic tumour containing tissues than in normal liver tissue. ** 
P<0.001, * P=0.002 versus normal liver (Wilcoxon signed ranks test, with downward adjustment for 
multiple comparisons; AU: arbitrary units).
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Table 1 T umour to normal liver ratios of MMP-2 and -9 activity in 
liver metastases from colorectal cancer
Tumor to normal liver ratio
Median Range
Active MMP-2 22 15.0 0.0 - 634.7
ProMMP-2 32 17.6 1.6 - 2334.7
Active MMP-9 29 6.2 0.0 - 111.5
ProMMP-9 32 2.9 0.5 - 10.2
Patient data were excluded when activity in normal liver equaled zero
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Figure 3 Ratio of active matrix metalloproteinase
(MMP) 2 and 9 to latent proenzymes in a liver 
metastases from colorectal cancer, b transitional tissue 
and c normal liver. Data were obtained by quantitative 
gelatin zymography. Horizontal bars represent median 
values, boxes the interquartile range and vertical lines 
represent the 10-90 per cent range * P<0.010 (Wilcoxon 
signed ranks test). Ratios were significantly higher for 
both MMPs (P<0.033) in tumour-containing tissues than 
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B ro a d -s p e c tru m  M M P a c t iv ity  a s s a y
M etastatic tum our and transitional tissue showed sim ilar broad-spectrum  MMP activities 
which were both significantly h igher (P<0.001 and P=0.003, respectively) than those 
m easured in paired normal liver tissue (F ig u re  4). The m etastatic tum our to normal liver 
ratio was 1.35 (median value).
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Figure 4 Broad-spectrum MMP activity in liver metastases (n=32), transitional tissue (M-NL; n=26) 
and normal liver (n=32). Data were obtained by fluorometric MMP activity assay and measured as relative 
fluorescence units (RFU) per second. Horizontal bars represent median values, boxes the interquartile 
range and vertical lines the 10-90 per cent range. **P <0.001, *: P=0.003 versus normal liver (Wilcoxon 
signed raks test with downward adjustment for multiple comparisons).
M M P a c t iv it ie s  a n d  c lin ic o p a th o lo g ic a l p a ra m e te rs
W hen com paring clin icopathological param eters w ith MMP levels in m etastatic tumour, 
transitional tissue and normal liver no significant differences were found fo r gender, age, 
or tim e of d iagnosis (synchronous vs m etachronous; sam ples from the six patients w ith 
recurrent disease w ere excluded). The degree o f d ifferentiation o f m etastatic tissues 
were also not related to MMP activity levels.
Tum our size showed a corre lation w ith MMP activity (T ab le  2). In m etastases o f 5 cm or 
sm aller both active (P=0.031) and proM M P-2 (P=0.040) levels were higher than in 
larger tumours. The sam e was true for active MMP-9, both in tum our (P=0.006) and 
transitional tissue (P=0.043). In normal liver tissue no relation w ith tum our size was 
found.
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Liver m etastases o f patients w ith elevated preoperative CEA serum levels (more than 5 
Mg/L) showed significantly h igher active MMP-2 levels in the transitional tissues 
(P=0.026). The levels o f proM M P-2 were also h igher in transitional tissue but this 
difference did not reach statistical significance. M M P-9 showed no relationship w ith 
CEA blood levels.
Table 2 Cinicopathological parameters o f liver metastases from CRC in relation to MMP-2 and -9 activity
na
Activeb
MMP-2
Pro-
MMP-2
Active
MMP-9
Pro-
MMP-9
Liver metastasis diameter (cm)
tumour
1-5 
> 5 
P
22
8
5.48
1.01
0.031*
16.28
7.12
0.040*
5.98
1.83
0.006*
73.45
43.29
0.097
transitonal
1-5 
> 5
P
19
6
2.30
0.29
0.106
5.87
2.38
0.246
3.36
0.91
0.043*
34.78
31.99
0.400
Preoperative CEA (ng/L) blood level
tumour
low (< 5.0) 
high (> 5.0)
P
13
19
3.71
4.34
0.545
11.12
11.83
0.970
3.65
5.45
0.495
61.62
73.21
0.343
transitional
low (< 5.0) 
high (> 5.0)
P
11
16
1.29
2.58
0.026*
3.06
9.04
0.148
2.91
3.33
0.451
32.90
38.83
0.942
Disease-free period (months)
tumour
short (1-5) 
long (6 or longer)
P
4
23
9.96
2.99
0.022*
26.65
10.77
0.095
14.96
3.70
0.095
109.58
63.78
0.095
transitional
short (1-5) 
long (6 or longer)
P
3
20
6.64
1.31
0.012*
14.99
3.15
0.035*
29.00
2.80
0.046*
133.07
31.97
0.026*
Preoperative chemotherapy
tumour
within 1-4 months 
none or not within 6 months 
P
9
20
4.03
4.73
0.694
10.77
11.66
0.729
10.20
3.68
0.532
91.84
49.82
0.026*
transitonal
within 1-4 months 
none or not within 6 months 
P
7
19
2.30
1.78
0.910
9.53
3.25
0.427
2.59
3.01
0.534
40.41
34.77
0.692
normal liver
within 1-4 months 
none or not within 6 months 
P
9
20
0.05
0.02
0.167
0.99
0.48
0.274
1.39
0.62
0.140
33.10
21.88
0.030*
a Only evaluable cases were included. b MMP activity in median values (arbitrary units/mg protein). 
Statistical significant differences are shown with an * (P<0.05). Mann-Whitney U-test for comparison of 
two groups.
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In order to exam ine the potentia l value o f MMP activity to act as a prognostic factor for 
the course o f d isease after m etastasectom y, data w ere grouped in relation to the 
disease-free period. For this purpose, data from patients who underwent incomplete 
m etastasectom y (n=3), defined by the presence o f tum our cells w ith in a 1 cm perim eter 
o f the plane o f resection, or who died w ith in a few  days after operation (n=2) were 
excluded from analysis. MMP levels in m etastatic tum our and transitional tissue were 
generally h igher in the patients having a short d isease-free period. Active MMP-2 levels 
were s ignificantly h igher (P=0.022) in tum our tissues from patients developing recurrent 
liver d isease w ith in six m onths after operation than in tum our tissues from those 
show ing recurrence at a later tim e or none at all. In the transitional tissues active MMP- 
2 and -9 and proM M P-2 and -9 were also significantly h igher in the early-recurrent 
m etastatic tumours.
The adm in istration o f chem otherapy w ith in  a four-m onth period preceding the 
m etastasectom y, raised m edian proM M P-9 levels in m etastatic tum our tissue (P=0.026) 
and in normal liver tissue (P=0.030). Chem otherapy did not a lter e ither active MMP-9 
nor active or proM M P-2 levels in any o f the tissues.
C lin icopathological param eters w ere also corre lated w ith tissue MMP activities, as 
m easured by the broad-spectrum  MMP activity assay. M edian activ ity levels in 
m etastatic tum our tissue were 1.41 RFU/s/m g protein in males and 1.68 RFU/s/m g 
protein in females. This difference in gender jus t reached statistical significance 
(P=0.047). In transitional tissue and normal liver no such difference was seen. O ther 
clin icopathological param eters did not corre late w ith broad-spectrum  MMP activity 
levels.
Discussion
CRC liver m etastases contain substantia lly elevated levels o f gelatinase and overall 
MMP activ ity as com pared to non-tum our liver tissue. The increase in activ ity is more 
pronounced for MMP-2 than for MMP-9. Also, the ratio between active and latent 
enzym es is h igher fo r MMP-2 than for M M P-9 in m etastatic tissue, transitional tissue 
and normal liver tissue. Gelatin zym ography has been used before, but only in a 
qualitative way, to exam ine gelatinase activ ity in CRC liver m etastasis. The presence of 
proM M P-2 and -9 has been dem onstrated in both m etastatic and normal liver tissue 
while active enzym es were only found in m etastatic tissue5,11,13. The present 
quantita tive approach confirm s these data, but also dem onstrates that normal liver 
tissue often contains low levels of the active form s from both MMP-2 and -9. High 
resolution scanning, im proved software and a different m ethodology (e.g. dialysis o f the
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extracts) may account fo r this finding. The presence o f active enzym es in all tissues is 
confirm ed by the present data from the broad-spectrum  activity assay and is in 
agreem ent w ith data from Am biru e t al., who found (using another assay m ethod) a high 
capacity fo r collagen type IV degradation in normal liver tissue20.
The increase o f MMP activ ity in m etastatic tissue com pared to normal tissue appears to 
be paralleled by increases in the respective m R N As11,12. The increased active to 
proform ratio o f both M MPs in m etastatic tissues is a new finding, also described very 
recently in prim ary CRC7, and pertains particularly to MMP-2. W hen regarding active 
form and proform as product and source, respectively, it suggests a tum our-re la ted  
change in the regulation of proMMP activation. In prim ary CRC it has been shown that
MMP-2 activation requires co-operation between tum our and strom a cells as well as
21extracellu lar m atrix com ponents21. It was also found that the m RNA expression o f the 
MMP-2 inhib itor TIM P-2 did not change while the M M P-2/TIM P-2 ratio increased. 
Enhanced expression and activity o f gelatinase activators like MT1-MMP, plasmin, 
MMP-1 and M M P-1322,23, changes in cell m atrix interactions or decreased expression of 
MMP inhibitors m ay all cause an increase in MMP activation in CRC liver metastasis, 
but so fa r data on these enzym es and interactions are unavailable.
Next to increased rates o f activation, the active to proform ratios are h igher fo r MMP-2 
than fo r M MP-9 in the tissues exam ined. This suggests a difference in proform 
activation between the two gelatinases. Both have been shown to d iffer at the
24 22
transcriptional level24, in the ir w ay of secretion and as substrates fo r activators22. 
Differences in the availability o f specific MMP activators or divergent m echanism s of 
regulation may be the cause o f this apparent distinction, which may suggest that MMP-2 
is the more effective protease in m etastatic tum our invasion and progression.
The few  studies reported so fa r on protease activities in CRC liver m etastasis have not 
addressed the ir re lationship w ith clin icopathological parameters. Such inform ation is 
quite relevant in determ ining the biological role o f M MPs in the process o f m etastatic 
tum our growth and development. Tum ours sized larger than 5 cm express lowered 
levels o f active and latent MMP-2 and -9 suggesting that larger tum ours have lost the ir 
momentum  in invasion and progression. In seem ing contrast is the finding o f a positive 
corre lation between size and disease recurrence and surv iva l15. However, review ing 
these data, Nordlinger e t al. found this not always to be true15. It may also reflect patient 
phenom enology rather than underlying biology. To clarify this issue it would be of 
interest to determ ine the protease activities in m icrom etastasis and small tum ours (< 
2cm).
A  high preoperative CEA level, in prim ary CRC, is related to an increased risk fo r future 
m etastatic d isease and can be indicative for undetected dissem inated d isease25. In 
search o f new tum our m arkers w ith prognostic value a corre lation between CEA and 
MMP activity would seem prom ising. In the present series, enhanced levels of active
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MMP-2 in the transitional tissue, which includes the invasive edge, corre late w ith high 
preoperative CEA serum levels.
The re lationship between MMP-2 and -9 activ ity and tum our recurrence has not been 
exam ined before. This parameter, even when analysed fo r 32 patients univariately, can 
be indicative o f its potentia l predictive value. The data show that both active and 
proform MMP-2 and -9 are s ignificantly enhanced in the m etastatic tissues o f tum ours 
that recur in liver w ith in six m onths after essentia lly curative liver m etastasectom y. The 
increase is most pronounced fo r the active form  of MMP-2 in tum our and transitional 
tissues. These results suggest that investigations into MMP activity may not only be of 
value in understanding tum our biology but may also yield a new tool fo r determ ining 
therapeutic strategies and prognosis.
Recent chem otherapy is shown to result in an increase o f proM M P-9 levels in both 
m etastatic and normal tissue, suggesting an effect that is not necessarily cancer 
specific. This increase can be the result o f an increased activ ity or presence of 
in flam m atory cells such as m acrophages and neutrophils which are known to express 
and secrete large am ounts o f proM M P-9 in response to stim ulation. Little is know about 
the effect of chem otherapy on MMP proteolysis but the data suggest an effect of 
uncertain specificity, which must be kept in m ind if the expression o f MMPs is 
investigated in patients treated w ith chem otherapy.
In conclusion we find increased enzym e activ ity and increased active to proform ratios 
o f both gelatinases in m etastatic and transitional tissues com pared to normal liver tissue 
in CRC liver metastasis. D ifferences are observed between the levels o f active enzym e 
of MMP-2 and MMP-9, which are also d ifferently corre lated to clin icopathological 
param eters. Both gelatinases are unfavourably linked to early recurrent disease. These 
results em phasise the im portance o f collecting data on proteinase activ ity o f individual 
M MPs to u ltim ately understand the biology o f CRC m etastasis and to develop ideas 
concerning intervention strategies and the ir use as prognostic indicators.
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Abstract
Background  P lasm a levels of M atrix M eta lloprote inases (MM Ps) m ay yield im portant 
inform ation in patients suffering from colorecta l cancer but the effect o f surgery, a 
com m on treatm ent m odality in these patients, on circulating MMP levels is currently 
unknown. The aim of this study was to assess w hether plasm a M MP-2 and MMP-9 
levels are affected by operative procedures.
M ethods  In total 128 patients undergoing elective surgery for colorecta l cancer (n=66), 
liver m etastases from colorecta l origin (n=50) and arthrosis o f the hip (n=12) were 
included in the study. G elatinase activ ity was m easured, using quantita tive gelatin 
zym ography, in plasma obtained before operation and one week, one m onth and three 
m onths postoperatively.
Results  One w eek after operation a significant increase in proM M P-9 activity was 
m easured after colorecta l surgery (260%, p=0.0038), liver surgery (285%, p<0.0001) 
and hip surgery (217%, p=0.012) as com pared to preoperative levels. A fte r one month 
proM M P-9 activ ity had returned to preoperative levels. No effect on proM M P-2 activity 
was measured.
Conclusion  Operative procedures have a profound but transient effect on plasm a MMP- 
9 activity. If used to assess disease status, postoperative plasma MMP levels should be 
interpreted w ith caution.
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Introduction
M atrix m eta lloprote inases (MM Ps) are a fam ily o f at least 23 z inc-dependent 
endopeptidases capable o f degrading and rem odeling all com ponents o f the 
extracellu lar m atrix (ECM). They are secreted as inactive pro-enzym es by a variety of 
cells, need activation prior to adequate function, are inhibited by 1:1 binding to specific 
tissue inhibitors o f M MPs (TIM Ps) and are involved in m any physiological and 
pathological processes1. The ir key-ro le in m alignant processes is evident from a 
theoretical point o f v iew  once realized that typical m alignant properties such as tissue 
infiltration, basal m em brane degradation, outgrow th o f m etastatic cells and 
ang iogenesis all require m assive ECM breakdown and remodeling. Indeed elevated 
tissue levels o f various M MPs have been shown in num erous m alignancies and their 
presence in colorecta l cancer both in the prim ary tum or and in m etastases is well 
established2-4.
The observation by Zucker and co-workers that plasma levels of M MP-9 are increased 
in patients w ith colorecta l cancer inspired m any authors to investigate the possibility of 
using circulating M MPs as a screening m ethod fo r detecting colorecta l cancer or to 
corre late certain panels of M MPs and TIM Ps w ith stage o f d isease and clinical 
outcom e5-7. Results o f these efforts so fa r have been conflicting, possibly due to 
different ways o f m easuring M MPs and TIM Ps (ELISA versus gelatin zym ography) or 
variations in blood sam pling (serum versus p lasm a)8,9
So far, the potentia l o f fo llow ing blood MMP levels to m onitor the (lack of) progress in 
tum or growth and to exam ine the effectiveness o f anti-cancer treatm ent has hardly been 
investigated. The only data available concern patients w ith adrenal tum ors10. Any use of 
plasma MMP activ ity to m onitor patients w ith colorecta l cancer may be ham pered by the 
fact that m ost o f these patients w ill have to undergo extensive surgery at som e point 
during the ir treatm ent. A  num ber o f M MPs appear to be upregulated during wound 
repair11 and therefore the ir levels in the circulation m ight (tem porarily) increase. This is 
im portant to know if blood MMP values are under consideration to be used in the 
assessm ent o f the status o f the disease. Since it is currently unknown w hether surgical 
procedures affect the activ ity o f plasma M MPs at all, w e have exam ined the gelatinase 
activity in pre- and postoperative sam ples from patients undergoing surgery for 
(advanced) colorecta l cancer and from patients w ith a benign disorder requiring m ajor 
surgery.
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Patients and methods
P a tie n ts
In total 128 patients requiring elective surgical procedures in our hospital w ere included 
in this study. Patients were divided into three categories: patients w ith colorecta l cancer 
(n=66; 27 women; m edian age 63 yrs; range 29-86), patients w ith liver m etastases of 
colorecta l origin (n=50; 15 women, 35 men; m edian age 61.5 yrs; range 26-78) and 
patients w ith arthrosis o f the hip jo in t (n=12; 11 women, one man; m edian age 67.5 yrs; 
range 56-86). None of the patients w ith in the latter group had a history o f cancer. 
O perative procedures included anterior resections, abdom inoperineal resections and 
sigmoid resections fo r patients w ith colorectal cancer, all form s of liver resections for 
patients w ith liver m etastases and placem ent o f total hip prostheses for patients w ith 
arthrosis o f the hip. A ll patients received prophylactic antib iotics prior to surgery. The 
presence of a m alignant colorecta l tum or or liver m etastases was confirm ed by 
histological exam ination o f the operation specim en from all patients.
Preoperative and 1 w eek postoperative blood sam ples were obtained in heparin 
containing anticoagulant tubes from all 128 included patients. From the 66 colorectal 
cancer patients a 1- and a 3-m onths postoperative blood sam ple was obtained in 33 
and 35 patients respectively and from the 50 patients w ith m etastatic liver disease in 35 
and 31 patients, respectively. A  1-month postoperative blood sam ple was obtained from 
all 12 arthrosis patients.
Blood sam ples were centrifuged at 5000 rpm fo r 10 min w ith in one hour after collection 
and plasma was stored at -80°C until analysis. Informed consent was obtained from 
each patient and all procedures were approved by the institutional ethics committee.
G e la tin  z y m o g ra p h y
Four ml o f heparin plasma was diluted in 16 ml T ris-buffer (50mM Tris, 0.2mM NaCl, 
5mM CaCl2 pH 7.5) and 20 ml sam ple buffer (0.125 M Tris-HCl, pH 6.8, 17.4% (w/v) 
glycerol, 4% sodium dodecylsu lphate (SDS) and 0.01%  brom ophenol blue). Five ml of 
this solution was loaded onto a 7.5%  (w/v) standard SD S-polyacrylam ide gel containing 
2 mg/m l gelatin (Type A: from  Porcine skin, Sigm a Chemical, St Louis, M issouri, USA) 
as a substrate. The electrophoresis was perform ed under non-reducing conditions w ith 
a M ini-Protean II (Bio-Rad, Hercules, CA, USA) at 15 m A per gel while stacking and at 
20 mA per gel during the separating phase until the blue stained front reached the 
bottom of the gel. A fte r electrophoresis, gels were washed three tim es in 2.5%  (v/v) 
Triton X-100 for 10 m inutes to rem ove SDS and washed tw ice in buffer containing 50 
mM Tris-HCl, 5mM CaCl2 and 0.1% Triton X-100 (pH 7.8). Subsequently the gels were 
incubated overnight at 37°C in the latter buffer, under gentle agitation. Zym ogram s were 
stained w ith 0.25%  (w/v) Coom assie Brilliant Blue R250 dissolved in 40%  methanol and
60
EFFECT OF SURGERY ON CIRCULATING MMP LEVELS
10% glacial acetic acid. Gels were destained in the sam e solution w ithout Coom assie 
Blue. C lear zones against a dark blue background, indicating lysis o f gelatin, visualized 
proteolytic activities. Loading o f the gels was such that proteinase activ ity was linear 
w ith gelatin lysis. Collagenase from  Clostridium  Histolyticum  (Type VII, Sigma 
Chem ical) was electrophoresed on each gel as an internal standard.
Q uantification o f the proteinase activities, expressed as arbitrary units per ml sample, 
was perform ed using a Sharp JX-330 scanner and Im agem aster ID software 
(Amersham, Pharm acia Biotech, Uppsala, Sweden). In between com parison o f values, 
obtained on different gels, was perform ed using the internal standard present on each 
gel. The presence o f true MMP activ ity was confirm ed by adding 10 mM EDTA or 1 mM 
1,10’phenantroline, both MMP inhibitors, to the buffers used after electrophoresis. The 
position o f the gelatinases was established by e lectrophoresis o f human recom binant 
MMP-2 (1 ng/lane) and M MP-9 (0.5 ng/lane; O ncogene Research Products, Cambridge, 
MA, USA). Activation o f the recom binant proform s was achieved by incubation w ith 1 
mM p-am ino-phenylm ercuric acetate (APMA).
S ta t is t ic a l a n a ly s is
Com parisons between preoperative and postoperative MMP levels were perform ed 
using the two-ta iled W ilcoxon m atched-pairs signed ranks test. Com parisons of MMP 
levels between different patient groups were perform ed using the M ann-W hitney U-test. 
D ifferences were considered statistically s ignificant when p<0.05. If m ultiple 
com parisons were made, pairw ise com parisons w ere done using a level o f significance 
o f a ’=2a/k, w here a=0.05 and k is the total num ber o f pairw ise com parisons.
Results
Gelatin zym ography revealed the presence o f the proform s of both MMP-2 and MMP-9 
in all patient plasm a samples. However, the active form s of the MMPs were not 
detected: no gelatino lytic activ ity was found at the positions o f the APM A-activated 
recom binant human standards. F ig u re  1 also illustrates, fo r two typical patients, the 
changing pattern observed after operation.
The m edian absolute plasma levels (with range) fo r both proM M P-2 and proM M P-9 in 
the three patient groups are represented in Tab le  1. It is remarkable, although w ithout 
relevance fo r the purpose o f the present study, that at all tim e points proM M P-2 and 
proM M P-9 levels were higher in the orthopedic patients than in the patients w ith 
colorecta l cancer or those w ith liver m etastasis. In neither o f the patient groups 
proM M P-2 levels changed w ith time. However, in all three groups the m edian values for
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plasma proM M P-9 m easured at one w eek after operation were s ignificantly h igher than 
those m easured before operation. A fte r one month, circulating levels appeared to be 
back to normal.
A B C D  E F G  H I J
Figure 1 Gelatin zymography of human plasma. Typical examples of plasma from patients 
operated for colorectal cancer (E-G) and liver metastases (H-J). Lanes represent samples obtained 
before operation (E and H), 1 week after operation (F and I) and 1 month after operation (G and J). 
Zymography of human recombinant MMP-2 and MMP-9 is shown before (A and C) and after activation by 
APMA (B and D).
Table 1 Plasma gelatinase activity
Preoperative 1 w eek 1 month
ProMMP-2
Arthrosis 258* (177-338) 228* (97-294) 271* (194-364)
Liver 134 (63-309) 126 (68-249) 129 (41-274)
CRC 138 (66-395) 130 (36-327) 152 (66-291)
ProMMP-9
Arthrosis 62 (16-185) 134a (14-218) 56 (17-222)
Liver 32 (2-171) 58b (10-276) 31 (5-238)
CRC 37 (5-235) 69c (6-270) 30 (9-166)
Median (with range) gelatinolytic activity in arbitrary units. *P<0.0001 versus liver and CRC groups; 
aP=0.012, bP<0.0001, cP=0.0038 versus preoperative levels.
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Because of the relatively w ide range of plasma MMP levels m easured between patients, 
the values in the postoperative sam ples from  each patient were also expressed as a 
percentage o f the level in the corresponding preoperative sample. If represented this 
w ay (F ig u re  2) it is clear that on the average plasma proM M P-9 activity was 
significantly increased seven days after operation as com pared to the preoperative 
values in patients receiving hip surgery (by 217%, p=0.012), liver surgery (by 285%, 
p<0.0001) and colorecta l surgery (by 260%, p=0.0038). None of the values m easured 
after one or three m onths was statistically different from preoperative values. For 
proMMP-2, no changes were observed after operation.
Discussion
M MPs and the ir inhib itors play a crucial role in the pathogenesis o f colorecta l cancer. 
The possib ility to m easure the ir activity in human blood has raised great interest in 
these enzym es since this opens the possibility to investigate the ir use as serological 
tum or markers. In order to be valuable as a means fo r follow-up, the influence of 
com m on treatm ent m odalities fo r colorecta l cancer on the activ ity o f MMPs in plasma 
has to be assessed. Since most patients w ith colorecta l cancer will have to undergo 
surgery at som e point during the treatm ent the influence o f surgery on MMP activ ity was 
determ ined in this study. ProM M P-9 activ ity in plasma is shown to be profoundly, 
although transiently, affected by surgical procedures while the activ ity o f proM MP-2 
rem ains unaffected.
Various explanations are possible w ith respect to the increased postoperative activity of 
proM M P-9 in plasma. Firstly, peroperative tissue handling o f tum or tissue, which is 
known to contain elevated levels of M M Ps2, m ay lead to spillage o f these MMPs into the 
circulation. However, the observation that proM M P-9 activity is elevated in a sim ilar 
m anner in patients undergoing hip surgery suggests that increased postoperative 
proM M P-9 activ ity should be regarded as an aspecific  response to m ajor surgery 
irrespective o f the underlying pathology.
Secondly, the healing wound m ay be regarded as the source fo r the increased system ic 
proM M P-9 activity. Tarlton and coworkers found elevated levels o f both proM M P- 2 and 
proM M P-9 in wound flu id early after colorecta l surgery. M M P-9 was increased 
im m ediate ly after operation and decreased to baseline levels after 4 days, while MMP-2 
was elevated later in the process12. A  sim ilar pattern was described for early wound 
healing after inguinal surgery13. Thus, leakage of wound flu id into the circulation one 
w eek after operation is expected to yield increased plasma levels o f proM M P-2 and
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baseline levels o f proM MP-9. S ince the opposite was found in the present study wound 
flu id seem s to an unlikely source of elevated plasma MMPs.
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Figure 2 Relative plasma gelatinase activity. Gelatinolytic activity of MMP-9 (gray bars) and MMP- 
2 (black bars) is expressed as percentage (mean+SEM) of the preoperative value for patients operated 
for athrosis of the hip (A), liver metastasis (B) and colorectal cancer (C). * P=0.012, ** P<0.0001,
*** P=0.0038.
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Finally, e levated MMP activ ity in plasma m ay be the result o f increased de novo 
synthesis as a response to surgery. Such a physiological system ic response may 
involve the release of pro-inflam m atory cytokines and growth fac to rs14. By signaling 
through the m itogen activated protein kinase (M APK) pathway these factors can 
eventually lead to activation o f the nuclear transcription factor AP-1. It has been 
proposed that activation of AP-1 is responsib le fo r maxim al activation o f MMP 
expression in response to stress. Interestingly, binding sites fo r AP-1 are present in the 
prom otor o f the M MP-9 gene while lacking in the gene of M M P-215. This phenom enon 
may explain the increased activ ity o f plasma proM M P-9 in response to surgery, and the 
absence of an effect on MMP-2, as found here. C irculating neutrophils are im portant 
sources o f proM M P-9 and are activated as part o f the in flam m atory response to 
surgery14. Therefore we suggest that the postoperative increase o f proM M P-9 activ ity in 
plasma is the result o f de novo synthesis by neutrophils as part of the physiological 
system ic response to surgical stress.
A  sim ilar pattern has recently been described by M ayers and co-workers who found 
elevated levels o f proM M P-9 in plasma and cardiac tissue of patients im m ediate ly after 
cardiac surgery. Interestingly, e levated levels of proM M P-2 w ere found in cardiac tissue 
but not in p lasm a16. Increased plasma M M P-9 activity a fter cardiac surgery has been 
confirm ed by others who hypothesize that increased MMP activity results from the 
system ic in flam m atory response to card iopulm onary bypass during surgery17,18.
A  finding which is not d irectly related to the above is the s ignificantly lower levels of 
proM M P-2 activ ity observed in the plasm a of patients adm itted fo r surgery for 
(advanced) colorecta l cancer as com pared to patients suffering form hip arthrosis. 
A lthough a com parison o f plasm a proM MP activ ity between the different patient groups 
was not the prim ary goal o f this study and groups were not m atched fo r gender and 
age, a decreased plasma level o f proM M P-2 may be a typical feature of patients 
suffering from  (advanced) colorectal m alignancy. This has been confirm ed in a next
19study w here this group has been com pared to a m atched group of healthy vo lun tee rs19. 
In conclusion, the present data show that proM M P-9 activ ity in plasma is tem porarily 
increased in response to surgical stress w hile  activ ity o f proM M P-2 is not affected. This 
finding m ay have im portant consequences fo r the possible use o f circulating M MPs as 
m arkers fo r the progression of various m alignancies. It illustrates that MMP activities in 
plasma can be affected by factors unrelated to tum or invasion and m etastasis. In 
particular, data on early postoperative MMP activity should be interpreted w ith caution in 
this respect.
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Abstract
Background  The matrix metalloproteinases and their inhibitors are known to be involved 
in the process of tumor invasion and progression. Our objective was to investigate the 
potential diagnostic and prognostic value of plasma matrix metalloproteinase-2, -9 and 
tissue inhibitor of metalloproteinase-1 in colorectal cancer.
M ethods  Gelatinase bioactivity and immunoreactivity of pro-matrix metalloproteinase-2, 
-9, tissue inhibitor of metalloproteinase-1 and carcinoembryonic antigen were 
determined simultaneously in preoperative plasma and serum of colorectal cancer 
patients (n=94) and in healthy controls (n=51).
Results  Plasma pro-matrix metalloproteinase-2 levels were lower in colorectal cancer 
patients (P<0.0001) than in controls and its gelatinolytic activity revealed inverse 
correlation with adverse clinicopathological parameters, such as lymph node 
involvement (P=0.017), stage (0, I, II vs III, IV; P=0.012) and the carcinoembryonic 
antigen level (P=0.016). Pro-matrix metalloproteinase-9 levels did not differ between 
patients and controls. Pro-matrix metalloproteinase-2 gelatinolytic activity showed 
potential value in colorectal cancer diagnosis, identifying patients with 70% sensitivity at 
95% specificity. Pro-matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 
and carcinoembryonic antigen all showed lower sensitivities. Combining pro-matrix 
metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 measurements 
increased the sensitivity significantly to 84%. With respect to prognosis, tissue inhibitor 
of metalloproteinase-1 showed value in predicting disease outcome in our patient group, 
whereas pro-matrix metalloproteinase-2 and -9 did not. The combination of tissue 
inhibitor of metalloproteinase-1 and carcinoembryonic antigen was better in predicting 
3-year survival than tissue inhibitor of metalloproteinase-1 alone, but it remains to be 
determined if the combination would be a better marker for survival than 
carcinoembryonic antigen alone.
Conclusion  Low pro-matrix metalloproteinase-2 levels and high tissue inhibitor of 
metalloproteinase-1 levels correlate with parameters of colorectal cancer disease. 
These correlations may be used in the search for new markers in colorectal cancer 
diagnosis and prognosis.
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Introduction
At the present there is no specific tumor marker with a high sensitivity for the diagnosis 
of colorectal cancer (CRC). Various prognostic markers have been reviewed by McLeod 
and Murray1 but they had to conclude that more studies are needed especially focusing 
on paneled markers in large numbers of patients preferably at a single disease stage. 
The family of matrix metalloproteinases (MMP) and its inhibitors, the tissue inhibitors of 
metalloproteinases (TIMPs), may harbor such markers and have been subject of recent 
investigations in this regard.
The MMP-family consists of at least 23 members representing a large class of zinc- 
dependent proteases involved in the degradation and remodeling of the extracellular 
matrix both in normal tissue development and in pathological conditions. One of these 
conditions is cancer and different MMPs are involved in its characteristic and repetitive 
cycle of tumor cell - extracellular matrix interaction, matrix degradation and tumor cell 
migration2. The gelatinases, MMP-2 and -9, in particular have been studied in this 
regard because of their specificity for breaking down the collagen of basement 
membranes3. The MMP enzymes are either secreted or transmembrane proenzymes 
requiring post-secretory activation. The TIMPs are the endogenous inhibitors of MMPs 
that form 1:1 complexes with the activated MMPs4 or their latent proenzymes5. Four 
members are currently identified, with TIMP-1 and -2 being characterized most 
extensively. Recently, Zeng and colleagues6 found a positive correlation between TIMP- 
1 mRNA level and advanced CRC stage. Subsequently, circulating TIMP-1 was 
reported to be a strong prognostic marker in determining patient survival7 and to display 
diagnostic sensitivity and specificity for detecting CRC8.
Knowledge on the diagnostic and prognostic value of MMPs in CRC patient blood, as 
measured by enzyme-linked immunosorbent assay (ELISA), is still scarce. Oberg9 
reported a limited prognostic value for the preoperative assay of MMP-2, MMP-9, TIMP- 
1 and TIMP-2. However, their study was performed on serum which may not be the 
right choice since such samples may mostly contain MMPs released in vitro as a result 
of clotting and/or neutrophil degranulation10,11. Zucker and colleagues analysed both 
MMP-9 and the MMP-9/TIMP-1 complex separately in plasma and found that the 
combination of both measurements may be clinically useful for predicting survival12,13. 
Moreover, in a recent study by Tutton e t al. plasma levels of both MMP-2 and MMP-9 
were suggested to be noninvasive markers of disease status during CRC follow-up14. 
Instead of measuring immunoreactivity by ELISA, one may also measure the bioactivity 
of MMP-2 and MMP-9 by means of gelatin zymography. This technique yields 
quantitative data on proteinase activity of both the active and latent forms of specific 
gelatinases. With regard to CRC this method has been used mostly on tissue extracts 
and hardly on plasma15,16. The latter reports neither pursue possible correlations
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between MMP activities and clinicopathological parameters nor do they explore the 
possible diagnostic and/or prognostic value of these measurements.
In the present study we have measured proMMP-2 and proMMP-9 gelatinolytic 
bioactivity and proMMP-2, -9, TIMP-1 and carcinoembryonic antigen (CEA) 
immunoreactivity in preoperatively collected plasma and serum samples from 94 CRC 
patients and related these values to clinicopathological parameters, diagnosis and 
prognosis. This study combines both types of measurements and examines the 
potential diagnostic and/or prognostic value simultaneously.
Materials and methods
P a tie n ts  a n d  c o n tro l s u b je c ts
Ninety-four patients with primary CRC were included in this prospective study. There 
were 57 men and 37 women with a median age of 63 years (range 28-86 years). Neo­
adjuvant therapy was given to 13 patients, all with cancer in the rectal area. One 
received both chemo- and radiotherapy and 12 patients were irradiated preoperatively. 
Postoperatively, 19 patients received adjuvant therapy (mostly chemotherapy); 17 of 
these were stage III patients. Tumor staging was according to the TNM-classification. 
There were three patients with stage 0, in situ  carcinoma (TisN0M0), 17 patients with 
stage I (T1-2N0M0), 30 patients with stage II (T3-4N0M0), 22 patients with stage III 
(TxN1-2M0) and 22 patients with stage IV (TxNxM1) disease. Patients were followed 
prospectively and dates of recurrence and causes of death were recorded. The median 
follow-up was 27.5 months (range 0-56 months). Within the follow-up period, 22 patients 
died of CRC and four patients died due to other causes. The control group consisted of 
51 healthy blood donors, 26 men and 25 women with a median age of 55 years (range
45-69).
B lo o d  c o lle c t io n s  a n d  s a m p le  p re p a ra tio n
Venous blood samples were obtained with informed consent from all individuals and 
with permission of the institutional ethical committee. All blood samples of CRC patients 
were drawn preoperatively. Heparin plasma was collected for zymographic analysis and 
the MMP-2 and TIMP-1 ELISA; ethylenediaminetetraacetic acid disodium salt-plasma 
was collected for the MMP-9 ELISA. Serum for CEA analysis was obtained from 75 
patients and 51 healthy donors. Plasma and serum were obtained after centrifugation at 
1500 g for 10 min. and stored at -80°C  prior to assay.
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Z y m o g ra p h y  (Z) a n d  E L IS A  (E) m e a s u re m e n ts
Zymography was used to quantify the proteolytic activity of the gelatinases MMP-2 and - 
9. ELISA was used to determine the immunoreactivity. According to the manufacturer, 
the antibodies used recognize both free and TIMP-complexed proforms, but not the 
active forms, of the gelatinases. Both analytical techniques thus recognize the free and 
TIMP-complexed forms of proMMP-2 and -9, therefore data obtained by zymography 
will be referred to as proMMP(Z) data and those obtained by ELISA as proMMP(E) 
data.
G e la tin  z y m o g ra p h y
The zymography process separates the MMPs from TIMP, but not dimeric MMPs or 
some other MMP complexes17. Since no active forms of the gelatinases were found in 
any of the plasma samples analysed, data reflect levels of free circulating proMMP plus 
its TIMP-bound complexes.
Zymography was performed as described previously18. Four ^  of heparin plasma was 
diluted in 16 ^  Tris-buffer (50 mM Tris, 0.2 mM NaCl, 5 mM CaCl2, pH 7.5) and 20 ^  
sample buffer (0.125 M Tris-HCl, pH 6.8, 17.4% (w/v) glycerol, 4% sodium 
dodecylsulphate and 0.01% bromophenol blue). Five ^  of this final solution was loaded 
onto the sodium dodecylsulphate-polyacrylamide gel.
ELIS A
Plasma MMP-2, MMP-9 and TIMP-1 concentrations were measured with commercially 
available, two-step, sandwich BIOTRAK™ ELISA kits (RPN 2617, RPN 2614 and RPN 
261, respectively, from Amersham Pharmacia Biotech, Uppsala, Sweden). The assays 
were performed in accordance with the manufacturer’s instructions. For the MMP-2 
ELISA heparin plasma was diluted 1:50 with assay buffer. For the MMP-9 ELISA 
ethylenediaminetetraacetic acid disodium salt-plasma was diluted 1:10 with assay 
buffer. For the TIMP-1 ELISA heparin plasma was diluted 1:40 with assay buffer. The 
assay recognizes free TIMP-1 and that complexed with MMPs. The sensitivity of these 
assays was 0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9 and 1.25 ng/ml for TIMP-1, 
respectively.
Serum CEA levels were measured by enzyme immunoassay (Axsym; Abbott 
Laboratories, Chicago, IL). The normal range for CEA is between 0.5 to 5 ng/ml.
S u rv iv a l a n d  d ise a se -fre e  p e r io d  a n a ly s is
The Kaplan-Meier method was used in the analysis of relations between MMP, TIMP-1 
and CEA levels with the length of survival and the disease-free period. Follow-up for 
these analyses was limited to 36 months. All 94 patients were included in survival 
analysis. The equality of survival distributions in patients with high and low plasma MMP
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or TIMP-1 levels were compared by stratifying patient data into two groups with the 
median being the cut-off value. The cut-off value for CEA was set at 30 ng/ml. The end 
point for survival analysis was death due to CRC.
Analysis of association between MMP, TIMP-1 and CEA levels and the disease-free 
period was performed on 71 of 94 patients. Patients with stage IV disease (n=22) and 
those with incomplete resection of the primary tumor (n=1) were excluded from analysis. 
Within the follow-up period 12 of 71 patients developed recurrent disease or 
metastases. Patient data were stratified into two groups (high and low) using the same 
cut-off values from the survival analysis. Separately, an analysis of MMP, TIMP-1 and 
CEA levels and disease-free period was also performed on stage 0, I and II patients 
(n=49).
S ta t is t ic a l a n a ly s is
The Mann-Whitney U-test and Kruskal-Wallis one-way analysis of variance with 
independent samples were used to test for differences between groups. In-between 
comparison was performed using Dunn’s post-test. The correlation coefficient according 
to Spearman (rs) was used to test for correlations. Sensitivity and specificity of MMPs, 
TIMP-1 and CEA for diagnosing CRC were summarized in Receiver Operating 
Characteristic (ROC) curves and the Areas Under the Curve (AUC). The 95% 
confidence intervals for the sensitivities at 95% specificity were calculated by the 
Fisher’s exact test. Differences between AUCs were estimated with the method of 
DeLong et al. for comparing correlated ROC curves19. When combining data of two 
potential markers, sensitivity and specificity were calculated by logistic regression. The 
Kaplan-Meier method was used in survival and disease-free period analysis and the 
log-rank test was used to test for equality between groups. All differences were 
considered statistically significant at the P<0.05 level.
Results
M M Ps, TIMP-1 a n d  CEA in  CRC p a tie n ts  a n d  c o n tro ls
In the plasma samples, from patients and controls, latent proform of MMP-2 and -9 was 
found with zymographic analysis, but no active forms. Zymography and ELISA both 
demonstrated significantly (P<0.0001) lower plasma levels of proMMP-2 and equal 
levels of proMMP-9 in CRC patients if compared to healthy controls (Tab le  1). TIMP-1 
and serum CEA were significantly (P<0.0001 and P=0.0001, respectively) higher in 
CRC patients.
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Zymography, which measures gelatinolytic activity, and ELISA, which measures 
immunoreactivity, yield data representing essentially different properties of the MMPs. 
Relatively weak correlations between both techniques were found for proMMP-2 in CRC 
(rs=0.256; P=0.013) and control plasma samples (rs=0.329; P=0.019), but correlations 
for proMMP-9 were virtually absent (rs=0.123; P=0.242 and rs=0.206; P=0.148, 
respectively).
Table 1 ProMMP-2, -9, TIMP-1 and CEA levels: Zymographic and ELISA data from crc patients and controls
Zymography (Arbitrary Units/ml) 
proMMP-2 proMMP-9
ELISA (ng/ml) 
proMMP-2 proMMP-9 TIMP-1 CEA
CRC 135 (66 - 395) 38 (5 - 236) 655 (369 - 1940) 10 (0 - 159) 966 (150 - 3842) 3 (<1 - 1200)
Controls 249 (151 - 340) 46 (17 - 97) 849 (456 - 1261) 14 (1 - 178) 756 (517 - 1178) 1 (<1 - 5)
P < 0.0001 0.390 < 0.0001 0.159 < 0.0001 0.0001
Results are presented in medians with the range in brackets. ProMMP-2 and -9 zymographic and 
proMMP-2, -9, TIMP-1 and CEA ELISA measurements were performed on 94, 94, 93, 93, 91 and 75 CRC 
patient samples, respectively, and on 51 control samples. Mann-Whitney U-test was performed for 
nonparametric comparison of two groups.
C o rre la tio n s  b e tw e en  M M P le v e ls  a n d  c lin ic o p a th o lo g ic a l p a ra m e te rs
ProMMP-2(Z) levels, as measured by zymography, were significantly (P=0.017) lower in 
patients with lymph node involvement (N1) than in those without (N0) (T ab le  2). 
Patients with a high serum CEA (>30 ng/ml) showed significantly (P=0.016) lower levels 
of proMMP-2(Z) than patients with a low serum CEA. A correlation between proMMP- 
2(Z) and stage of disease was only found when data from stage III and IV patients were 
taken together. The advanced stages showed lower levels than the earlier stages (0, I 
and II; P=0.012; not shown). ProMMP-2(Z) did not differ with age, sex, tumor size, depth 
of invasion (T-classification) or distant metastasis.
ProMMP-2(E) levels, as measured with ELISA, were inversely and weakly correlated 
with tumor size (rs=-0.215; P=0.043). However, when stratified into categories, as 
shown in Table 2, no significance was observed. ProMMP-2(E) levels depended on the 
presence of distant metastatic disease, as diagnosed at time of operation or within the 
next 6 months. With metastatic disease present, proMMP-2(E) levels were significantly 
(P=0.029) reduced. No other correlations were found.
Both proMMP-9(Z) activity and proMMP-9(E) immunoreactivity showed a weak inverse 
correlation with age. The correlation coefficients in patients and controls for proMMP- 
9(Z) were -0.298 (P=0.004) and -0.414 (P=0.003), respectively. For proMMP-9(E) the
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correlation was statistically significant in controls only (rs= -0.283; P=0.044). 
Furthermore, patients with tumors larger than 10 cm had significantly higher (P=0.030) 
proMMP-9(Z) activity than those with smaller tumors and patients with T3- and T4- 
classified tumors also showed significantly (P=0.002) higher plasma levels than those 
with other T-classification.
Table 2 Correlations between MMP and TIMP-1 levels and clinicopathological parameters in CRC patients
P aram ete r
Z ym ography ELISA
No.* p roM M P -2 proM M P-9 No proM M P-2 proM M P -9 No TIM P-1
T u m o u r size
< 5 cm 45 139 37 44 704 8 44 950
5 - 9.9 cm 35 129 34 35 656 8 35 979
10 cm  > 11 170 100 11 525 18 9 995
P 0.409 0.030 P 0.073 0.812 P 0.395
T  c lassifica tion
T is-1-2 26 145 24 26 697 12 26 928
T3-4 67 130 47 66 623 9 64 982
P 0.719 0.002 P 0.524 0.702 P 0.433
N c lass ifica tion**
N0 49 157 38 48 695 8 47 878
N1 22 115 58 22 682 5 22 932
P 0.017 0.301 P 0.747 0.289 P 0.709
D is tan t m e tas tases***
M0 66 138 39 65 702 7 64 888
M1 23 125 28 23 584 20 22 1362
P 0.530 0.294 P 0.029 0.045 P 0.000
Stage
0 3 162 59 3 702 28 3 725
I 17 1 42 35 17 656 7 17 931
II 30 1 65 46 29 702 9 28 879
III 22 115 58 22 682 5 22 932
IV 22 125 30 22 580 19 21 1385
P 0.110 0.294 P 0.250 0.133 P 0.000
C EA
<30 ng/m l 61 137 38 60 662 8 60 921
>30 ng/m l 14 95 23 14 580 19 12 1207
P 0.016 0.172 P 0.129 0.657 P 0.000
*Not all patients (n = 94) were included because of exclusion or missing data. **TxNxM1 patient data
were excluded in this parameter. ***M1 refers to patients with distant metastases at the time of operation 
or within 6 months postoperatively.
C o rre la tio n s  b e tw e en  TIMP-1 le v e ls  a n d  c lin ic o p a th o lo g ic a l p a ra m e te rs
In CRC patients and in controls TIMP-1 levels increased with age. Correlation was 
weak, but statistically significant (rs=0.286; P=0.006 and rs=0.336; P=0.016, 
respectively). Patients with distant metastatic disease had significantly (P=0.000) higher 
levels of TIMP-1 than those without distant metastatic disease (T ab le  2). Also, TIMP-1 
was correlated to tumor stage (P=0.000). After post-tests (not shown) patients with 
stage IV tumors were found to exhibit higher TIMP-1 plasma levels than patients with
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stage 0, I, II or III tumors (all P<0.01). TIMP-1 and CEA serum levels correlated 
positively and showed the highest correlation coefficient in this study: 0.459 (P=0.000). 
In patients with a high CEA (>30 ng/ml), TIMP-1 levels were higher than in patients with 
a low CEA (P=0.000).
S p e c if ic ity  a n d  s e n s it iv ity  o f  M M Ps, TIMP-1 a n d  CEA
The relationship between specificity and sensitivity of proMMPs, TIMP-1 and CEA 
measurements (ROC curves) in CRC diagnosis is illustrated in F ig u re  1. The ROC 
curves are based on the proMMP-2, -9 (Z and E), TIMP-1 and CEA levels in 94 CRC 
patients and 51 healthy donors. When analysing zymographic data at 95% specificity, a 
sensitivity of 70% was found for proMMP-2(Z). The sensitivity was much lower, 39%, for 
proMMP-2(E). The sensitivities for proMMP-9(Z) and proMMP-9(E) were 20% and 5%, 
respectively. For TIMP-1 and CEA sensitivities at 95% specificity were 56% and 43%, 
respectively. The AUC, which represents the diagnostic ability of a test, was highest 
(0.93) for the combination of proMMP-2(Z) and TIMP-1 levels (T ab le  3). This 
combination had a significantly increased AUC if compared to either proMMP-2(Z) 
(P=0.02) or TIMP-1 (P<0.0001) alone. For this combination the sensitivity, at 95% 
specificity, for diagnosing CRC was 84%.
100 - Specificity(%)
Figure 1 Reciever operating curves for plasma MMPs, TIMP-1 and CEA in patients with primary
CRC. I=combination of proMMP-2(Z) and TIMP-1; II=proMMP-2(Z); III=TIMP-1; IV=proMMP-2(E); 
V=serum CEA; VI=proMMP-9(Z); VII=proMMP-9(E). (Z) and (E) refer to analysis by zymography and 
ELISA, respectively.
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ROC curves and AUCs were also determined for early stage CRC. These were based 
on data from patients with stage 0, I and II CRC (n=50) and the healthy donors (n=51). 
For this group, somewhat lower but essentially similar sensitivities were found. 
Sensitivity, at 95% specificity, was 64% for proMMP-2(Z), 42% for TIMP-1, and 75% 
when both parameters were combined. Sensitivity, specificity and AUCs are 
summarized in Tab le  3.
Table 3 C alcu la ted  sens itiv ities  o f p roM M P -2,-9 ,T IM P -1 and C EA  fo r d iagnos ing  C R C  at 95%  spec ific ity
A na lys is
S tage 
o f d isease No.
S ensitiv ity  (% ) at 
95%  spec ific ity 95%  CI A U C SE 95%  CI
p roM M P -2 (Z )* A ll 94 70 60-79 0.89 0.026 0.83-0.94
p ro M M P -2 (E )t A ll 93 39 29-49 0.73 0.042 0.65-0.81
proM M P -9(Z ) All 94 20 13-30 0.46 0.047 0 .37-0 .55
proM M P -9(E ) All 93 5 2-12 0.43 0.047 0 .33-0 .52
TIM P-1 A ll 91 56 45-66 0.81 0.036 0.74-0.88
C EA All 75 43 31-55 0.70 0.046 0 .61-0 .79
proM M P -2(Z ) 0, I and II 50 64 49-77 0.86 0.037 0.79-0.94
proM M P -2(E ) 0, I and II 49 33 20-48 0.69 0.058 0.58-0.80
proM M P -9(Z ) 0, I and II 50 18 9-31 0.46 0.059 0.34-0.57
proM M P -9(E ) 0, I and II 49 0 0-7 0.41 0.057 0 .31-0 .53
TIM P-1 0, I and II 48 42 28-57 0.77 0.047 0.68-0.87
C EA 0, I and II 41 30 17-47 0.63 0.062 0 .51-0 .75
C om bination
proM M P -2(Z ) + TIM P-1 A ll 91 84 74-90 0.93 0.021 0.89-0.97
proM M P -2(Z ) + TIM P-1 0, I and II 48 75 60-68 0.91 0.029 0.85-0.97
AUC=ares under the curve; SE=standard error. (Z)* and (E)** refer to gelatin zymography and ELISA, 
respectively.
M MP, TIMP-1 a n d  CEA le v e ls  in  re la tio n  to  p a t ie n t p ro g n o s is
TIMP-1 and CEA, but not MMPs, correlated significantly with survival as shown by 
Kaplan-Meier curves (F ig u re  2). Patients with high TIMP-1 plasma levels (F igure 2E) 
exhibited a 3-years postoperative survival probability of 53% (95% CI, 36-69%), which is 
lower than that for patients with low circulating levels (92%; 95% CI, 82-101%). Thus, 
patients with high TIMP-1 levels had shorter survival (P=0.0003). Such correlation with 
survival was also shown for serum CEA (P=0.0000; Figure 2F). Panels of TIMP-1 
combined with proMMPs did not improve the prognostic value if compared to TIMP-1 
alone. This is illustrated by Figure 2G, which shows the difference in survival between 
patients with both high TIMP-1 and high proMMP-9(E) and those with both low TIMP-1 
and low proMMP-9(E). The combination of TIMP-1 and CEA (F igure 2H) yielded a result 
similar to that of CEA alone, and better that that of TIMP-1 alone.
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ng/ml (II). P-values by log-rank test are presented within the figures. AU:
Figure 2 Survival after 
resection for colorectal 
cancer. Each panel shows 
survival curves for groups 
selected on the basis of 
various preoperative
measurements. 
A=ProMMP-2(Z): activity < 
(I) or > (II) 135 AU/mg 
protein. B=ProMMP-2(E): (I) 
activity < (I) or > (II) 660 
ng/ml. C=ProMMP-9(Z): 
activity < (I) or > (II) 38 
AU/mg protein. D=ProMMP- 
9(E): activity < (I) or > (II) 10 
ng/ml. E=TIMP-1: activity < 
(I) or > (II) 970 ng/ml. 
F=CEA: serum levels < (I) 
or > (II) 30 ng/ml. G=TIMP-1 
and proMMP-9(E)
combined: TIMP-1 levels < 
970 ng/ml and proMMP- 
9(E) activity < 10 ng/ml (I) 
H=TIMP-1 and CEA combined: 
> 970 ng/ml and CEA levels > 30 
arbitrary units.
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The length of the disease-free periods among curatively operated patients (n=71) was 
similarly analysed but no differences were found between the disease-free periods and 
the levels of proMMPs, TIMP-1 or CEA. The median cut-off values used were the same 
as in the survival analysis. When analysing the disease-free period in early stage 
patients (0, I and II; n=49) alone, again no differences were found between high and low 
circulating levels.
Discussion
MMPs and their natural inhibitors have a proven role in tumor invasion and 
progression20. In this study, we supply and analyse preoperative levels of the circulating 
gelatinases MMP-2 and MMP-9, as measured by two different techniques, and TIMP-1. 
This approach has yielded new insight in the possible diagnostic and prognostic value 
of circulating enzyme levels in CRC. CRC patients exhibit lower levels of circulating 
proMMP-2, equal levels of proMMP-9 and higher levels of TIMP-1 than healthy controls, 
with late stage cancer patients showing more pronounced effects than patients with 
early stage cancer. It appears that the combination of proMMP-2, as measured by 
zymography, and TIMP-1 may be a more sensitive tool in CRC diagnosis than those 
available today. While the MMP levels have no prognostic value, TIMP-1 and CEA, 
analysed separately or in combination, are found both to be potential markers for 
predicting patient prognosis.
Using zymography, active forms of gelatinases have not been detected in plasma or 
serum, either in our study or in others. The active enzymes are almost uniquely found in 
tissue samples21,22. It is believed that in blood the amount of active forms constitute less 
than 1% of the total MMP levels23.
Under denaturing but non-reducing conditions, gelatin zymography detects both free 
and TIMP-complexed proforms of the gelatinases24. The same molecules are also 
recognized by the BIOTRAKtm ELISA system. The fact that weak correlations, at best, 
are found between both techniques may be explained by potentially different 
specificities towards the free and complexed proenzymes. In addition, dissociation of 
the proMMP/TIMP complexes by the detergent (sodium dodecylsulphate) may not be 
complete in the zymographic method22,24 and unsuspected ELISA reactivity towards 
dimers or other possible complexes of proMMP17,25 might also contribute to different 
findings between techniques.
The finding that plasma proMMP-2 levels, measured by either method, are lower in 
CRC patients than in healthy controls has not been reported before. Although MMPs 
have been investigated widely, reports on zymographic analysis of plasma samples,
80
PLASMA MMP AND TIMP-1 AS MARKERS IN COLORECTAL CANCER
comparing cancer patients with controls, are scarce and difficult to compare. The 
studies available so far use either a different sort of sample (serum or acidified plasma), 
constitute of small patient groups, compare patients with non-age-matched controls or 
exclude stage IV patients15,22. However, our observation of decreased levels of 
proMMP-2(E) corresponds to previous findings in serum9, as obtained by the use of the 
same ELISA system as employed by us. Interestingly, Oberg and colleagues have 
measured both free proMMP-2 and the proMMP-2/TIMP-2 complex separately and 
found that only the latter is lower in CRC samples. The BIOTRAKtm ELISA measures 
both forms and one may therefore speculate that the proMMP-2/TIMP-2-complex and 
not the free form dominates the results obtained by this assay. Tutton e t a l.14 measured 
comparable amounts of pro MMP-2(E) in plasma of CRC patients but found much lower 
levels in healthy controls. They used a different assay and substrate specificity may 
differ12, which may explain this discrepancy. Also, differences may exist between the 
control groups, e.g. with regard to age, or in the methods of blood sample collection11. 
Fujimoto and co-workers26 have used a similar ELISA system to ours and found free 
and complexed proMMP-2 serum levels to be lower in stomach and pancreatic cancer 
but higher in hepatocellular carcinoma. This indicates that differences between patients 
and controls may also depend on the type of cancer.
Biochemically and physiologically, the exact relationship between proMMP-2, TIMP-2 
and the activating membrane-bound MMP MT-1-MMP27,28 is still not fully elucidated, as
29are other interactions with biologically active molecules within the extracellular matrix29. 
Pozzi and colleagues30 found that reduced MMP-9 plasma levels resulted in decreased 
synthesis of angiostatin with consequent increase of tumor growth and vascularization. 
One could speculate that such mechanism may also apply to MMP-2. Still, as yet it 
remains difficult to draw conclusions pertaining to the precise role of proMMP-2 and the 
meaning of low circulating levels for CRC invasion and progression.
Low levels of proMMP-2(Z) appear to be associated with lymph node metastasis, stage 
(0, I, II vs III, IV) high CEA and low proMMP-2(E) with distant metastatic disease (Table
2). Although these correlations are only moderately related to staging they are in 
agreement with zymographic data from a previous study on CRC tumor tissue18 
demonstrating an inverse correlation between active and proMMP-2 with tumor staging. 
However, any comparison between findings on tissue and blood levels must be done 
with caution because complex formation, degradation and proform activation may well 
be different in these two compartments. Investigations into correlations between 
proMMP-2 ELISA data and clinicopathological parameters, and especially stage of 
disease, in other types of cancer have not revealed convincing discriminative value. 
This also seems to be true for CRC. Therefore, it appears that, for proMMP-2, 
zymographic data holds more promise for predictive value than that obtained by ELISA.
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Both proMMP-9(Z) and proMMP-9(E) plasma levels are similar in CRC patients and 
controls. Levels of proMMP-9(Z) activity in plasma have been reported in one previous 
study15 with a similar result. In contrast, others have found increased levels in CRC 
patients with ELISA12,14. Zucker and colleagues used a different immunoassay, included 
plasma samples taken both before and after operation, and compared results with non­
age matched controls, which may explain the apparent discrepancy with the current 
results. However, Sonnante e t al. have also used the Biotrak™ ELISA31. Possibly, their 
contrasting result may be explained by the different origin of control samples: while we 
have obtained plasma from age-matched healthy blood donors, they have collected 
blood from hospitalized subjects without cancer. Furthermore, the use of different 
plasma tubes may also contribute to variations in the levels measured11. Recently it was 
shown that the location of blood sampling, peripheral or from the portal vein, may also 
determine the levels found32. A more standardized analysis is required to allow 
meaningful comparison of ELISA data.
ProMMP-9(Z) levels increase with tumor size and tumor depth. These new observations 
correspond well to the biological function of the cellular sources of MMP-9, i.e. tumor- 
induced stroma cells and host inflammatory cells2. ProMMP-9(E) is increased in patients 
with metastatic disease, which result is sim ilar to earlier observations13. No correlation 
with stage has been reported in either study suggesting that this finding is more related 
to the presence of distant metastatic disease than to the characteristics of primary 
tumors at different stages of tumor progression. The inverse correlation of proMMP-9(Z 
and E) levels with age is an observation that is probably not directly related to the 
cancer process as it is found in both patients and controls. One could speculate that 
enhanced levels of MMP-9 in cancer are part of a host reaction against tumor presence. 
This reaction may be beneficial when tumor cells are attacked, but if only surrounding 
matrix is degraded tumor growth may even be facilitated. Much is still unknown about 
the physiological role of MMP-9 activity, its induction and its regulation.
The level of TIMP-1 in plasma is increased in CRC compared to controls and correlates 
with stage of disease. Also TIMP-1 is elevated in patients having high CEA serum 
levels. These findings are in agreement with previous studies on circulating TIMP-1 in 
CRC, using different kinds of ELISA systems8,33,34. The weak correlation with age, also 
reported before7,33, is found in both patients and controls suggesting a non-cancer 
related phenomenon. Due to the equal distribution within groups of other 
clinicopathological parameters and the relatively weak correlation we consider it to be 
without influence on our other findings. High TIMP-1 levels in cancer seem in 
contradiction with the expected anti-invasive activity of this inhibitor. However, recent 
studies show additional, although still poorly characterized, biological activities of TIMP- 
1, such as growth stimulation and inhibition of apoptosis35,36, which may act
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independently from its expected antiproteolytic activity and may contribute to its 
correlation with cancer.
The correlation between TIMP-1 plasma levels and CRC found in the present study 
suggests a moderate ability to discriminate the CRC patients from healthy persons. The 
sensitivity at 95% specificity is considerable and in agreement with results from Holten- 
Anderson and colleagues8. However, the proMMP-2(Z) plasma level appears to 
correlate stronger with disease presence, and combining both proMMP-2(Z) and TIMP- 
1 enhances this correlation even further, resulting in a test with 84% sensitivity at 95% 
specificity. Such good performance is also found when only the early stage cancer 
patients are included, which affirms the importance of this finding. However, it should be 
emphasized that our data have been obtained by analysing preoperative samples from 
symptomatic patients and also that these variables, as yet, do not specifically select 
patients who could benefit from selected therapy, such as for example adjuvant 
chemotherapy. Evaluating the TIMP-1/proMMP-2(Z) combination in a prospective 
screening population, which includes also other types of gastrointestinal disease, such 
as inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis), adenomas, 
gastritis, etc. might result in a different sensitivity or specificity. As a reference, the 
sensitivity should have a range better than 50 to 83% at 98% specificity, which is
37displayed by the faecal-occult-blood test currently used as a diagnostic tool37.
Next to its correlation with the presence of CRC disease, the correlation of TIMP-1 with 
survival has been confirmed. Previous studies have reported increased tissue TIMP- 
1mRNA expression in CRC38, breast cancer39 and lung cancer40, in association with 
poor patient survival. Similar results have been found for circulating TIMP-1 levels, 
measured by ELISA, in different types of cancer34,41. These studies are all single marker 
studies. The present data, extending those of Holten-Anderson8, suggest that TIMP-1, 
in a panel with CEA, may be a better marker for predicting survival than TIMP-1 alone 
or any combination of TIMP-1 with MMPs. It remains to be demonstrated if TIMP-1 in 
combination with CEA has better predictive value than CEA on its own.
C o n c lu s io n s
The present study shows that gelatinolytic proMMP-2 activity, alone or in a panel with 
TIMP-1, correlates with the presence of CRC disease, and may be of value in CRC 
diagnosis. We have demonstrated that TIMP-1, and not MMP-2 or -9, has potential to 
be a marker for predicting patient survival. In order to evaluate the clinical significance 
of these findings and their potential in the diagnosis of CRC, different gastrointestinal 
diseases and non-symptomatic cancers should be included. ProMMP-2 must be studied 
both as a single marker and in a panel with TIMP-1, CEA and other potential markers. 
Finally, potential prognostic markers should be studied in larger and more diverse
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patient groups than presented here, in order to ultimately determine their value at any 
stage.
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Abstract
Background  To investigate if plasma matrix metalloproteinase (MMP)-2 or -9 are better 
markers for disease activity than carcinoembryonic antigen (CEA) in the postoperative 
follow-up of colorectal cancer patients.
M ethods  A  prospective study was performed including 61 patients operated for primary 
colorectal cancer. The follow-up was for at least 2 years and postoperative blood 
samples were obtained periodically with 3-month intervals. Plasma gelatinase activity 
was measured with quantitative gelatin zymography and serum CEA with a specific 
immunoassay.
Results  Zymographic analysis of plasma samples revealed the presence of the 
proforms, but not the active forms, of both MMP-2 and -9. Prior to the detection of 
recurrent disease or metastasis in potentially curatively operated colorectal cancer 
patients, the changes in proMMP-2, -9 and CEA blood levels were determined. 
ProMMP-2 and -9 plasma levels changed little in this period and changes between 
patients with and without disease relapse were not statistically significant. In contrast, 
patients with disease relapse showed a significant increase (P=0.002) in CEA in the two 
consecutive serum samples prior to the detection of recurrent disease or metastasis. 
Similarly, prior to death due to colorectal cancer, proMMP-2 and -9 plasma levels 
showed no significant change, whereas CEA levels increased considerably and 
significantly (P<0.001) when compared to changes found in survivors.
Conclusion  Plasma proMMP-2 and -9 activities show no potential value as prognostic 
markers in the follow-up of colorectal cancer.
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Introduction
Colorectal cancer is one of the most frequently occurring forms of cancer in developed 
countries and is the third most common cause of death from cancer after lung cancer 
and prostate or breast cancer1. After curative surgery about 40-50% of patients still die 
of recurrent disease and metastasis2,3. Early diagnosis of cancer can improve the 
overall survival and it seems to be expected that patients could also benefit from the 
early discovery of recurrent local disease and metastasis. More accurate information on 
the disease status and earlier discovery of recurrent disease would allow the 
assignment of patients to specific treatment options such as repeated surgery, systemic 
chemotherapy or even more aggressive or experimental therapy, which are all 
modalities potentially capable of increasing the length or rate of survival in colorectal
4-6cancer4 6.
The discovery of recurrences or metastases prior to their clinical manifestation is not a 
simple task and at the moment no adequate tools are available in colorectal cancer. The 
best prognostic tumor marker as yet appears to be the carcinoembryonic antigen (CEA). 
While the CEA serum level provides some prospective information on disease status, 
especially regarding the presence of metastatic disease, its sensitivity for local regional 
recurrences is low7. Also, at best, only a modest survival advantage has been reported 
in follow-up programs using CEA7,8. Still, new prognostic tumor markers should at least 
prove to be better than CEA.
Many bioactive and genetic marker molecules can be considered as potential 
prognostic markers, but a logical option would be to search among those molecules that 
are specifically necessary for the invasive process. One possible advantage, above 
molecules chosen more randomly, is that when efficacy is proven they may also be 
targets for anticancer therapeutic strategies. The matrix metalloproteinases (MMPs) 
could be such markers2,9.
The MMP-family consists of at least 21 closely related members with proteolytic activity 
and is involved in the invasive process of many types of cancer including colorectal 
cancer9. The MMPs are collectively capable of degrading essentially all components of 
the extracellular matrix in normal and abnormal cell physiology. Among the various 
subgroups of MMPs, i.e. the collagenases, stromelysins, matrilysins, gelatinases, 
membrane-bound MMPs and others, the gelatinases MMP-2 and -9 are believed to be 
the most crucial in tumor invasion and metastasis because of their capacity to degrade 
collagen type IV10, an essential component of the basement membrane, which is the 
first barrier in cancer invasion. So far, in colorectal cancer the diagnostic and prognostic 
value of MMP-2 and -9 measurements have been studied largely in tissues obtained at 
operation and in preoperative blood samples.
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In order to find new and better prognostic markers, various biomarkers have been 
studied in the follow-up of cancer, as and attempt to monitor the disease11-13. 
Consecutive postoperative measurements may yield additional information pertaining to 
the development of recurrences, metastatic disease and patient survival. There are no 
published reports as yet on the value of circulating MMP-2 and -9 activity in the 
postoperative follow-up of colorectal cancer. As a means to assess their potential in this 
respect, we performed a prospective study on a limited number of patients. MMP-2 and 
-9 activities were, together with CEA levels, measured in consecutive blood samples 
after curative surgery for colorectal cancer. Changes in activity were investigated for 
correlation with the development of recurrent disease and association with survival.
Materials and methods
P a tie n ts  a n d  b lo o d  s a m p le s  c o lle c t io n
Sixty-one patients (35 male) with histologically verified colorectal cancer were included 
in this prospective study. The mean age of patients at the time of surgery was 63 years 
(range 34-86). The distribution of disease stage was as follows: 16 patients with stage 
0/I, 24 with stage II, 14 with stage III and 7 with stage IV disease. Follow-up 
investigations and blood sampling were integrated in a regular surveillance program 
shown in F ig u re  1. Blood samples were not collected within the first 30 days after 
surgery because of possible influence of the operative procedure14. The median length 
of postoperative follow-up was 30.9 months (range 5.5 -  55.9). All patients provided an 
informed consent and the study protocol was approved by the institutional ethics 
committee.
The changes in the levels of MMP-2, -9 and CEA in the circulation were studied prior to 
disease relapse or death due to cancer. Essentially, patient blood samples were 
obtained every 3 months and the change in circulating levels follows from the difference 
between two consecutive samples. The plasma and serum samples considered in this 
study were all obtained within the first 2 years after operation.
Disease relapse was studied in 50 out of the 61 patients, excluding stage IV patients 
(n=7) and patients with incomplete data (n=4). From the 50 patients, 5 developed local 
recurrent disease and 2 developed metastases to the liver within 2 years after 
operation. The median period to disease relapse was 11.3 months (range 4.6 -  15.0). 
The changes in circulating levels were investigated prior to clinical detection. For this 
purpose the two closest samples preceding the diagnosis of disease recurrence were 
taken (median period of sampling: 6.0 months after operation; range 4.5 - 10.5), and
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compared with changes in consecutive samples of patients without disease relapse 
(n=43), obtained in a similar period of time after primary operation.
Survival was studied in 54 out of 61 patients, excluding 7 patients with incomplete data. 
Six of the 54 patients died due to colorectal cancer within 2 years after operation; their 
median survival was 14.7 months (range 5.5 - 23.6). The change in circulating levels in 
the nonsurvivors was investigated in the period prior to death (median period of 
sampling: 9.0 months after operation; range 1.5 - 13.5) and compared with the changes 
found in samples of surviving patients (n=48), obtained in a similar period of time.
Diagnosis Surgery 0 -  30 days
Consecutive samples taken at:
postoperatively
31 -  140 
days
3
months
3
months
Every 3 
months
H 1T IT
s1 s2 s3 s4-s8
Follow-up period of at least two years
Figure 1 Schedule for postoperative blood sample collection. s = Sample.
G e la tin  z y m o g ra p h y
Gelatin zymography was used to quantify the presence of activated and latent forms of 
the gelatinases MMP-2 and -9. Zymography was performed as described previously15. 
Four microliters of heparin plasma was diluted in 16 Ml of Tris-buffer (50 mM Tris, 0.2 
mM NaCl, 5 mM CaCl2, pH 7.5) and 20 Ml of sample buffer (0.125 M Tris-HCl, pH 6.8, 
17.4% (w/v) glycerol, 4% sodium dodecylsulfate and 0.01% bromophenol blue). Five 
microliters of this final solution was loaded onto the sodium dodecylsulfate- 
polyacrylamide gel.
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CEA E LIS A
Serum CEA levels were measured by enzyme immunoassay (Axsym; Abbott 
Laboratories, Chicago, Ill., USA). The normal range for CEA in healthy controls is 
between 0.5 and 5 ng/ml.
S ta t is t ic a l a n a ly s is
The Wilcoxon matched-pairs signed-ranks test was used for differences between 
consecutive samples. The Mann-Whitney U-test was used to test for differences 
between patient groups. All differences were considered statistically significant at the 
P<0.05 level.
Results
C irc u la tio n  m a rk e rs  p r io r  to  d ise a se  re c u rre n c e  a fte r  s u rg e ry  fo r  c o lo re c ta l 
c a n c e r
In contrast to our earlier findings in tissue extract15, no active forms of the gelatinases 
were found in any of the plasma samples analysed (F ig u re  2) and therefore the data 
reflect the gelatinolytic activity of proMMPs.
MMP-2 MMP-9
- + - +
M  *  j  ' ' ’
Figure 2 Gelatinolytic activity in plasma samples from colorectal cancer patients as detected by 
quantitative zymography. Also present are recombinant proMMP-2 and -9, before (-) and after (+) 
activation with p-amino-phenylmercuric acetate. 1-3 represent samples from a control patient (1), a 
patient with disease relapse (2) and a patient not surviving the observation period (3), respectively; both 
the second last (a) and final (b) samples are shown.
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Both plasma proMMP-2 and -9 activities appeared to rise between the last two 
consecutive samples collected prior to the confirmation of disease recurrence (F ig u re
3). However, while the median percentage increase of proMMP-2 and -9 activity was 18 
and 76%, respectively, variation between the 7 patients was high. In the 43 patients 
without disease recurrence in the follow-up period, the median change, observed in a 
similar postoperative period, was -1% for proMMP-2 and -2%  for proMMP-9, 
respectively. Since in the latter group a number of patients also exhibited a substantial 
increase in plasma gelatinase activity, and therefore again variations were fairly large, 
the apparent difference with the group of patients with an established recurrence 
remained nonsignificant (P=0.520 and P=0.317 for proMMP-2 and -9, respectively).
Disease Disease
Figure 3 Changes in circulating proMMP and 
CEA in patients with and without recurrent 
disease. Data represent the percentage change of 
proMMP-2 and -9 activity and CEA 
immunoreactivity between consecutive blood 
samples in 7 patients with recurrent disease (left) 
and in 43 patients without recurrence (right) in the 
follow-up period. Horizontal bars represent the 
median values, boxes represent the interquartile 
range, and vertical lines represent the 5-95% 
range of the observations. *P<0.05; ns = not 
significant.
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CEA serum levels in the patients with disease recurrence were significantly elevated 
(P=0.031) in the final sample prior to its diagnosis (mean: 4.7 +/- 6.5 ng/ml) if compared 
to the second last sample (mean: 2.5 +/- 1.9 ng/ml). In patients without recurrence there 
was no difference between these values (1.7 +/- 1.2 ng/ml vs. 1.7 +/- 1.6 ng/ml). As a 
consequence, the median percentage increase in CEA serum levels in the 7 patients 
with recurrent disease was 33%, which was significantly (P=0.002) greater than that 
observed (0%) in the same time frame in the 43 patients where no recurrent disease 
was found during the follow-up period.
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Figure 4 Changes in circulating proMMP and 
CEA in nonsurvivors and survivors. Data represent 
the percentage change in proMMP-2 and -9 activity 
and CEA immunoreactivity between consecutive 
blood samples in 6 patients who died of colorectal 
cancer (left) and in 48 patients that survived (right) 
the follow-up period. The observation period was for 
at least 2 years. Horizontal bars represent the 
median values, boxes represent the interquartile 
range, and vertical lines represent the 5-95% range 
of the observations. *P<0.05; ns = not significant.
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C irc u la tio n  m a rk e rs  p r io r  to  dea th  a fte r  s u rg e ry  fo r  c o lo re c ta l c a n c e r
Six out of 54 patients died within 2 years after primary operation. Prior to death, these 6 
patients showed no difference in proMMP-2 and -9 activity between two consecutive 
samples. The samples were taken as closely as possible to the event of death, and at 
least within the final year. The median percentage changes in proMMP-2 and -9 activity 
in the nonsurvivors were 0 and -43% , respectively. These changes were statistically not 
different to those observed in a corresponding time frame in the 48 patients who did 
survive the follow-up period (6% and 2%, respectively; F ig u re  4).
In contrast to the gelatinase levels, CEA serum levels in the nonsurvivors were 
significantly (P=0.031) higher in the final sample than in the second last sample prior to 
death. Consecutive samples from survivors, collected within a corresponding 
postoperative time period, showed no changes. Thus, the median percentage increase 
in CEA serum levels in nonsurvivors was 118%, which was significantly (P<0.001) 
greater than that measured in survivors (0%; F ig u re  4).
The difference in the postoperative course between blood gelatinase activities on the 
one hand and the CEA level on the other is illustrated in F ig u re  5  for 2 patients who did 
not survive the observation period.
Figure 5 Postoperative blood gelatinase activities and CEA level in 2 patients (A and B) who did 
not survive the observation period. s1 = the first blood sample after operation, is set at 100%; o = 
ProMMP-2; ■ = ProMMP-9; ▲ = CEA.
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Discussion
A valuable prognostic marker is a variable that provides prospective information on the 
patient outcome, is complementary to pathological data from diagnostic samples and 
guides therapeutic decisions. In colorectal cancer, survival and recurrence of disease 
are closely related to the stage of the disease at the time of diagnosis4,16-18. Moreover, 
the depth of invasion and infiltration of lymph nodes or distant organs, defined in TNM 
staging, are the current variables that determine treatment strategy in clinical practice. 
Many studies on tumor markers aimed to find better prognostic markers at the time of 
diagnosis with the intent to improve patient selection for specific follow-up programs. 
However, until now, no variable has been found that surpasses the stage of the disease
19as a prognostic facto r19.
Preoperatively, and in postoperative follow-up, there may exist better alternatives in 
selecting treatment strategies than the stage of the disease. CEA has a low 
preoperative prognostic value but has been recommended for postoperative 
surveillance20,21. In a meta-analysis it was shown that an intensive follow-up program
that included CEA measurements improved the 5-year survival by 9%8. However, other
22studies have shown only marginal improvement in survival, or none at all22. Ideally, a 
prognostic marker would only predict those recurrences that can be operated on with 
curative intent and allow an individualized follow-up. CEA as a marker does not posses 
these characteristics23 and therefore we have investigated the possible prognostic value 
of plasma MMP activity, using CEA as a reference marker.
The idea that MMPs could be candidates for determining prognosis in the follow-up of 
colorectal cancer stems from data on tissue samples and preoperative blood samples, 
obtained also in other types of cancer. In colorectal cancer, the mRNA expression of 
MMP-2 and -9 in tumor tissue have been reported to correlate with the tumor stage24-26.
Total type IV collagenase activity (i.e. MMP-2 and -9) in tumor tissue was higher in
18patients with recurrent disease than in those without recurrences18. With regard to 
preoperative blood levels, most data represent immunoassays and appear to 
demonstrate encouraging results for MMP-9 as being potentially useful in predicting 
survival27,28. In addition, MMP-2 or -9 purportedly show potential value as predictors of 
recurrence and metastasis in urothelial, ovarian, pancreatic, hepatocellular, lung and 
breast cancer9. When surveying these results, it certainly seems worthwhile to pursue 
the idea that MMPs may predict presymptomatic recurrences or metastases.
The present analysis, based on postoperative data obtained from a limited but 
representative group of colorectal patients, comprises the first attempt to investigate the 
use of circulating MMP bioactivity in the follow-up of cancer. For the reference marker, 
CEA, we found changes in serum levels to be highly correlated with disease recurrence 
and death due to colorectal cancer. These results are in agreement with previous
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studies by others on the value of CEA as a prognostic marker29,30. In the present series, 
a substantial rise in CEA levels was observed in consecutive samples, both prior to the 
detection of recurrent disease and prior to death due to colorectal cancer.
However, neither proMMP-2 nor -9 activity in plasma appears to be of value for 
monitoring disease status in patients operated for colorectal cancer. ProMMP-2 activity 
in consecutive samples changed only mildly and was not related to the course of 
disease. ProMMP-9 activity levels changed more widely, the median value being higher 
prior to relapse and somewhat lower before death, compared to controls. Still, changes 
were not significantly different from those in patients without relapse or in surviving 
patients. The latter indicates that proMMP-9, like proMMP-2, has no potential value as a 
prognostic marker in colorectal cancer follow-up.
This result may be disappointing and, in the light of the literature mentioned above, 
unexpected. Still, it is entirely conceivable that tumors grow and invade tissue, using 
MMPs to degrade matrix, without 'spill over' of enzyme activity into the circulation, that 
is, to such extent that significant changes occur.
Oberg e t al.31 reported only a limited value of preoperative serum analyses of MMP-2 
and -9 immunoreactivity for tumor staging and prognosis, while our own data32 on 
enzyme activity in preoperative plasma suggest no prognostic value for MMP-9 and only 
potential diagnostic value for MMP-2. On the tissue level, it has been reported that MMP
33enzymatic activity is not related to disease-free 5-year survival33 and that there is no 
correlation between tumor cell MMP-2 or -9 immunoreactivity and tumor stage or overall 
survival in colorectal cancer patients34. Thus, while the involvement of MMP activity in 
tumor growth and metastasis appears undisputed, conflicting data are still being 
generated as to the suitability of this class of enzymes to act as markers for disease.
In conclusion, we have demonstrated that the plasma proMMP-2 and -9 activity does 
not change particularly prior to disease relapse or death due to colorectal cancer and 
therefore we expect no prognostic value of these tumor-related variables. The fact that 
the CEA level rises in these periods confirms its status as a sensitive marker of disease 
recurrence. When placing the intricate problem of predicting the course of diseases into 
perspective, one must keep in mind that, if a marker with high prognostic value is found 
and implemented in regular surveillance its benefit to survival still depends to a large 
extent on the treatment options at hand. Therefore, the search for better prognostic 
markers must coincide with the development of new therapeutic strategies.
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CHAPTER 7
Abstract
Background  The degradation of the extracellular matrix is intrinsic to the invasion and 
progression of cancer. Matrix metalloproteinase (MMP)-2 and -9 and their natural 
inhibitors are involved in this process. The study aims to investigate if plasma MMP-2, - 
9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) can be predictive markers in the 
diagnosis and prognosis of colorectal cancer (CRC) metastatic liver disease.
M ethods  Fifty-seven patients undergoing liver metastasis operation were followed 
prospectively. ProMMP-2, -9 and TIMP-1 plasma levels were determined by 
zymography and ELISA, before and after the resection of liver metastases. Data were 
compared with those of healthy controls (n=51) and primary CRC patients (n=57). The 
diagnostic and prognostic potential was investigated with ROC-curves and Kaplan­
Meier survival analysis.
Results  Plasma proMMP-2 levels were lower (P<0.001), and TIMP-1 levels higher 
(P<0.001) in CRC metastatic liver disease than in healthy controls. If compared to those 
in primary CRC patients, no differences were found. In ROC-curves, the area under the 
curve was 0.48 and 0.61 for proMMP-2 and -9, respectively. Plasma proMMP-2, -9 and 
TIMP-1 levels were unsuitable to predict survival. In both diagnostic and prognostic 
examinations, CEA proved to be a better marker. In the post-operative follow-up, 
protracted low levels of proMMP-2 seemed related to disease recurrence.
Conclusion  The preoperative plasma proMMP-2, -9 and TIMP-1 levels have no potential 
value as diagnostic or prognostic markers in CRC liver metastatic disease. The 
postoperative course of proMMP-2 should be investigated further as a tool to diagnose 
liver metastasis recurrence.
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Introduction
Patients with untreated hepatic metastases of colorectal cancer (CRC) are unlikely to 
survive longer than five years 1,2 Systemic and regional chemotherapy can prolong the 
median survival time 3 but resection of the metastasis is ultimately the only treatment 
option with a substantial chance for cure. Unfortunately, within two years after the 
resection, two-thirds of the patients develop recurrent disease 2,4.
In order to choose the appropriate treatment for metastatic disease after CRC 
discriminative tools are needed. A proven impossibility to resect all tumour and extra- 
hepatic disease constitute the only firm contra-indication to hepatic resection 1. 
Currently, patient prognosis and patient selection for treatment are based largely on 
factors such as the size and number of liver tumours, the involvement of lymph nodes at 
the time of primary disease, the disease-free interval between colon and liver disease 
and the preoperative carcinoembryonic antigen (CEA) level 1,5 While increased serum 
CEA is convincingly linked to the presence of liver metastasis, it appears questionable if 
it correlates with prognosis 6. Also, some patients with CRC and CRC liver metastases 
retain normal CEA levels. Therefore, the development of more powerful diagnostic and 
prognostic markers remains highly necessary.
The degradation of the extracellular matrix is intrinsic to the invasion and progression of 
cancer 7. The matrix metalloproteinases (MMP) appear to be the terminal effectors of 
the proteolytic cascade in matrix degradation 89. Both the gelatinases MMP-2 and 
MMP-9 can degrade collagen IV, the major structural component of basement 
membranes. The tissue inhibitors of matrix metalloproteinase-1 and -2 (TIMPs) are the 
natural inhibitors of MMP-9 and MMP-2, respectively, and are part of a family of 
homologous proteins that potentially may act anti-metastatically.
There is considerable evidence for the involvement of MMPs in colorectal cancer 10. For 
instance, active and latent MMP-2 tissue levels are higher in tumour than in normal 
tissues 11,12. Increased tissue levels of proMMP-9 have been found early in the 
transition from colon adenoma to adenocarcinoma 13 and enhanced tissue levels of 
TIMP-1 correlate with poor prognosis in CRC 10 Consequently, gelatinases and their 
inhibitors represent logical candidates in the search for diagnostic and prognostic 
markers in CRC-related disease.
In contrast to tissue, little is known about MMPs in the blood of CRC patients. So far, 
there are no data on circulating gelatinase and TIMP levels measured at the time of 
resection of metastatic disease. This report aims to examine the possible diagnostic and 
prognostic value of blood MMP-2, -9 and TIMP-1 levels, as measured before and after 
potential curative hepatic resection for CRC metastases. Since CEA is currently used as 
a marker of tumour burden in clinical practice 1,5,14 it is used as a reference marker.
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Materials and methods
P a tie n ts  a n d  c o n tro l s u b je c ts
From September 30, 1997 until October 1, 2000, 57 patients (37 male) with CRC liver 
metastases were included in this prospective study. In all, the primary tumour had been 
resected previously. The median age at the time of surgery was 59 years (range 35-78). 
All patients went into surgery with curative intent and some were also treated with 
radiofrequency ablation or cryotherapy. Still, at laparotomy the disease in 20 patients 
proved to be too extensive to proceed with further surgery or other treatment. Thirty- 
seven patients were thus considered potentially cured by the operation.
The median follow-up after operation was 37 months (range 1-68 months). Twenty-nine 
of the 37 patients developed recurrent disease. Twenty-one patients had recurrences 
that included the liver, four patients had metastasis to the lung, brain and/or skin and 
four had abdominal recurrences. The median time to disease relapse was eight months 
(range 1-59). The 3-years disease-related survival rate was 49% for the total group and 
61% for the 37 patients that underwent potentially curative operation.
Ninety-four patients (57 male) with primary CRC were included as a reference group. 
Their median age was 63 years (range 28-86). Data on these patients were obtained 
from a previous study 15 Additionally, a control group of 51 healthy blood donors (26 
male) was included. Their median age was 55 years (range 45-69).
B lo o d  c o lle c t io n  a n d  a n a ly s is
Venous blood samples were obtained with informed consent from all individuals and 
with permission of the institutional ethics committee. Blood samples of all CRC patients 
were drawn preoperatively. Postoperative sampling was conducted in the CRC liver 
metastasis patients in the first month after operation and then approximately every 3 
months. If possible, sufficient blood was collected for processing into multiple samples 
of serum and both heparin- and EDTA-plasma. Both plasma and serum were obtained 
after centrifugation at 1500 g for 10 min and were stored at -80°C  prior to assay. 
Zymography was performed as described previously 11,16 Four Ml of heparin plasma 
was diluted in 16 Ml Tris-buffer (50 mM Tris, 0.2 mM NaCl, 5 mM CaCl2, pH 7.5) and 20 
Ml sample buffer (0.125 M Tris-HCl, pH 6.8, 17.4% (w/v) glycerol, 4% sodium 
dodecylsulphate and 0.01% bromophenol blue). Five Ml of this solution was loaded onto 
the sodium dodecylsulphate-polyacrylamide gel. Gel electrophoresis was performed 
using a mini-gel system apparatus (Bio-Rad, USA). Gelatinolytic activity is expressed in 
arbitrary units (AU) per ml.
Plasma proMMP-2, -9 and TIMP-1 immunoreactivity was measured with commercially 
available, two-step, sandwich BIOTRAKtm ELISA kits (Amersham Pharmacia Biotech, 
Uppsala, Sweden). The assays were performed in accordance with the manufacturer’s
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instructions. For the MMP-2 ELISA, heparin plasma was diluted 1:50 with assay buffer. 
For the MMP-9 ELISA, EDTA-plasma was diluted 1:10 with assay buffer. For the TIMP- 
1 ELISA, heparin plasma was diluted 1:40 with assay buffer. The latter assay 
recognizes both free TIMP-1 and that complexed with MMPs. The sensitivities of these 
assays were 0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9 and 1.25 ng/ml for TIMP-1, 
respectively. Serum CEA levels were measured by enzyme immunoassay (Axsym; 
Abbott Laboratories, Chicago, Ill., USA). The normal range for CEA in healthy controls 
is between 0.5 and 5 ng/ml.
In order to prevent confusion, data concerning the proMMP blood levels obtained by 
zymography and ELISA are referred to as (Z) and (E) data, respectively.
The s p e c if ic ity  a n d  s e n s it iv ity  o f  p re o p e ra tiv e  M M P a n d  CEA fo r  d ia g n o s in g  l iv e r  
m e ta s ta tic  d ise a se
The ability to distinguish CRC patients with hepatic metastatic disease from those 
without metastatic disease, based on proMMP(Z) or CEA blood levels, was 
investigated. Fifty-seven patients with hepatic metastases were compared to 34 patients 
from the reference group who previously underwent resection of primary CRC and were 
at least two years free of disease. From the latter group no complete MMP(E) data were 
available. The median time of sampling of the preoperative blood samples from the 
hepatic metastasis group was 9 months after primary CRC operation. The samples 
from the reference group were collected within a similar period. The specificity and 
sensitivity, expressed in the area under the curve (AUC), determines the potential value 
of the diagnostic test and is best illustrated by a receiver operating characteristic (ROC) 
curve.
P re o p e ra tiv e  M M P a n d  CEA a n d  th e ir  re la tio n  to  s u rv iv a l
The correlation of proMMP-2, -9, TIMP-1 and CEA levels with the length of disease- 
specific survival in patients that were potentially cured after resection was investigated. 
The survival analysis was performed with the Kaplan-Meier method. Five of the 37 
patients died of unknown causes and were excluded from analysis. Patients that were 
alive and one patient with a non-CRC death were regarded as censored observations at 
the end of their follow-up. Survival distributions in patients with high and low proMMP or 
TIMP-1 levels were compared by stratifying patient data into two groups with the 
median being the cut off value. The cut off value for CEA was set at 5 ng/ml.
The e ffe c ts  o f  l iv e r  s u rg e ry  on  M M P a n d  CEA le v e ls
The percentage change between pre- and postoperative levels of proMMP(Z) and CEA 
were determined in order to evaluate the effect of CRC liver metastasis operation on 
blood levels in those patients that were potentially cured after operation (n=37). ELISA
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data on MMPs and TIMP-1 were incomplete. ProMMP(Z) and CEA comparisons 
involved 16 and 33 evaluable cases, respectively. ProMMP(Z) data are based on the 
comparison of the preoperative levels with those measured between 30 and 60 days 
after operation, since earlier levels may be affected by the healing response 17 The 
CEA results are based on the comparison of preoperative levels with those measured 
within one month after operation.
C h ange s  in  M M P a n d  CEA p r io r  to  d ise a se  re la p se
After liver surgery, the changes in the blood levels of proMMP-2, -9, TIMP-1 and CEA 
were followed. The reported changes were calculated from the difference between the 
last two consecutive samples taken before the discovery of disease relapse. The 
samples used were all obtained within the year preceding the discovery of disease 
relapse. The first sample was taken at least one month after surgery and there was a 
period of at least 30 days between the second last and the last sample; the time 
between the last sample and the discovery of disease relapse was never longer than 6 
months. On the basis of these requirements 20, 18 and 24 patients yielded data on 
proMMP(Z), proMMP(E) and CEA, respectively. The percentage change in the relapse 
group was compared to the changes found in the blood samples of patients that did not 
relapse within two years after operation (n=8). The mean time of sampling after liver 
surgery was approximately 8 months and was similar in both groups.
S ta t is t ic a l a n a ly s is
The Mann-Whitney U-test was used to test for differences between two groups. For 
paired testing, the Wilcoxon signed ranks test was used. The one-way analysis of 
variance and the Kruskal-Wallis test were used to test for differences between more 
than two groups. In-between comparisons were performed using the Tukey-Kramer 
multiple-comparisons test, Dunn’s multiple-comparisons test or the Mann-Whitney U- 
test with an adjusted P value (P<0.05/k, with k being the number of comparisons made). 
The sensitivity and specificity of proMMP, TIMP-1 and CEA data in diagnosing CRC 
liver metastatic disease were illustrated in ROC curves. The 95% confidence intervals 
(CI) for the sensitivities at 95% specificity were calculated by the Fisher’s exact test. 
Differences between AUCs were estimated with the method of DeLong et al. 18 The 
Kaplan-Meier method was used in survival analysis. Equality between groups was 
determined with the log-rank test. All differences were considered statistically significant 
at the P<0.05 level.
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Results
P re o p e ra tiv e  MMP, TIMP-1 a n d  CEA le v e ls
In both patients and controls, zymographic analysis of plasma samples demonstrated 
the presence of measurable levels of the latent forms of MMP-2 and -9, while the active 
forms were absent. Thus, the zymographic data reflect levels of free circulating 
proMMPs plus those previously bound to TIMPs.
In preoperative plasma of CRC liver metastasis patients, both zymography and ELISA 
demonstrated significantly (P<0.001) lower levels of proMMP-2 and equal levels of 
proMMP-9 if compared to healthy controls. Plasma TIMP-1 and serum CEA levels were 
significantly (both P<0.001) higher than in controls.
In comparison to preoperative plasma levels from primary CRC patients, similar levels 
of proMMP-2, -9 and TIMP-1 were found. The serum CEA levels were significantly 
(P<0.001) higher in patients before liver metastasis operation than before primary CRC 
operation (T ab le  1).
Table 1 ProM M P-2, -9, TIM P-1 and C EA  levels in co lorecta l cance r patients and contro ls
Zym ography (AU /m l) ELISA  (ng/m l)
proM M P-2 proM M P-9 proM M P-2 proM M P-9 TIMP-1 CEA
H ealthy sub jec tsa 249 
(151 - 340)
46
(17 - 97)
849 
(456 - 1261)
14 
(1 - 178)
756 
(517 - 1178)
1
(<1 - 5)
P rim ary C R C b 135 
(66  - 395)
38 
(5 - 236)
655 
(369 - 1940)
10 
(0 - 159)
966 
(150 - 3842)
3
(<1 - 1200)
L ive r M etastas is 140 30 643 12 1031 9
D isease0 (63-280) (2-189) (385-1289) (0-271) (13-2083) (1-650)
P a-b < 0.001 0.390 < 0.001 0.159 < 0.001 < 0.001
P b-c 0.810 0.326 0.559 0.916 0.452 < 0.001
P a-c < 0.001 0.390 < 0.001 0.159 < 0.001 < 0.001
Results are presented in medians with the range in brackets. Zymographic and ELISA data were obtained 
from 51 healthy subjects, 94 primary CRC patients and 57 CRC liver metastasis patients; in the latter 
groups immediately prior to operation. Post-hoc testing was performed by Dunn's multiple comparisons 
test. AU: Arbitrary Units.
P re o p e ra tiv e  p roM M P (Z ) a n d  CEA as  a d ia g n o s tic  to o l
A ROC curve, plotting the specificity against the sensitivity, is shown in F ig u re  1. At 
95% specificity (i.e. maximum of 5% false positives), zymographic data yielded very low 
sensitivities of 11% (95% CI: 4-23%) and 21% (95% CI: 11-34%) for proMMP-2(Z) and 
proMMP-9(Z), respectively. For CEA, sensitivity at 95% specificity was 61% (95% CI:
46-74%). The AUC, representing the diagnostic ability of a test, was the highest (0.92)
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for CEA. This was significantly (P<0.001) higher than for proMMP-2(Z) and proMMP- 
9(Z). Their AUCs were 0.48 and 0.61, respectively, and were not statistically different 
(P>0.05) from the AUCs of tests that are positive or negative just by chance.
GOd0OT
Figure 1 ROC curves for 
plasma proMMP-2, -9 and CEA 
levels in CRC liver metastatic 
disease. I= CEA. II= proMMP- 
9(Z). III= proMMP-2(Z). (Z) 
refers to analysis by 
zymography.
100-Specificity (%)
P re o p e ra tiv e  MMP, TIMP-1, a n d  CEA le v e ls  a n d  c lin ic o p a th o lo g ic a l p a ra m e te rs
Higher preoperative proMMP-2(Z) levels were found in patients with a short (<36 
months) disease-free period after liver resection (P=0.023; Tab le  2). Significantly 
(P=0.019) higher levels of proMMP-9(Z) were found in patients with abnormal CEA
Table 2 Correlations between plasma proMMP and TIMP-1 levels and clinicopathological parameters 
in CRC liver metastasis patients
________ Zymography _____________ ELISA_______________
Parameter n* proMMP-2 proMMP-9 n* proMMP-2 proMMP-9 n* TIMP-1
Age
<60 years 28 134 35 27 585 13 27 921
>60 years 25 145 30 27 652 9 27 1129
P 0.715 0.482 P 0.284 0.341 P 0.015
CEA
<5 ng/ml 18 132 23 19 652 8 19 953
>5 ng/ml 30 143 45 32 636 13 31 1070
P 0.198 0.019 P 0.3274 0.096 P 0.189
Chemotherapy
Pre-op. (0-4 months) 16 158 24 14 656 5 14 1042
no 22 138 40 23 652 15 23 1021
P 0.199 0.848 P 0.650 0.010 P 0.888
Disease free-period**
yes (>36 months) 7 108 15 7 649 6 7 926
no/short 26 144 29 27 657 13 26 1049
P 0.023 0.523 P 0.676 0.249 P 0.281
* Only evaluable cases were included. ** This parameter was measured only in potentially curatively
operated patients. Zymographic activity levels are in arbitrary units/ml. ELISA levels are in ng/ml.
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levels (>5 ng/ml). ProMMP-9(E) levels were three times lower (P=0.010) in patients that 
recently (within 0-4 months before operation) received chemotherapy. TIMP-1 levels 
were related to patient age, with significantly (P=0.015) higher levels in patients older 
than 60 years.
No relations were found with gender, stage and location of the original primary tumour, 
and the number and size of liver metastatic lesions.
P re o p e ra tiv e  MMP, TIMP-1 a n d  CEA le v e ls  a n d  s u rv iv a l
The preoperative proMMP-2, -9 and TIMP-1 levels in potentially cured patients did not 
correlate significantly with disease-related survival as determined by the Kaplan-Meier 
method. Results on proMMP-2(Z) and CEA are illustrated by Kaplan-Meier curves in 
F ig u re  2. Patients with high proMMP-2(Z) levels (> 135 AU/ml) showed no statistically 
significant difference (P=0.161) in survival when compared to patients with lower levels 
(Fig. 2A). Contrary to the data on proMMP-2, -9 and TIMP-1, patients with preoperative 
CEA levels above 5 ng/ml showed a significantly worse disease-related survival 
(P=0.030) than patients with low preoperative levels (Fig. 2B). The 3-year postoperative 
survival probability was 53% (95% CI: 28-79%) in patients with CEA serum levels above 
5 ng/ml and 74% (95% CI: 52-96%) in patients with lower levels.
TIME (MONTHS) TIME (MONTHS)
Figure 2 Survival in CRC patients after potentially curative resection of liver metastases. Each 
panel shows survival curves for two groups (high and low levels) selected on the basis of preoperative 
measurements. (A) Survival of patients based on proMMP-2(Z) levels: I = gelatinolytic activity < 135 
AU/ml; II = gelatinolytic activity > 135 AU/ml. (B) Survival of patients based on CEA levels: I = serum level 
< 5 ng/ml; II = serum level > 5 ng/ml. P-values by log-rank test are presented within the figures. (Z) refers 
to analysis by zymography.
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The e ffe c ts  o f  l iv e r  s u rg e ry  on  M M P a n d  CEA le v e ls
After surgery, proMMP-2(Z) plasma levels increased by 12% in potentially cured 
patients. The median preoperative level of 127 AU/ml rose to 141 AU/ml (P=0.018). 
Changes in proMMP-9(Z) levels did not reach statistical significance. Median CEA 
levels fell from 5.1 ng/ml to 2.1 ng/ml (P<0.001).
The changes found were not dependent of the type of procedure that was performed 
(resection, local tumour ablation, or a combination of both).
C h ange s  in  M M P a n d  CEA p r io r  to  d ise a se  re la p se
No significant changes in the blood levels of proMMP-2(Z and E), proMMP-9(Z and E) 
and TIMP-1 were found before disease relapse (T ab le  3). In patients that remained 
disease-free (at least two years) after the resection of liver metastatic disease the 
proMMP-2(Z) levels increased significantly (P=0.040) over time. Still, no significant 
differences were observed between the two groups for any of these parameters.
Table 3 The changes in proMMP, TIMP-1 and CEA levels prior to disease relapse
Non-Relapse group Relapse group
Parameter Value1 Change2
(%)
Value Change
(%)
Comparisons
P
proMMP-2(Z)
samples A3 
samples B3
n=8 n=20
146
162
} 73.9* 175 } 
149 }
1.2
73.9 vs. 1.2 
0.195
proMMP-9(Z) n=8 n=20
samples A 
samples B
23
40
} 53.0 42 } 36 } -22.0
53.0 vs. -22.0  
0.533
proMMP-2(E) n=7 n=18
samples A 704
} 9.3 870 } 0.4
9.3 vs. 0.4
samples B 831 827 } 0.423
proMMP-9(E) n=7 n=18
samples A 
samples B
7
6 } -12.3 6 } 11 } 7.6
-12.3 vs. 7.6 
0.357
TIMP-1 n=7 n=18
samples A 
samples B
1060
1003 } -5.1
1040 } 
1067 } 1.5
-5.1 vs 1.5 
0.590
CEA n=8 n=24
samples A 1.1
} 0.0 2 1  } 25.7** 0.0 vs. 25.7
samples B 1.0 3.3 } 0.014
1 ; Values are presented in medians and refer to activities in arbitrary units/ml for proMMP(Z) data and 
refer to immunoreactivity in ng/ml for proMMP(E), TIMP-1 and CEA data. 2 ; The median percentage
change was calculated from the difference between A and B in each patient. 3 ; Samples A represent the 
median level in all second last samples taken prior to diagnosis of disease relapse. Samples B represent 
the median level in all last samples taken prior to diagnosis. * and ** ; The changes in activity were
significantly different from 0 with P=0.040 and P<0.001, respectively.
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Median CEA serum levels increased significantly (P<0.001) in the patients that relapsed 
after liver operation and remained low in those which were disease-free after two years. 
The difference in the percentage change (26% vs 0%) in the two groups was statistically 
significant (P=0.014). F ig u re  3  illustrates, in three representative patients, how blood 
proMMPs(Z), TIMP-1 and CEA levels behave prior to the discovery of disease relapse.
Figure 3 Postoperative blood proMMP-2, -9(Z), TIMP-1 and CEA levels during disease relapse 
after potentially curative liver tumour resection. Data are given for three (A,B,C) representative patients. 
s i = first sample: taken at least 1 month after resection. s2-3 = consecutive samples after the first. s 2nd 
last = second last sample before disease relapse. s final = last sample before disease relapse. s1 is set at 
100%. o = CEA; ■ = proMMP-2; □ = proMMP-9; and A = TIMP-1. (Z) refers to analysis by gelatin 
zymography.
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Discussion
The current study was undertaken primarily to assess the potential for preoperative 
plasma proMMP-2 and -9 levels to act as diagnostic or prognostic markers in CRC liver 
metastatic disease. The data presented here, though obtained on a study population of 
moderate size, yield no indication for such potential at all. Measurements taken after 
liver surgery indicate that the postoperative course of proMMP-2 should be investigated 
further since it shows some promise in diagnosing liver metastasis recurrence.
The rationale for investigating these parameters is a firm one. The involvement of 
MMPs and TIMPs in cancer has been shown convincingly 9,19 In CRC, clear 
correlations have been found between disease progression and tissue levels of various 
MMPs, among them the gelatinases 20,21. Still, little is known about the relation between 
circulating MMP and TIMP levels and the development of cancer. A certain degree of 
diagnostic and prognostic power has been reported for circulating MMP-9 in lung 
cancer 22,23, head and neck squamous cell cancer 24 and in papillary thyroid cancer 25. 
Sonnate e t al. have suggested that plasma MMP-9(E) may be an independent marker 
of CRC, potentially predicting invasion and metastasis 26. In a preceding paper, we have 
established that preoperative proMMP-2 blood levels correlate with CRC diagnosis, 
identifying patients with 70% sensitivity at 95% specificity. In a combination with TIMP- 
1, this diagnostic sensitivity increases even to 84%. In addition, circulating TIMP-1 has a 
prognostic value similar to CEA in predicting patient survival 15
While proMMP-2 plasma levels reportedly show potential as a diagnostic marker 
(AUC=0.89) in primary CRC 15, this diagnostic potential was absent in CRC liver 
metastasis (AUC=0.48). This apparent contradiction may be the result of the different 
reference groups used. In primary CRC, preoperative plasma levels have been 
analysed against those in healthy subjects. Here, we have analysed the preoperative 
levels in CRC metastatic liver disease against samples of curatively operated CRC 
patients. The latter patients were sampled 9 months after the primary operation and 
remained disease-free for at least two years. This group has been chosen as a 
reference group because it corresponds best to those patients that are actually 
screened for liver metastases in clinical practice. Surprisingly, in an additional analysis 
(results not shown) it was established that, if samples from the reference group were 
taken 18 months, instead of 9, after primary CRC operation, the diagnostic ability of 
proMMP-2 increased (AUC=0.67). It thus seems that the plasma proMMP-2 levels 
increase slowly after curative operation toward those of healthy controls. However, 
despite this observation, one must conclude that neither proMMP-2 nor for that matter 
proMMP-9 or TIMP-1, have any convincing diagnostic value during the formation of liver 
metastases in CRC patients.
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The present data demonstrate that circulating proMMP-2, -9 and TIMP-1 levels do not 
discriminate between primary CRC and CRC metastatic disease. This finding indicates 
that the same enzymes appear to be involved in primary CRC and in metastatic disease 
in the absence of the primary tumour (which has been resected). CEA behaves 
differently: circulating CEA levels are higher in the presence of liver metastasis than in 
primary disease. CEA seems, therefore, to be the marker most related to the actual 
metastatic process.
With respect to the relations with clinicopathological parameters, decreased 
preoperative proMMP-2 levels appear to be linked with a longer disease-free period. 
This finding seems contrary to expectations when considering the other findings in this 
study. However, the “within-the-group”-comparison pertains to a small sample size of 
curatively operated patients only, which may influence the outcome. Plasma proMMP-9 
levels are higher in patients which have received recent chemotherapy. Such an
increase has also been found in our previous study on tissue levels in CRC liver
12metastatic disease Possibly, chemotherapy triggers the patient’s immune system in 
such a way that macrophages and neutrophils, both sources for MMP-9, secrete their 
proteases. If so, this must be taken into account when MMP-9 would become a 
therapeutic target in any type of cancer treatment that involves chemotherapy or 
immunotherapy. The relation between TIMP-1 and age in primary CRC has been 
described previously 27, but is also present in healthy controls 28 and thus probably not 
specifically related to cancer.
The preoperative plasma levels of proMMP-2, -9 and TIMP-1 do not predict patient 
survival and therefore CEA remains the best circulating marker now available for 
predicting survival in metastatic CRC. Perhaps the finding, as it relates to TIMP-1, is 
somewhat unexpected since TIMP-1 reportedly has shown predictive power in this 
respect in primary CRC 15,27.
As expected for a marker of tumour burden, CEA levels go down after potentially 
curative resection of the liver metastases. ProMMP-2 levels increase somewhat toward 
the levels that are more representative of healthy controls. An interesting new finding is 
that, prior to a documented disease relapse, CEA levels rise again in most cases while 
previously increasing levels of proMMP-2 apparently become stable. On the contrast, 
the proMMP-2 levels in non-relapsing continue to increase (Table 3). One could 
speculate that prolonged low levels of plasma proMMP-2 after curative liver metastases 
resection are indicative of incomplete resection or disease recurrence. In those patients 
where a repeat resection of liver metastases is clinically still possible, this finding could 
be of therapeutic value, especially for those patients that have tumours without 
increased CEA levels. In order to fully establish the value of this finding, further data are 
needed.
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In conclusion, the importance of optimal diagnostic and prognostic markers, essential in 
the selection of specific patients for specific treatment protocols, should again be 
emphasized. Because of their undisputed involvement in cancer growth and metastasis, 
circulating gelatinases should be fully analysed for this purpose. However, neither 
preoperative plasma proMMP-2 or proMMP-9 nor TIMP-1 exhibits diagnostic or 
prognostic value in CRC liver metastatic disease. Their concentrations are largely 
similar to those found in primary CRC and appear to be unrelated to patient survival. 
Still, the apparent prolonged low level of proMMP-2 after liver resection in relation to 
disease recurrence is certainly of interest and warrants further investigation as to its 
diagnostic potential.
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SUMMARY AND FOLLOW-UP STUDIES
Summary
Despite the always-ongoing development of more diverse and specialized methods of 
cancer treatment, half of the patients with localized tumours still die from metastatic 
disease. This outcome may improve when more reliable predictive markers of tumour 
progression become available, because patients with asymptomatic disease, early- 
stage cancer or micrometastasis may then benefit from an earlier selection for specific 
treatment, such as adjuvant or experimental therapy.
Colorectal cancer (CRC) is one of the most frequent cancers in the Western world, and 
represents an important cause of death. Its mortality has known hardly any overall 
reduction in the last 20 years whereas its incidence is still increasing. In CRC, surgery is 
often the primary treatment of choice. However, many patients subsequently show 
disease relapse through recurrent local tumour or outgrowth of metastases. Both the 
recurrence of disease and survival in colorectal cancer are related to the stage of 
disease at the time of diagnosis. Therefore, it seems reasonable to expect that 
diagnosis of cancer at an early stage can improve the survival rate. At first 
carcinoembryonic antigen (CEA) was considered a potential diagnostic tool, but studies 
from the last decade show that this marker is more valuable in CRC follow-up than in 
early diagnosis. In studies with a large population, it has been shown that the faecal- 
occult-blood test is a good diagnostic tool in CRC and that population-wide screening 
can reduce CRC mortality. However, until this and other potential markers have been 
fully evaluated regarding their (cost-) effectiveness, many putative markers remain to be 
investigated. Because some of these compounds are clearly involved in cancer biology, 
they may prove to be more effective tools than those already developed and presently 
available.
It is undisputed that the matrix metalloproteinases (MMPs) and their inhibitors, the 
tissue inhibitors of metalloproteinases (TIMPs), play an important role in cancer biology 
and therefore potentially represent great promise as diagnostic and/or prognostic tools. 
The MMP-family has been shown to be involved in processes related to tissue 
development and repair, for instance cell motility, release of growth factors and 
extracellular matrix remodelling. These mechanisms are of major importance for tumour 
progression, invasion and metastasis and the role of the MMPs herein has been 
demonstrated in many studies reported in recent years (chapter 1). In CRC tissues, the 
expression of various MMPs is enhanced and positive correlations have been found 
with tumour stage and survival. Amongst the MMPs, the gelatinases MMP-2 and MMP- 
9 are of particular interest because of their capacity to degrade collagen IV, the major 
component of basement membrane that separates different cellular compartments. It 
seems clear that investigations into the diagnostic and prognostic value of the
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gelatinases and their inhibitors may yield new information regarding their use as 
markers and add more knowledge regarding the biology of CRC.
So far, in CRC the focus of investigation of MMP presence has been mainly on the level 
of mRNA expression and protein localization. Actual (bio)activity of the gelatinases has 
scarcely been investigated. For this reason, we have examined their actual activity in 
CRC patients, both in tumour and in healthy tissue and in plasma. For the analysis of 
proteinase activity, gelatin zymography and a broad-spectrum MMP bioassay have 
been used. Advanced scanning and imaging techniques allow the quantitative 
measurement of both the latent and the active form of MMP-2 and -9.
In chapter 2, we describe the investigation of the tissue levels of active and latent 
MMP-2 and -9 in both tumour tissue and distant normal mucosa, obtained at operation 
from 73 CRC patients. Both latent and active gelatinases, as measured with 
zymography, showed enhanced levels of activity in tumour versus normal tissue. This 
activity is most likely real in vivo bioactivity because it was also enhanced in a broad- 
spectrum MMP activity assay, which is sensitive to specific MMP inhibitors. If MMPs 
were bound to MMP specific inhibitors, no activity would have been found in the latter 
assay.
The MMP-2 levels were especially enhanced, resulting in a tumour to normal ratio of 8.6 
for the active form. With the active form being stronger increased than the latent form, 
this suggests that mediators in the activation pathway of MMP-2 are upregulated. Such 
does not appear to apply to MMP-9 since its latent form increased more than its active 
form. No significant differences were found between samples obtained from the true 
tumour tissue compared to those taken from the invasive edge.
In relation to clinicopathological parameters, the active and latent MMP-2 levels were 
inversely correlated with the stage of disease. This finding may indicate a more 
pronounced role for MMP-2 in the early stages of CRC than in the advanced stages. To 
investigate this further, more patients displaying the early stages of CRC are needed.
The relationship between gelatinase activity and metastatic disease from CRC is 
described in chapter 3. In liver tumours and in transitional tissue containing the invasive 
edge, the activity of both gelatinases was increased compared to that in distant normal 
liver tissue. In addition, the ratio between active and latent form was higher in tumour 
than in normal liver for both MMP-2 and MMP-9. This latter observation shows not only 
that in tumour the gelatinolytic activity is increased in absolute sense, but it also 
suggests that the rate of conversion of latent to active form is increased. When 
comparing both gelatinases, MMP-2 has the higher tumour to normal activity ratio in 
both primary and metastatic disease. Furthermore, MMP-2 has the higher active to 
latent ratio. These results indicate differences between both gelatinases, concerning
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their expression, translation or degree of activation. Consequently, we believe that the 
two MMPs should be investigated and considered as different and separate markers of 
cancer progression. It also follows that, if these MMPs are considered as therapeutic 
targets, any inhibition of their activity should be type-specific.
In liver metastatic disease, tumours smaller than 5 cm had higher levels of active and 
latent MMP-2 than the larger tumours. Furthermore, high active MMP-2 tumour tissue 
levels correlated with shorter disease-free periods after metastatic tumour resection. 
This latter finding may indicate prognostic value and warrants further investigation. 
ProMMP-9 levels were increased in normal and metastatic tissue of patients that 
received preoperative chemotherapy. The relation between MMP-9 and chemotherapy 
should be considered in future investigations aimed at MMP-9.
The two previous studies show that gelatinase activity is increased in CRC and that it 
may have predictive value in patient prognosis. However, because the disease is 
already manifest, such data will not provide diagnostic information. Therefore, another 
focus of research has been on the gelatinase levels in blood. The advantages of 
sampling blood are that such samples are easier to obtain, are potentially more versatile 
(different types of anticoagulant or serum) and can be harvested frequently, 
consecutively, before and after operation, and from different control groups. In addition, 
most importantly, both diagnostic and prognostic value can be assessed.
In determining the best way of measuring MMP activity in blood, both the type of sample 
and the time of sampling have been considered. Based on the results described in the 
literature we have chosen plasma samples with heparin as anticoagulant. Serum 
samples seem not appropriate because during the clothing process additional MMPs 
may be released. The best moment for sampling blood, in respect to the time of 
operation, was established in a study described in chapter 4. In primary CRC, in liver 
metastasis after CRC and in arthrosis of the hip, the gelatinase activity was measured in 
blood obtained immediately before surgery and 1 week, 1 month and 3 months 
postoperatively. All three operations had a profound, but transient, effect on the level of 
plasma proMMP-9, but not on that of proMMP-2. The proMMP-9 level increased 
significantly after 1 week but returned to the preoperative level after 1 month. Activated 
gelatinases were not detected in blood. Clearly, surgical stress elevates the proMMP-9 
level in the circulation, and postoperative samples should be used for monitoring 
disease activity only when obtained at least 1 month after operation.
Furthermore, lower plasma levels of proMMP-2 were found in patients with CRC and in 
CRC liver metastatic disease than in patients with arthrosis. This surprising observation 
may represent a cancer-specific phenomenon that will be addressed further in the next 
paragraph.
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After establishing the presence of altered levels of active and latent gelatinases in CRC 
tissues and the effects of surgery on circulating levels, we subsequently focussed on 
the pre- and postoperative levels of MMP-2 and MMP-9 in blood and investigated their 
value as predictive markers. The gelatinase levels were measured with both 
zymography and ELISA. The endogenous MMP inhibitor TIMP-1 and the reference 
tumour marker CEA were also measured. In chapter 5, the following questions have 
been addressed: What are the levels of preoperative MMP-2, -9, TIMP-1 and CEA in 
blood of CRC patients as compared to those in healthy controls? How do the levels 
relate to the clinicopathological parameters, and what value do they have in the 
diagnosis and prediction of survival?
Despite the clear and elevated presence of the active form of MMP-2 and -9 in tumour 
tissue, it remained undetected in blood, both in cancer patients and in healthy controls. 
Maybe the active form is quickly degraded in tissue and does not reach the circulation 
at all or is not measured because it becomes irreversibly bound to non-specific 
inhibitors in the blood.
Plasma proMMP-2 levels were lower in CRC patients than in healthy controls (or 
arthrosis patients; chapter 4). The levels even correlated inversely with adverse 
clinicopathological parameters such as lymph node involvement, stage of disease and 
the CEA level. One could speculate that in CRC, and particularly in the early stages, 
proMMP-2 activation is much more effective than in healthy controls, resulting in 
lowered plasma levels. It is even conceivable that the proform is bound and 
subsequently activated or degraded preventing spill over into the circulation.
ProMMP-9 levels did not differ between patients with CRC and healthy controls. 
However, patients with larger and more invasive tumours showed higher proMMP-9 
plasma levels. Possibly, this elevated presence of proMMP-9 is triggered by an 
immunologic response which is evoked by such tumours.
TIMP-1 and CEA blood levels, as measured with ELISA, were both higher in CRC than 
in healthy controls. Enhanced immunoreactivity of TIMP-1 correlated with metastatic 
disease and increased CEA levels.
The ability to distinguish CRC patients from healthy controls, based on the preoperative 
blood protein level, may indicate the potential diagnostic value of these protein markers. 
Using ROC-curves, it was established that proMMP-2 activity, as measured with 
zymography, exhibited the highest sensitivity in detecting CRC patients at 95% 
specificity. In a combination with TIMP-1, this sensitivity was even higher. ProMMP-9 
showed very low diagnostic power. To fully understand the diagnostic power of lowered 
plasma proMMP-2 in combination with elevated TIMP-1 more research is needed. For 
example, one should include more diverse patient groups, such as patients with 
adenomas, inflammatory bowel disease and asymptomatic disease.
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The value of gelatinases, TIMP-1 and CEA in predicting survival was investigated with 
the Kaplan-Meier method. Preoperative gelatinase bioactivity or immunoreactivity 
showed no predictive value, whereas both TIMP-1 and CEA were good markers. 
Patients with high TIMP-1 or CEA levels showed a significantly lower three-year survival 
rate than those with low levels. Combining both markers seems to increase the 
predictive value for survival even more.
Thus, preoperative sampling revealed that proMMP-2 shows potential value in the 
diagnosis of CRC, but not in prognosis, and proMMP-9 shows no significant predictive 
value at all. Furthermore, it is suggested that combining tumour markers, even when 
obtained via different analytical techniques, are the way of the future in search for better 
predictive markers.
The predictive value of postoperative measurements of the gelatinases and CEA are 
investigated in a study described in chapter 6. CEA blood levels were proven to be 
elevated in samples from patients well before the diagnosis of CRC recurrence (local or 
metastatic disease), whereas the proMMP-2 and -9 blood levels did not change 
significantly. The gelatinases therefore do not seem useful for the diagnosis of 
prediction of disease recurrence in the period after surgical removal of the primary 
tumour. Furthermore, CEA levels kept increasing until patients died of CRC whereas the 
gelatinases did not change in this period. Often, CEA is referred to as a marker of 
tumour load and therefore the observations regarding this marker could have been 
expected. It is clear that the levels of proMMP-2 and -9 in blood are not related to 
cancer in the way CEA is. This does not mean that MMPs are not involved in tumour 
progression, but their role is definitely different to that of CEA.
Considering the results described in chapter 5 and those described in this chapter, the 
question arises why preoperative plasma proMMP-2 levels seem to exhibit diagnostic 
value, whereas those found postoperatively appear to have no such potential. The 
answer may be found in the diverse groups used for comparison. In the preoperative 
study, data from patients with clinically diagnosed cancer were compared with healthy 
controls. In the postoperative study, proMMP-2 levels were determined in disease-free 
patients before disease recurrence and compared with levels in patients that did not 
suffer from recurrences. In the latter comparison, the clinical differences seem much 
smaller between the compared groups, and such an approach seems to be preferable 
to the first, but in order to draw valid conclusions regarding the diagnostic potential this 
needs further investigation.
Because of a similar need for more reliable markers in metastasized CRC, the pre- and 
postoperative diagnostic and prognostic value of MMPs was investigated in patients 
with liver metastasis. The results of such investigation are described in chapter 7. Fifty-
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seven patients underwent liver metastasis operation and were followed in time. 
ProMMP-2, -9 and TIMP-1 plasma levels were determined before and after the 
resection of liver metastases. Data were compared with those of healthy controls (n=51) 
and primary CRC patients (n=94). Once more, it appeared that proMMP-2, rather than 
proMMP-9, shows potential as a marker in cancer. Plasma proMMP-2 levels are lower, 
and TIMP-1 levels are higher in CRC metastatic liver disease than in healthy controls. If 
compared to those in primary CRC patients, no differences were found. ProMMP-9 
levels did not differ between any set of groups compared.
CEA levels increased between healthy subject and patients with primary CRC, but were 
even higher in patients with liver metastatic disease. Others have also described this 
finding and it thus affirms that our study group is representative and may be compared 
to those in other studies. In addition, the data show again, that the gelatinases clearly 
relate differently to CRC progression than CEA, and that the gelatinases appear to be 
involved in metastatic disease in essentially the same way as in primary disease.
The search for relations between clinicopathological parameters and preoperative 
proMMP and TIMP-1 levels showed that plasma proMMP-9 deceased after recent 
chemotherapy. The latter is interesting because tissue levels increased after 
chemotherapy (chapter 3). To understand this difference, further investigation is 
needed.
Analysis of plasma samples taken before the resection of CRC liver metastasis 
indicated no value for either the gelatinases or TIMP-1 in diagnosis or prognosis, while 
protracted low levels of proMMP-2 after liver metastasis resection seemed to predict 
disease recurrence. In the patients that did not develop disease recurrence, plasma 
proMMP-2 levels increased toward the levels of healthy controls. When considering this 
finding it becomes obvious that monitoring patients individually seems of great 
importance and that changes in levels may hold more predictive value than the absolute 
levels. In future studies, we recommend that this aspect should gain more attention. 
Furthermore, the postoperative course of proMMP-2 should be investigated in more 
detail for its potential of diagnosing metastatic recurrences. The finding that TIMP-1 has 
diagnostic and prognostic potential in primary disease but not in metastatic disease 
gives also rise to further investigations and should include different types of cancer.
Follow-up studies
The main goal of the studies reported here has been to investigate the potential 
predictive value of gelatinase activity in CRC. In our opinion the study population 
available was large enough to indicate any such potential, if present. However, definite
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conclusions must await evaluation in larger studies including, not only more patients 
from all stages, but also different reference groups such as healthy controls, patients 
with inflammatory bowel disease and patients with colorectal adenomas.
In CRC patients, both active and latent MMP-2 tissue levels correlated with stage in 
primary disease and appeared to be unfavourably linked, together with active and latent 
MMP-9, to the event of early recurrent disease after liver metastatectomy. With the 
importance of finding new predictive markers in mind, we recommend to analyse these 
correlations further, in the same way we already did for the gelatinase activity in blood. 
The tissue levels of the gelatinases may very well turn out to be relevant for predicting 
patient prognosis, alone or in combination with other markers.
In blood from CRC patients, latent MMP-2 levels were lower than those measured in 
plasma obtained from healthy controls, while concentrations of latent MMP-9 remained 
unchanged. Furthermore, preoperative proMMP-2 levels, as measured with 
zymography, showed potential diagnostic value in primary CRC, together with TIMP-1. 
The same appeared to be the case for postoperative proMMP-2 levels measured before 
disease relapse in metastatic cancer. It is presently unknown if this phenomenon is 
specific for CRC or occurs also in other types of cancer and this should be investigated. 
The circulating gelatinases seem not to hold any promise for predicting patient 
prognosis, but the diagnostic value of lowered, or protracted low proMMP-2 levels, has 
potential and should be examined more extensively, preferably in a larger group of CRC 
patients, in patients with adenomas and in patients with inflammatory bowel disease. In 
addition, it seems important to investigate not only absolute levels but also changes in 
levels and correlate them to those found in control groups that are clinically most 
relevant.
Ultimately, our studies in blood and tissue show that MMP-2 and MMP-9 relate very 
differently to the cancer process, although they are both gelatinases. This finding may 
explain why broad-range synthetic MMP inhibitors in patient trials have not been 
successful. Therefore, we recommend that future research should focus on the 
individual characteristics of markers, rather than those of a particular group or type. In 
addition, apart from this study, it remains important to keep investigating the MMP- 
family, to unravel the mechanisms behind their expression, activation and inhibition, and 
to extend our findings and those of others regarding the diagnostic and prognostic 
value.
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Samenvatting
Ondanks de alsmaar verdergaande ontwikkelingen van meer diverse en 
gespecialiseerde behandelmethoden van kanker, sterft nog steeds de helft van de 
patiënten met een kwaadaardig gezwel aan uitgezaaide ziekte. Dit vooruitzicht kan 
verbeteren op het moment dat er meer betrouwbare voorspellende merkstoffen van 
tumorprogressie beschikbaar komen, omdat patiënten met asymptomatische ziekte, of 
met ziekte in een vroeg stadium of met micro-uitzaaiingen dan voordeel kunnen hebben 
van een eerdere selectie voor specifieke behandeling zoals adjuvante of experimentele 
therapie.
Dikkedarm- en endeldarmkanker, ook wel colorectaal carcinoom (CRC) genoemd, is 
een van de meest voorkomende vormen van kanker in de Westerse wereld en is 
daarmee een belangrijke doodsoorzaak. De sterfte aan CRC is in de laatste 20 jaar 
nauwelijks afgenomen, terwijl het aantal ziektegevallen nog steeds aan het toenemen 
is. In eerste instantie kiest men veelal voor chirurgisch ingrijpen bij deze tumoren. 
Postoperatief krijgen echter veel patiënten een terugkeer van ziekte of uitgroei van 
uitzaaiingen. Zowel het terugkeren van ziekte, als de uiteindelijke overleving bij CRC, is 
gerelateerd aan het stadium van de ziekte op het moment dat de diagnose gesteld 
wordt. Daarom lijkt het redelijk om aan te nemen dat als de diagnose kanker in een 
vroeg stadium wordt gesteld, dat dan ook de overlevingkans toeneemt. In eerste 
instantie werd aangenomen dat het in het serum aan te tonen carcino-embryonaal 
antigeen (CEA) een potentiele diagnostische parameter zou kunnen zijn, maar 
onderzoeken van de laatste 10 jaar hebben laten zien dat deze merkstof waardevoller is 
voor het bepalen van het beloop van CRC dan voor de vroege diagnostiek. In 
onderzoeken in een grote populatie is gebleken dat het op occult bloed testen van de 
ontlasting (occult faecaalbloed-test) een goed diagnosticum is voor CRC en dat een 
bevolkingsonderzoek de sterfte aan CRC zou kunnen doen afnemen. Echter, tot deze 
en andere potentiële merkstoffen/indicatoren volledig zijn geëvalueerd met betrekking 
tot de (kosten-)effectiviteit, blijven er nog vele mogelijke merkstoffen over om te 
onderzoeken.
Het is onbetwist dat de matrixmetalloproteïnases (MMPs) en hun remmers, de tissue 
inhibitors of metalloproteinases (TIMPs), een belangrijke rol spelen in de biologie van 
kwaadaardige tumoren en daarmee een grote belofte inhouden als diagnostische en/of 
voorspellende tumormerkstoffen. De MMP-familie heeft laten zien betrokken te zijn in 
processen die gerelateerd zijn aan weefselontwikkeling en reparatie, zoals 
celverplaatsing, afgifte van groeifactoren en herstructurering van de extracellulaire 
matrix. Deze mechanismen zijn van groot belang voor tumorprogressie, invasie en 
uitzaaiing en de rol van de MMPs is hierbij gebleken in vele onderzoeken in de 
afgelopen jaren (hoofdstuk 1). In CRC-weefsel is de aanmaak van verschillende MMPs
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verhoogd en zijn er positieve verbanden gevonden met het stadium van de tumor en de 
lengte van overleving. Van de MMPs zijn de gelatinases, MMP-2 en MMP-9, van 
bijzondere belang vanwege hun vermogen om collageen IV af te breken; dit is de 
belangrijkste component van de basaalmembraan die een scheiding vormt tussen 
verschillende cellulaire compartimenten. Het is duidelijk dat onderzoek naar de 
diagnostische en prognostische (voorspellende) betekenis van de gelatinases en hun 
remmers nieuwe informatie kan opleveren aangaande het gebruik van deze enzymen 
als merkstoffen en meer kennis zal toevoegen voor de biologie van CRC.
Tot nu toe lag de nadruk van het onderzoek naar MMPs bij CRC op de hoogte van de 
boodschapperRNA-productie en op het lokaliseren van MMP-eiwit. Feitelijke 
(biologische) activiteit van de gelatinases is nog nauwelijks onderzocht. Daarom hebben 
we hun feitelijke activiteit in CRC-patiënten onderzocht, zowel in tumor- als in gezond 
weefsel en in bloedplasma. Gelatine-zymografie en een biologische bepaling voor 
breed-spectrum MMP-activiteit werden gebruikt voor het analyseren van de eiwit- 
afbrekende (proteolytische) activiteit. Geavanceerde scan- en 
beeldverwerkingtechnieken maken het mogelijk zowel de inactieve als actieve vorm van 
MMP-2 en -9 kwantitatief te meten.
In hoofdstuk 2 beschrijven we het onderzoek naar de weefselwaarden van actief en 
inactief MMP-2 en -9 in tumorweefsel en in verderop gelegen normaal darmslijmvlies, 
verkregen van 73 patiënten met CRC. Zowel inactieve als actieve gelatinases, gemeten 
met zymografie, vertonen verhoogde activiteitswaarden in tumor ten opzichte van 
normaal weefsel. Zeer waarschijnlijk is deze activiteit echte in vivo biologische activiteit 
omdat deze ook verhoogd was in een breed-spectrum MMP-activiteitsbepaling, die 
gevoelig is voor MMP-specifieke remmers. Als MMPs gebonden zouden zijn aan MMP- 
specifieke remmers dan zouden er in deze laatste bepaling geen activiteiten gevonden 
zijn. Met name de MMP-2-waarden waren verhoogd wat resulteerde in een tumor­
normaal ratio van 8,6 voor de actieve vorm. Omdat de actieve vorm meer verhoogd is 
dan de inactieve vorm, suggereert dit dat de mediatoren van de activeringsroute van 
MMP-2 verhoogd zijn. Dit lijkt niet te gelden voor MMP-9, omdat daarvan de inactieve 
vorm meer toeneemt dan de actieve vorm. Er werden geen significante verschillen 
gevonden tussen monsters die verkregen werden van puur tumorweefsel en van 
monsters van het invasieve front.
In relatie tot klinische en/of pathologische parameters, bleek dat de actieve en inactieve 
MMP-2-waarden een omgekeerd verband hadden met het stadium van ziekte. Deze 
waarneming houdt mogelijk in dat MMP-2 een belangrijkere rol heeft in de vroege stadia 
van CRC dan in de vergevorderde stadia. Meer patiënten in de vroege stadia van CRC 
zijn nodig om dit verder te onderzoeken.
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De relatie tussen gelatinase-activiteit en uitgezaaide ziekte in CRC wordt beschreven in 
hoofdstuk 3. In levertumoren en in overgangsweefsel met daarin de invasierand was 
de activiteit van beide gelatinases verhoogd ten opzichte van verderop gelegen normaal 
leverweefsel. Bovendien was voor MMP-2 en MMP-9 de ratio tussen de actieve en de 
inactieve vorm hoger in tumoren dan in normale lever. Deze laatste waarneming laat 
niet alleen zien dat in tumoren de gelatinase(gelatine-afbrekende)-activiteit in absolute 
zin verhoogd is, maar het suggereert ook dat de mate van omzetting van inactief MMP 
naar actief MMP verhoogd is. Als we beide gelatinases vergelijken dan is de verhouding 
van activiteit in tumor ten opzichte van normaal het hoogst voor MMP-2. Bovendien 
heeft MMP-2 de hogere ratio van actief ten opzichte van inactief. Deze resultaten geven 
verschillen aan tussen de twee gelatinases aangaande de genexpressie, de vertaling 
naar eiwit en de mate van activering. Daarom zijn we van mening dat de twee MMPs 
onderzocht en beschouwd moeten worden als twee verschillende, los van elkaar 
staande merkstoffen van tumorprogressie. Ook volgt hieruit dat, indien deze MMPs 
worden overwogen voor therapeutische doelen, elke remming van hun activiteit MMP- 
specifiek moet zijn.
In geval van leveruitzaaiingen hadden metastasen, kleiner dan 5 cm, hogere actieve en 
inactieve MMP-2-waarden dan grotere. Ook correleerden hogere actieve MMP-2- 
waarden in de metastase met kortere ziekte-vrije perioden na chirurgische verwijdering. 
Deze laatste bevinding geeft een mogelijke voorspellende waarde aan en vereist nader 
onderzoek. ProMMP-9-waarden in patiënten die preoperatief chemotherapie hadden 
gekregen waren verhoogd in normaal en in uitgezaaid weefsel. De relatie tussen MMP- 
9 en chemotherapie moet in toekomstige onderzoeken naar MMP-9 aandacht krijgen.
De twee voorgaande studies laten zien dat gelatinase-activiteit bij CRC tumoren 
verhoogd is en dat het mogelijk voorspellende waarde heeft bij het bepalen van de 
prognose. Omdat de ziekte reeds manifest is, zal dergelijke informatie niet leiden tot 
diagnostische informatie. Om die reden is een ander deel van het onderzoek gefocust 
op de gelatinases in bloed. De voordelen van het verzamelen van bloed zijn dat deze 
monsters makkelijker te verkrijgen zijn, dat ze meer divers zijn (verschillende soorten 
antistolling of serum), dat ze frequenter en achtereenvolgend, voor en na de operatie en 
van verschillende controlegroepen verkregen kunnen worden. Erg belangrijk daarbij is 
bovendien dat zowel de diagnostische als prognostische waarde kan 
wordenvastgesteld.
Om op de beste manier MMP activiteit in bloed te meten werd zowel rekening 
gehouden met het type monster als met het moment van afname. Op basis van 
resultaten, beschreven in de literatuur, hebben we gekozen voor bloedplasma met 
heparine als antistollingsmiddel. Serum (plasma uit gestold bloed) leek minder geschikt 
omdat gedurende het stollingsproces extra MMPs in het bloed vrijkomen. Het beste
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moment voor het nemen van bloedmonsters in relatie tot het tijdstip van operatie werd 
vastgesteld met het onderzoek beschreven in hoofdstuk 4. Bij primair CRC, bij 
leveruitzaaiingen en bij artrose (gewrichtsaandoening) van de heup werd de gelatinase- 
activiteit gemeten in bloed dat verkregen werd voor de operatie en 1 week, 1 maand en 
3 maanden nadien. Bij alle drie de patientgroepen was er een duidelijk, maar 
voorbijgaand, effect op de hoogte van proMMP-9-waarden in bloedplasma. Dit effect 
was er niet voor proMMP-2. De proMMP-9-waarden namen significant toe in de 1ste 
week na operatie maar gingen na 1 maand terug naar het preoperatieve niveau. Actieve 
vormen van de gelatinases werden niet in het bloed gevonden. Het is duidelijk dat 
(chirurgische) stress door de operatie de circulerende proMMP-9 waarden doet 
toenemen en dat postoperatieve monsters ter bepaling van het ziektebeloop beter 
alleen dan kunnen worden gebruikt als zij tenminste 1 maand na de operatie worden 
afgenomen.
Daarnaast werden er lagere proMMP-2-waarden gevonden in patiënten met een primair 
CRC en CRC met leveruitzaaiingen dan in patiënten met artrose van de heup. Deze 
opmerkelijke bevinding is mogelijk een kankerspecifiek fenomeen en zal meer aandacht 
krijgen in de volgende paragraaf.
Nu we de aanwezigheid van veranderende waarden van actieve en inactieve 
gelatinases in CRC-weefsel en het effect van chirurgie op de waarden in de circulatie 
hebben vastgesteld, kunnen we ons vervolgens richten op de pre- en postoperatieve 
MMP-2- en MMP-9-waarden in bloed en hun betekenis onderzoeken als voorspellende 
merkstoffen. De gelatinases werden gemeten met zowel zymografie als met ELISA. De 
endogene MMP remmer TIMP-1 en de referentie merkstof CEA werden ook bepaald. In 
hoofdstuk 5 kwamen de volgende vragen aan de orde: wat zijn de preoperatieve MMP- 
2-, MMP-9-, TIMP-1- en CEA-waarden in bloed van CRC-patiënten ten opzichte van die 
in gezonde personen; hoe verhouden deze waarden zich tot de klinische en/of 
pathologische parameters; en welke betekenis hebben zij bij het stellen van de 
diagnose en het voorspellen van de overleving?
Ondanks de duidelijke en verhoogde aanwezigheid van de actieve vorm van MMP-2 en 
-9 in tumorweefsel, werden deze niet waargenomen in bloed van kankerpatiënten noch 
in gezonde controle personen die als controlegroep werd gebruikt. Het is mogelijk dat 
de actieve vorm snel afgebroken wordt en de bloedsomloop in het geheel niet bereikt of 
dat het niet gemeten wordt omdat het onomkeerbaar gebonden wordt aan niet- 
specifieke remmers in het bloed.
Plasma proMMP-2-waarden waren lager in CRC-patiënten dan in gezonde personen (of 
patiënten met artrose van de heup; hoofdstuk 4). De waarden correleerden zelfs 
omgekeerd met ernstige klinische en/of pathologische parameters zoals de 
betrokkenheid van lymfeklieren, het stadium van ziekte en de serum CEA-spiegel. Men
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zou kunnen speculeren dat in CRC, en in het bijzonder in de vroege stadia, proMMP-2- 
activering meer efficiënt is dan in gezonde controle personen en resulteert in lagere 
plasma waarden. Het is zelfs denkbaar dat de provorm gebonden is en geactiveerd 
wordt, of dat de provorm afgebroken wordt, beide resulterend in het voorkomen van 
overloop van provorm naar de bloedbaan.
ProMMP-9-waarden verschilden niet tussen patiënten met CRC en gezonde personen. 
Patiënten met grotere en meer invasieve tumoren lieten echter hogere proMMP-9- 
waarden zien. Mogelijk wordt deze verhoogde aanwezigheid van proMMP-9 
veroorzaakt door een immunologische reactie die uitgelokt wordt door degelijke 
tumoren.
TIMP-1 en CEA bloedwaarden, gemeten met ELISA, waren beide hoger in CRC dan in 
gezonde personen. Verhoogde immuunreactiviteit voor TIMP-1 correleerde met 
uitgezaaide ziekte met verhoogde CEA-waarden.
Het vermogen om CRC-patiënten van gezonde controles te onderscheiden op basis 
van preoperatieve bloedeiwitwaarden kan mogelijk de potentiële diagnostische waarde 
aangeven van deze eiwitmerkstoffen. Met ROC-krommen kon worden aangetoond dat 
proMMP-2-activiteit, gemeten met zymografie, de hoogste gevoeligheid 
tentoonspreidde voor het opsporen van CRC-patiënten met 95% specificiteit. In een 
combinatie met TIMP-1 was de gevoeligheid zelfs hoger. ProMMP-9 vertoonde een 
zeer laag diagnostisch vermogen. Om het diagnostisch vermogen van lagere plasma 
proMMP-2-waarden in combinatie met verhoogde TIMP-1-waarden volledig te begrijpen 
is meer onderzoek nodig. Men zou, bijvoorbeeld, meer verschillende patiëntengroepen 
bij het onderzoek moeten betrekken, zoals patiënten met adenomateuze poliepen, 
patiënten met darmontstekingen en patiënten met asymptomatische dikkedarmziekten. 
De voorspellende waarde van de gelatinases, TIMP-1 en CEA aangaande de 
overleving werd onderzocht met de Kaplan-Meier methode. Preoperatieve 
gelatinasebioactiviteit of immuunreactiviteit had geen voorspellende waarde, terwijl 
zowel TIMP-1 als CEA goede merkstoffen waren. Patiënten met hoge TIMP-1- of CEA- 
waarden hadden een significant lagere kans op overleving na drie jaar dan patiënten 
met lage waarden. Als beide merkstoffen gecombineerd werden leek de voorspellende 
waarde voor overleving zelfs toe te nemen.
Kortom, uit het preoperatief verzamelen kwam naar boven dat proMMP-2 potentiële 
waarde heeft in de diagnostiek van CRC, maar geen waarde heeft voor het bepalen van 
de prognose en dat proMMP-9 totaal geen voorspellende waarde heeft. Ook lijkt het 
erop dat het combineren van tumormerkstoffen, zelfs als ze verkregen zijn met 
verschillende analytische technieken, de methode van de toekomst is bij het vinden van 
betere voorspellende merkstoffen.
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De voorspellende waarde van postoperatieve metingen van de gelatinases en CEA 
werden onderzocht en beschreven in hoofdstuk 6. De CEA bloedwaarden bleken 
verhoogd te zijn in monsters van patiënten ruim voor de diagnose van de terugkeer van 
ziekte (lokaal of uitgezaaide ziekte), terwijl de proMMP-2- en proMMP-9-bloedwaarden 
niet significant veranderden. De gelatinases lijken daarom niet bruikbaar voor het 
vaststellen of het voorspellen van terugkeer van ziekte in de periode na de chirurgische 
verwijdering van de primaire tumor. Bovendien bleven de CEA-waarden stijgen tot het 
moment dat patiënten stierven aan CRC terwijl de gelatinasewaarden niet veranderden 
in die periode. De hoogte van de CEA-serumspiegel wordt vaak genoemd als een maat 
voor de hoeveelheid tumor en daarom hadden de waarnemingen aangaande deze 
merkstoffen verwacht kunnen worden. Het is duidelijk dat de proMMP-2- en proMMP-9- 
bloedwaarden niet aan kanker gerelateerd zijn zoals CEA dat is. Dit betekent niet dat 
MMPs niet betrokken zijn bij tumorprogressie, maar dat hun rol heel duidelijk anders is 
dan die van CEA.
Wanneer de resultaten uit hoofdstuk 5 en die uit dit hoofdstuk in overweging worden 
genomen, dan komt de vraag op waarom preoperatieve plasma proMMP-2 
hoeveelheden diagnostische waarde hebben terwijl de hoeveelheden die postoperatief 
gevonden werden niet deze potentie hebben. Het antwoord kan mogelijk gevonden 
worden bij de verschillende groepen die ter vergelijking gebruikt werden. In het 
preoperatieve onderzoek werden gegevens van patiënten met klinisch 
gediagnosticeerde kanker vergeleken met gezonde controle personen. In het 
postoperatieve onderzoek werden proMMP-2-waarden vastgesteld in ziekte-vrije 
patiënten als parameter voor de terugkeer van ziekte en vergeleken met de waarden in 
patiënten die geen terugkeer van ziekte hadden. In de laatste vergelijking lijken de 
klinische verschillen tussen de groepen die vergeleken werden veel kleiner en een 
dergelijke aanpak lijkt de voorkeur te hebben, echter om geldige conclusies te trekken 
voor het diagnostisch potentieel is verder onderzoek noodzakelijk.
Omdat er bij uitgezaaide CRC een vergelijkbare behoefte aan betrouwbare merkstoffen 
is, werden de pre- en postoperatieve diagnostische en prognostisch waarde van MMPs 
onderzocht in patiënten met leveruitzaaiingen. De resultaten van dit onderzoek worden 
beschreven in hoofdstuk 7. Zevenenvijftig patiënten ondergingen een operatie aan de 
leveruitzaaiingen en werden gevolgd in de tijd. De proMMP-2-, -9-, en TIMP-1-waarden 
in plasma werden bepaald voor en na de verwijdering van de leveruitzaaiingen. 
Gegevens werden vergeleken met die van gezonde personen (n=51) en met die van 
patiënten met primaire CRC (n=94). Ook hier bleek proMMP-2, meer dan proMMP-9, 
potentieel te hebben als merkstof. In vergelijking met gezonde personen waren de 
plasma proMMP-2-waarden lager en de TIMP-1-waarden hoger bij CRC- 
leveruitzaaiingen. Wanneer deze vergeleken werden met die in primaire CRC-patiënten
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werden er geen verschillen gevonden. ProMMP-9-waarden waren niet verschillend 
ongeacht welke groepen vergeleken werden.
De CEA waarden stegen tussen gezonde personen en patiënten met primaire CRC 
maar waren nog hoger in patiënten met leveruitzaaiingen. Anderen hebben dit ook 
waargenomen en dit bevestigt dat onze studiegroep representatief is en vergeleken kan 
worden met groepen in andere studies. Bovendien laten deze gegevens nogmaals zien 
dat de gelatinases overtuigend anders dan CEA gerelateerd zijn aan CRC-progressie 
en dat de gelatinases in essentie op een gelijke wijze betrokken lijken te zijn bij 
uitgezaaide ziekte als bij primaire ziekte.
Het zoeken naar relaties tussen klinische en/of pathologische parameters en 
preoperatieve proMMP- en TIMP-1-waarden tonen aan dat plasma proMMP-9-waarden 
afnemen na recente chemotherapie. Dit laatste in interessant want de waarden in 
weefsel nemen toe na chemotherapie (hoofdstuk 3). Om dit verschil te begrijpen is 
meer onderzoek nodig.
De analyse van de plasmamonsters die afgenomen werden voorafgaande aan de 
resectie van de CRC-leveruitzaaiingen toonden voor de gelatinases of TIMP-1 geen 
diagnostische of voorspellende waarde aan, terwijl langdurige lage proMMP-2-waarden 
na resectie van leveruitzaaiingen de terugkeer van ziekte voorspelden. In de patiënten 
die geen terugkeer van ziekte hadden namen de proMMP-2-waarden toe naar het 
niveau in de gezonde controlegroep. Wanneer deze waarneming in ogenschouw 
genomen wordt, is het duidelijk dat het individueel volgen van patiënten van groot 
belang lijkt en dat veranderingen in bloedwaarden mogelijk meer voorspellende waarde 
hebben dan absolute waarden. We dringen erop aan dat dit aspect meer aandacht krijgt 
in toekomstige studies. Bovendien zou het postoperatieve beloop van proMMP-2 in 
meer detail bestudeerd moeten worden op de potentie om terugkeer van uitzaaiingen te 
diagnosticeren. De waarneming dat TIMP-1 diagnostisch en voorspellend potentieel 
heeft in primaire ziekte maar niet in uitgezaaide ziekte nodigt ook uit tot verder 
onderzoek en zou verschillende typen van kanker erbij moeten betrekken.
Vervolg onderzoek
Het belangrijkste doel van de studies die hier beschreven zijn is geweest om de 
potentiële voorspellende waarde van gelatinase-activiteit bij CRC te onderzoeken. Naar 
onze mening was de beschikbare studiepopulatie groot genoeg om een dergelijk 
potentieel aan te tonen indien zij aanwezig is. Definitieve conclusies moeten echter 
wachten tot evaluatie in grotere studies waarbij niet alleen meer patiënten van alle 
stadia worden betrokken, maar ook verschillende referentiegroepen zoals gezonde
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controle personen, patiënten met darmontstekingen en patiënten met benigne 
darmtumoren.
Zowel actieve als latente (pro-)MMP-2-weefselwaarden correleerden bij CRC-patiënten 
met het stadium van primaire ziekte en leken, samen met actief en latent MMP-9, 
ongunstig samen te hangen met het hebben van vroege terugkeer van ziekte na een 
operatie voor leveruitzaaiingen. Gezien het belang van het vinden van nieuwe 
voorspellende merkstoffen raden wij aan deze verbanden verder te onderzoeken op 
eenzelfde wijze als wij reeds deden voor de gelatinase-activiteit in bloed. De 
weefselwaarden van de gelatinases, alleen of in combinatie met andere merkstoffen, 
kunnen zeer zeker belangrijk blijken te zijn voor het voorspellen van de prognose van 
de patiënt met CRC.
ProMMP-2-bloedwaarden van CRC-patiënten waren lager dan die in plasma van 
gezonde controle personen, terwijl de concentraties proMMP-9 onveranderd bleven. 
Daarnaast hadden de preoperatieve proMMP-2-waarden in primaire CRC, gemeten met 
zymografie, potentiële diagnostische waarde samen met TIMP-1. Hetzelfde leek te 
gelden voor postoperatieve proMMP-2-waarden die gemeten werden voordat er 
terugkeer van ziekte was bij uitgezaaide kanker. Momenteel is het onbekend of dit 
fenomeen specifiek is voor CRC of dat het ook bij ander vormen van kanker voorkomt. 
Dit zou onderzocht moeten worden.
De gelatinases in de bloedbaan lijken niet veelbelovend voor het voorspellen van de 
prognose van patiënten, maar de diagnostische waarde van verlaagde of langdurig lage 
proMMP-2-waarden heeft potentie en zou meer uitgebreid onderzocht moeten worden, 
bijvoorkeur in een grotere CRC-patiëntengroep, in patiënten met adenomateuze 
poliepen en in patiënten met darmontstekingen. Het lijkt bovendien belangrijk om niet 
alleen absolute waarden te onderzoeken maar ook de veranderingen in waarden en ze 
te correleren met die in controlegroepen die klinisch gezien het meest relevant zijn.
Onze onderzoeken in bloed en weefsel laten uiteindelijk zien dat MMP-2 en MMP-9, 
ondanks dat het beide gelatinases zijn, zeer verschillend gerelateerd zijn aan het 
kankerproces. Dit gegeven kan mogelijk ook verklaren waarom in 
patiëntenonderzoeken synthetische MMP-remmers met een breed bereik niet succesvol 
waren. We raden daarom aan dat onderzoek in de toekomst gericht moet zijn op 
individuele karakteristieken van tumormerkstoffen, meer dan op de karakteristieken van 
een groep of type van merkstoffen. Bovendien is het belangrijk, los van deze studie, om 
de MMP-familie te blijven onderzoeken, om de mechanismen van MMP-expressie, 
activering en remming te ontrafelen en om onze bevindingen en die van andere met 
betrekking tot de diagnostische en prognostische waarde uit te breiden.
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